{"id":104762,"date":"2025-02-07T15:55:13","date_gmt":"2025-02-07T15:55:13","guid":{"rendered":"https:\/\/touchendocrinology.com\/?p=104762"},"modified":"2025-02-07T17:05:41","modified_gmt":"2025-02-07T17:05:41","slug":"efficacy-and-safety-of-early-initiation-of-sodium-glucose-co-transporter-2-inhibitors-following-acute-myocardial-infarction-a-systematic-review-and-meta-analysis","status":"publish","type":"post","link":"https:\/\/touchendocrinology.com\/diabetes\/journal-articles\/efficacy-and-safety-of-early-initiation-of-sodium-glucose-co-transporter-2-inhibitors-following-acute-myocardial-infarction-a-systematic-review-and-meta-analysis\/","title":{"rendered":"Efficacy and Safety of Early Initiation of Sodium\u2013Glucose Co-transporter-2 Inhibitors Following Acute Myocardial Infarction: A Systematic Review and Meta-analysis"},"content":{"rendered":"<h1 id=\"8f0a3597-45eb-436b-b6de-d12f1c550c28\" class=\"jrnlHead1\"><span id=\"3df60a66-8716-47b3-9614-a78c70805285\">Article Highlights<\/span><\/h1>\n<p id=\"1b00c51c-aa44-4970-89be-3ba97cb47bbe\" class=\"jrnlSecPara\"><span id=\"9098d9ce-aadd-4ded-a748-8b183d907914\">Early use of sodium<span id=\"e933e5d6-0c89-4d8f-b5af-33191451f4c6\">\u2013<\/span>glucose co-transporter-2 inhibitors following myocardial infarction was associated with the following factors:<\/span><\/p>\n<ul id=\"07eb24fc-ec81-4af0-84e6-8ceb009cb8d3\">\n<li id=\"2606985d-6094-4180-9524-4033c4d153b8\" class=\"jrnlListPara\">\n<p id=\"6f8b69b7-d476-49af-889a-9c803661b86e\" class=\"jrnlListPara\"><span id=\"24dae008-5a47-4768-be94-c70171441415\"><span id=\"f8dcf60e-d460-4f21-a505-7b65334b186a\" class=\"changeCase sty cts-4\"><\/span>Lower hospitalization for heart failure (odds ratio [OR]: 0.75; 95% confidence interval [CI]: 0.62\u20130.90; p=0.002).<\/span><\/p>\n<\/li>\n<li id=\"779b45b8-2ee5-4d4e-b849-243a739d1c23\" class=\"jrnlListPara\">\n<p id=\"e41a5504-7ed6-4411-b7c2-acc657fb0f5c\" class=\"jrnlListPara\"><span id=\"7aa7ea6a-9483-4da0-aed6-2802c04764f8\">Similar cardiovascular deaths (OR: 1.04; 95% CI: 0.83\u20131.30; p=0.76).<\/span><\/p>\n<\/li>\n<li id=\"d3c87cdc-8a40-45ad-b3df-e610b190cfd5\" class=\"jrnlListPara\">\n<p id=\"575fa0f5-0f2a-4f93-bbf5-20ccc4676a85\" class=\"jrnlListPara\"><span id=\"7fe78911-4ede-4538-90ed-c3e0e63b8436\">Similar all-cause mortality (OR: 1.00; 95% CI: 0.82\u20131.21; p=0.98).<\/span><\/p>\n<\/li>\n<li id=\"67e45471-d507-43bd-80b6-273bd30adc73\" class=\"jrnlListPara\">\n<p id=\"df7efeef-326d-4864-a01f-75938b485932\" class=\"jrnlListPara\"><span id=\"69163327-9866-4cf3-bb2f-8dfd5c57934c\">Similar risks of ketoacidosis, acute renal failure or hepatic injury.<\/span><\/p>\n<\/li>\n<\/ul>\n<hr \/>\n<p>&nbsp;<\/p>\n<p id=\"949ccdc5-446d-4c65-8ef2-427a15d91640\" class=\"jrnlSecPara\">Early and timely percutaneous coronary intervention (PCI) therapies, effective anti-platelet therapy along with aggressive early lipid lowering with high-intensity statins and other lipid mediations are the current cornerstones for improving short- and long-term outcomes in patients with acute myocardial infarction (AMI).<span id=\"0d6fb54e-ab76-4047-93c3-651bd705372f\" class=\"jrnlBibRef\" data-citation-string=\" R1 \"><sup id=\"59c98f2b-97b3-4df8-8f0d-272275aaf42b\">1<\/sup><\/span>\u00a0However, despite these advances, a significant amount of residual cardiovascular (CV) risk remains in these patients for a recurrent CV event, especially in the initial few weeks of the index event. Sodium<span id=\"5a762b82-e2c9-4169-8a2c-b25f82cc9606\">\u2013<\/span>glucose co-transporter-2 inhibitors (SGLT2i) are considered to be the preferred agents for managing type 2 diabetes (T2D) in patients with established atherosclerotic cardiovascular disease (ASCVD) and those with multiple risk factors for ASCVD.<span id=\"89b8e429-df17-42d0-a9fa-6e2e74a4fb90\" class=\"jrnlBibRef\" data-citation-string=\" R2 R3 \"><sup id=\"bd3d4647-570b-4898-bdc1-baaa986f5fb7\">2,3<\/sup><\/span>\u00a0In addition, SGLT2i have established themselves as the preferred agents for reducing hospitalization for heart failure (HHF) in patients with heart failure with reduced and preserved ejection fraction, regardless of their underlying glycaemic status.<span id=\"b6b34e5a-0001-45cb-80be-9c615888d110\" class=\"jrnlBibRef\" data-citation-string=\" R2 R3 R4 \"><sup id=\"b0dae0bb-fafb-4b8f-848e-c709d869d832\">2\u20134<\/sup><\/span>\u00a0SGLT2i have demonstrated themselves to improve a broad range of CV outcomes, especially CV death and HHF in different randomized controlled trials (RCTs) and meta-analyses.<span id=\"b71d29ca-d942-4e5a-8752-e6feb6b2c7b1\" class=\"jrnlBibRef\" data-citation-string=\" R3 R4 R5 \"><sup id=\"2aa775e4-3772-4ca7-8a27-da222b434f87\">3\u20135<\/sup><\/span><\/p>\n<p id=\"2b5a4162-1ce7-4ca6-9ffb-c527956571a7\" class=\"jrnlSecPara\">Recently, several RCTs have been published evaluating the role of SGLT2i in myocardial infarction (MI).<span id=\"222b03e4-a745-477d-a5c3-17cb12be6197\" class=\"jrnlBibRef\" data-citation-string=\" R6 R7 R8 R9 \"><sup id=\"230897a9-9fdc-47cd-b293-40245c751978\">6\u20139<\/sup><\/span>\u00a0Traditionally, the use of SGLT2i, in general, has been avoided during acute illness (infections, surgery or acute events such as AMI) due to safety concerns primarily related to the increased risk of euglycaemic ketosis.<span id=\"18beade5-066d-4ec8-994c-4446452cd7f2\" class=\"jrnlBibRef\" data-citation-string=\" R10 \"><sup id=\"b7fecfe2-3d7b-46b0-86fe-a1fd7b5d26f9\">10<\/sup><\/span>\u00a0In addition, the effectiveness of a medicine in improving CV and mortality outcomes in patients with stable ASCVD and chronic heart failure does not guarantee its efficacy in AMI. A prime example is sacubitril-valsartan, which reduces CV deaths and HHF in patients with chronic heart failure with reduced ejection fraction but not when used in the setting of AMI (Prospective ARNI versus ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events after MI [PARADISE-MI trial];\u00a0<span id=\"d1c2c533-11dc-453d-bb80-a57adee20a1f\">ClinicalTrials.gov identifier:<\/span>\u00a0NCT02924727).<span id=\"dbda7432-f5f2-4df4-9adc-7a0ed01865be\" class=\"jrnlBibRef\" data-citation-string=\" R11 R12 \"><sup id=\"a4b49b58-bcb2-4409-8291-d7826d18525c\">11,12<\/sup><\/span>\u00a0This makes it even more important to study SGLT2i in AMI, despite their proven efficacy in chronic heart failure. A literature review revealed that no meta-analysis is available that has holistically analysed and summarized the clinical efficacy and safety of SGLT2i following MI. Hence, the aim of this systematic review and meta-analysis (SRM) was to evaluate the efficacy and safety of SGLT2i in MI.<\/p>\n<h1 id=\"1e12ab11-5135-49af-b199-71192e538972\" class=\"jrnlHead1\">Methods<\/h1>\n<h2 id=\"69c8a1b1-3d81-4b5c-95cf-5c5500d345f7\" class=\"jrnlHead2\">Methodology<\/h2>\n<p id=\"48fa0eab-bd9d-4fed-8a61-667a9c1b1699\" class=\"jrnlSecPara\">This meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklists and the procedures described in the Cochrane Handbook for Systematic Reviews of Interventions.<span id=\"745bffe4-8b27-43dc-97bd-8e1920c0ba95\" class=\"jrnlBibRef\" data-citation-string=\" R13 R14 \"><sup id=\"bf0f58ba-320c-4e2f-bff1-b83db3c9fa2d\">13,14<\/sup><\/span>\u00a0The SRM was registered with PROSPERO (CRD42024533973), and the protocol summary is accessible online. All RCTs published till March 2024 were considered for this meta-analysis. As ethical approval already exists for the individual studies included in the meta-analysis, no separate approval was required for this study.<\/p>\n<p id=\"ccc5e901-1478-4d58-88fe-2d969db21623\" class=\"jrnlSecPara\">Population, Intervention, Comparison, Outcomes and Study design was used as a framework to formulate eligibility criteria for the clinical trials in this SRM. The patient population (P) consisted of patients with MI; the intervention (I) was the use of SGLT2i along with the standard therapy for managing MI; the comparison or control (C) involved patients either on placebo or any other medication over the background standard therapy for MI; the outcomes (O) evaluated included all-cause death\/mortality, CV death, HHF, stroke, recurrence of MI, changes in N-terminal pro-b-type natriuretic peptide (NT-proBNP), weight, echocardiography parameters and any adverse effects noted; and RCTs were considered as the study type (S) for inclusion. This study comprised RCTs with study individuals aged at least 18 years. Only those RCTs were considered for this meta-analysis where SGLT2i was initiated within 2 weeks of the index MI event.<\/p>\n<p id=\"8e8807d3-1eb6-42a4-857d-8e3d6dea157c\" class=\"jrnlSecPara\">The primary outcome was to evaluate the changes in CV death, all-cause death\/mortality and HHF. The secondary outcomes of this study were to evaluate the alterations in echocardiographic parameters (left ventricular ejection fraction [LVEF]), NT-proBNP, high-sensitivity C-reactive protein (hs-CRP), occurrence of stroke, recurrence of MI, all-cause hospitalization and safety issues such as changes in weight, occurrence of ketoacidosis, acute renal failure and hepatic injury. Sub-group analysis was performed based on whether the control group received an active comparator (active control group) or a placebo (passive control group).<\/p>\n<h2 id=\"ce2fc6ee-1053-43ac-b074-a58ec3c59de9\" class=\"jrnlHead2\">Search method for identifying studies<\/h2>\n<p id=\"3f6c6285-55a9-41ca-b275-cccc54abbb28\" class=\"jrnlSecPara\">Several databases and registers, including MEDLINE (via PubMed), Scopus, Cochrane Central Register and ClinicalTrials.gov, were systematically searched. The search covered these sources from their commencement to 30 March 2024. The search terms were applied to titles only; the search technique followed a Boolean approach using the terms \u2018SGLT2\u2019 OR \u2018sodium glucose co-transporter-2 inhibitor\u2019 OR \u2018dapagliflozin\u2019 OR \u2018empagliflozin\u2019 OR \u2018canagliflozin\u2019 OR \u2018ertugliflozin\u2019 OR \u2018sotagliflozin\u2019 AND \u2018myocardial infarction\u2019.<\/p>\n<p id=\"64f4b850-97f3-4013-b5b2-e87056721e58\" class=\"jrnlSecPara\">Every recently published or unpublished clinical study in English was searched exhaustively and carefully. This search involved looking through pertinent publications and references found in the clinical trials included in the present work.<\/p>\n<h2 id=\"03f7a6a2-07da-4d89-a653-13959f77f896\" class=\"jrnlHead2\">Data extraction, study selection, measurement of treatment effects and data synthesis<\/h2>\n<p id=\"19fe5f2a-1651-4605-915b-84f624f2b739\" class=\"jrnlSecPara\">Four review authors independently conducted data extraction using standardized data extraction forms, with details provided elsewhere.<span id=\"6ec6af94-e4c4-404c-ba7d-718b3958196a\" class=\"jrnlBibRef\" data-citation-string=\" R15 R16 \"><sup id=\"67a4bdd1-40e4-4ced-9e31-3e73552b7e60\">15,16<\/sup><\/span>\u00a0The handling of missing data has also been elaborated upon in the same source.<span id=\"b09ab460-1bb5-4d1b-8b43-01f6adbc4fc1\" class=\"jrnlBibRef\" data-citation-string=\" R15 R16 \"><sup id=\"d0437670-5f77-4999-a497-d3bb84dcb305\">15,16<\/sup><\/span>\u00a0RevMan Web 2024 version was used for comparing the mean difference (MD) of the different primary and secondary outcomes between the SGLT2i and the control groups of the included studies. Random effects analysis models were chosen to address the anticipated heterogeneity due to variations in population characteristics and trial lengths. The inverse variance statistical method was applied for all instances. The meta-analysis encompassed forest plots that integrated data from a minimum of two trials. A significance level of\u00a0<span id=\"5ef78eea-7692-4085-82d6-bf61d713e5b4\" class=\"changeCase sty cts-4\"><span id=\"d66ce49d-7300-41a1-8ee9-1e61fd933df3\" class=\"styrm cts-10\">p<\/span><\/span><em id=\"2f7b3fbd-ec5c-405a-9e6e-785d25170c0a\"><span id=\"575b3fab-2d11-41f5-8b89-20359cb5cbaa\" class=\"changeCase sty cts-4\"><\/span><\/em>&lt;0.05 was used.<\/p>\n<h2 id=\"41dd6486-060f-4223-8dbe-210cb3e2faad\" class=\"jrnlHead2\">Assessment of risk of bias in the included studies<\/h2>\n<p id=\"57b5a831-f9b1-42e0-b5ea-7afe900dfb6c\" class=\"jrnlSecPara\">Three authors independently assessed the risk of bias (ROB) using the ROB assessment tool in Review Manager (Rev<span id=\"2ca48e4c-0433-4825-b5eb-6fe58db69a73\" class=\"changeCase sty cts-5\">M<\/span>an) Web Version 2024 (The Cochrane Collaboration, Oxford, UK, 2024) software. ROB assessment was performed under the following headings: adequate sequence generation (selection bias); adequate allocation concealment (selection bias); adequate prevention of knowledge of allocated interventions during the study; blinding of participants and personnel (performance bias); blinding of outcome assessors (detection bias); incomplete outcome data (attrition bias); and freedom from selective outcome reporting (reporting bias). Involvement of pharmaceutical organizations in the funding, conducting the study and preparing the draft was considered to be high ROB under other bias sub-headings.<\/p>\n<h2 id=\"924e5b5d-c131-4555-94b1-60f6aeef1324\" class=\"jrnlHead2\">Assessment of heterogeneity<\/h2>\n<p id=\"4b0d24e1-8a80-445e-8ad7-a92ed34c7cbf\" class=\"jrnlSecPara\">The assessment of heterogeneity was initially conducted by studying forest plots. Subsequently, a\u00a0<span id=\"fb10213d-72e9-4598-8b2b-712a42158ed7\" class=\"styrm cts-3\"><em id=\"0f475d60-f125-45dc-ba91-dab10769c522\" class=\"sty cts-3\">\u03c7<\/em><\/span><sup id=\"056c31cc-6d05-4d11-9427-f00a18de654e\">2<\/sup>\u00a0test was performed using N-1 degrees of freedom and a significance level of 0.05 to determine the statistical significance. The\u00a0<em id=\"3aa613b0-6f40-4e41-b794-d58eab0f54b5\" class=\"sty cts-3\">I<\/em><sup id=\"6e1f2fb7-d375-444d-9bfd-9b9bf29d9598\">2<\/sup>\u00a0test was also used in the subsequent analysis.<span id=\"bc06d895-86cf-4ec7-8048-6937755c5650\" class=\"jrnlBibRef\" data-citation-string=\" R14 \"><sup id=\"f289c845-e43e-4353-9c55-39b6cbb5b139\">14<\/sup><\/span>\u00a0The specifics of understanding\u00a0<em id=\"af841120-0ab9-4e14-a38c-828c9d663ed1\" class=\"sty cts-3\">I<\/em><sup id=\"cc0f7ee0-a3ed-4f21-8fc3-ab1c2c203ce1\">2<\/sup>\u00a0values have already been explained in depth elsewhere.<span id=\"29768031-9d00-4006-a75b-5070804ad29c\" class=\"jrnlBibRef\" data-citation-string=\" R15 R16 \"><sup id=\"4f0e4dc9-98ea-405e-86cc-ae121e0ad5cb\">15,16<\/sup><\/span><\/p>\n<h2 id=\"ca39d3e8-85c4-49cb-80d5-392e6fbd5cf5\" class=\"jrnlHead2\">Grading of the results<\/h2>\n<p id=\"2291b5a5-3980-479c-9aef-2891c470af10\" class=\"jrnlSecPara\">The Grading of Recommendations Assessment, Development and Evaluation methodology was used to determine the quality of evidence about each meta-analysis outcome.<span id=\"c06229e0-3f3d-4179-a7e1-2cb21c623ebf\" class=\"jrnlBibRef\" data-citation-string=\" R17 R18 \"><sup id=\"5824e40e-4a3c-43d9-a007-5ef3ee6566cb\">17,18<\/sup><\/span>\u00a0The details of generating the summary of findings (SoF) table and judging the quality of evidence as \u2018high\u2019, \u2018moderate\u2019, \u2018low\u2019 or \u2018very low\u2019 have been previously reported.<span id=\"b56cf162-31eb-4877-ad66-cd15e1c3ffa1\" class=\"jrnlBibRef\" data-citation-string=\" R15 R16 \"><sup id=\"697f0a85-d55e-4d4e-bc21-e188e85250f1\">15,16<\/sup><\/span><\/p>\n<h1 id=\"3103385c-fe70-4c84-b0ec-c6c849d50108\" class=\"jrnlHead1\">Results<\/h1>\n<p id=\"5c7203c2-7787-4944-bf43-626c62b2dd60\" class=\"jrnlSecPara\">This SRM was done as per the preregistered protocol with PROSPERO without any deviation (CRD42024533973). A total of 8,922 articles were found after the initial search (<em><span class=\"jrnlFigRef\" data-citation-string=\" F1 \">Figure 1<\/span><\/em>). Four hundred and eighty duplicates were removed following the screening of the titles, and the search was reduced to 106 articles. After further review of these 106 abstracts, the search was reduced to 12 studies, which were then evaluated in detail for inclusion in this meta-analysis (<span class=\"jrnlSupplRef\" data-citation-string=\" SM1 \"><em id=\"af2c72a1-a19d-4040-821a-9bc75ebafe49\" class=\"sty cts-6\">Supplementary Material 1<\/em><\/span>). Eight articles presenting data from six different RCTs (7,409 patients) that fulfilled all criteria were analysed in this meta-analysis.<span id=\"8e5cbbf5-c4d9-4248-a2cb-48307a783365\" class=\"jrnlBibRef\" data-citation-string=\" R6 R7 R8 R9 R19 R20 R21 R22 \"><sup id=\"056c3819-496d-409a-9b43-7b0720af4ec0\">6\u20139,19\u201322<\/sup><\/span><\/p>\n<div id=\"BLK_F1\" class=\"jrnlFigBlock\">\n<h2 id=\"F1\" class=\"jrnlFigCaption\"><span class=\"label\">Figure 1: <\/span>Forest plot highlighting the impact of early initiation of sodium<span id=\"a902e618-ad38-4bc6-97ea-bd2899a49fcf\">\u2013<\/span>glucose co-transporter-2 inhibitors in patients with myocardial infarction<\/h2>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-104772 size-full\" src=\"https:\/\/touchendocrinology.com\/wp-content\/uploads\/sites\/5\/2025\/02\/Screenshot-2025-02-07-150250.png\" alt=\"Figure 1: Forest plot highlighting the impact of early initiation of sodium\u2013glucose co-transporter-2 inhibitors in patients with myocardial infarction\" width=\"502\" height=\"747\" srcset=\"https:\/\/touchendocrinology.com\/wp-content\/uploads\/sites\/5\/2025\/02\/Screenshot-2025-02-07-150250.png 502w, https:\/\/touchendocrinology.com\/wp-content\/uploads\/sites\/5\/2025\/02\/Screenshot-2025-02-07-150250-202x300.png 202w, https:\/\/touchendocrinology.com\/wp-content\/uploads\/sites\/5\/2025\/02\/Screenshot-2025-02-07-150250-403x600.png 403w, https:\/\/touchendocrinology.com\/wp-content\/uploads\/sites\/5\/2025\/02\/Screenshot-2025-02-07-150250-34x50.png 34w\" sizes=\"(max-width: 502px) 100vw, 502px\" \/><\/p>\n<p class=\"jrnlFigFoot\"><em>(<span id=\"23a954da-a5eb-4603-b1b1-a83eff098ce7\" class=\"partLabel\">a<\/span>)<span id=\"5a69c261-0eb2-43aa-af35-b90f7abcbfec\" class=\"nonBreakingSpace\">\u00a0<\/span>Cardiovascular death; (<span id=\"d316e806-0622-447f-a735-5924bb0a6c06\" class=\"partLabel\">b<\/span>)<span id=\"bf0ebd38-aa84-4ff8-9e7b-7f89275f82cd\" class=\"nonBreakingSpace\">\u00a0<\/span><span id=\"eecba9d1-6a54-45a8-bfc3-5a956f898562\" class=\"changeCase sty cts-4\">a<\/span>ll-cause death\/mortality; (<span id=\"8f2399b1-2cc8-4038-b878-673666acfaf4\" class=\"partLabel\">c<\/span>)<span id=\"2be61386-8407-4041-a481-7ab6c86bbdaa\" class=\"nonBreakingSpace\">\u00a0<\/span><span id=\"129ab3cf-9e8d-46e4-a120-7d1906dcf8e7\" class=\"sty cts-4 changeCase\">ho<\/span>spitalization for heart failure; (<span id=\"06319fe0-984b-4107-848c-968b6d015d37\" class=\"partLabel\">d<\/span>)<span id=\"9658fd1c-390c-42f7-aa7e-6ea55acd40b1\" class=\"nonBreakingSpace\">\u00a0<\/span>LVEF; (<span id=\"67a003e7-8ec6-4c1d-b532-b4de7b597991\" class=\"partLabel\">e<\/span>)<span id=\"86f4b83c-619d-4eed-8992-33a2ad7e9f3a\" class=\"nonBreakingSpace\">\u00a0<\/span>NT-proBNP and (<span id=\"3ad48d89-802d-4189-a1aa-0a2fa101b381\" class=\"partLabel\">f<\/span>)<span id=\"c0088d2d-d4c5-40c1-a018-71cac1fe554a\" class=\"nonBreakingSpace\">\u00a0<\/span><span id=\"a3bb4200-0824-433c-880d-d88e78279fbd\" class=\"changeCase sty cts-4\"><span id=\"549dbacc-356d-42b5-9c83-dbcbdbdcc486\" class=\"changeCase sty cts-4\">per<\/span><\/span>centage change in NT-proBNP from baseline.<\/em><\/p>\n<p class=\"jrnlFigFoot\"><em>CI = confidence interval; df = degrees of freedom; IV = inverse variance; LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal pro-b-type natriuretic peptide; SD = standard deviation;\u00a0<span id=\"fac0ea2b-c121-4874-85cd-c64a28c6b369\">SGLT2i<\/span>\u00a0= sodium<span id=\"4eab894a-d9b4-4b8e-bb6d-c64a4dd04273\">\u2013<\/span>glucose co-transporter-2 inhibitors.<\/em><\/p>\n<\/div>\n<p id=\"d77b49eb-810b-4c9e-9c84-6dec81e8de37\" class=\"jrnlSecPara\">The study by James\u00a0<span id=\"998c30ef-263e-4e30-9def-d958f55790f7\" class=\"styrm cts-3\">et al<\/span>. was a double-blinded RCT comparing 1-year outcomes of dapagliflozin 10 mg\/day with placebo initiated in patients with AMI within 10 days of the index event (Dapaglifozin Effects on Cradiometabolic Outcomes in Patients with an Acute Heart Attack [DAPA-MI]<span id=\"1b0836a0-b9e4-4c37-8176-9ad19ed021b8\" class=\"changeCase sty cts-4\"><\/span>; ClinicalTrials.gov identifier: NCT04564742).<span id=\"40464166-cb0b-47b0-a8df-44706b428291\" class=\"jrnlBibRef\" data-citation-string=\" R6 \"><sup id=\"215a759e-8e54-409b-bcdd-ac8d077b7637\">6<\/sup><\/span>\u00a0The study by Butler\u00a0<span id=\"3502ddaf-0e54-41b6-ae1f-73d0445535ae\" class=\"styrm cts-3\">et al<\/span>. was a double-blinded RCT comparing outcomes in patients receiving empagliflozin 10 mg\/day with placebo when initiated with 14 days of AMI, having a mean follow-up of around 18 months (Empagliflozin after Acute Myocardial Infarction [<span id=\"b9cb07ba-8bfa-4947-8eaf-f952b2c00828\">EMPACT-MI]: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack [Myocardial Infarction]<\/span>; ClinicalTrials.gov identifier: NCT04509674).<span id=\"45a99596-506a-429c-8469-0c72abde4fbe\" class=\"jrnlBibRef\" data-citation-string=\" R7 \"><sup id=\"da8b33a9-6146-4548-9425-1f4f0a8f9ee5\">7<\/sup><\/span>\u00a0The study by Dayem\u00a0<span id=\"04e9ca19-c93e-4f9c-b8d3-bedbeb14187a\" class=\"styrm cts-3\">et al<\/span><em id=\"931535d4-71bd-4d63-8384-18e5f385388d\" class=\"sty cts-2\">.<\/em>\u00a0was a double-blinded RCT comparing 12-week outcomes of the impact on NT-proBNP and echocardiography parameters after the initiation of dapagliflozin 10 mg\/day with placebo in patients with AMI (Impact of Dapagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-diabetic Patients [DACAMI trial];\u00a0<span id=\"a2a09585-3124-4b39-8e0e-cf17d60d2750\">ClinicalTrials.gov identifier: <\/span>NCT05424315).<span id=\"d9677737-10f3-4e5b-b2c9-e5ec3992308a\" class=\"jrnlBibRef\" data-citation-string=\" R8 \"><sup id=\"a63c32e7-d546-4c1e-b750-a9e01501dc84\">8<\/sup><\/span>\u00a0In the DACAMI trial, dapagliflozin was started within 72<span id=\"a7721e6d-4204-447e-bbed-3a527b5fc3c5\" class=\"nonBreakingSpace\">\u00a0<\/span>h of\u00a0<span id=\"6449a2ca-1327-4abb-83e3-e7db53104b38\">ST elevation myocardial infarction<\/span>.<span id=\"45705450-45fe-4e61-97e3-019c0ea5a33d\" class=\"jrnlBibRef\" data-citation-string=\" R8 \"><sup id=\"83f06dc0-f3c8-48e5-a358-e85f9efa3e06\">8<\/sup><\/span>\u00a0The study by von Lewinski\u00a0<span id=\"ab58756f-8ed7-4b1e-bedf-a7b88b1f63c4\" class=\"styrm cts-3\">et al<\/span><em id=\"89ed91a1-f3a2-40eb-a18a-fd5ccb4fb7f4\" class=\"sty cts-2\">.<\/em>\u00a0was a double-blinded RCT evaluating 26-week outcomes of the impact on NT-proBNP and echocardiographic parameters after the initiation of empagliflozin 10 mg\/day with placebo, initiated within 72<span id=\"469a59d8-7238-4699-b3b2-4aca7c43ae2a\" class=\"nonBreakingSpace\">\u00a0<\/span>h of PCI in patients with AMI (Empagliflozin in Acute Myocardial Infarction [EMMY trial];\u00a0<span id=\"b0c9f57e-7242-4077-920b-3349317838c7\">ClinicalTrials.gov identifier: <\/span>NCT03087773).<span id=\"015eb520-d45f-4208-85a8-1091db4e21b3\" class=\"jrnlBibRef\" data-citation-string=\" R9 \"><sup id=\"8469cc59-d0de-4ecc-902a-782167c6e92e\">9<\/sup><\/span>\u00a0Benedikt\u00a0<span id=\"4aff281e-38b4-4049-8a71-037b13c672bc\" class=\"styrm cts-3\">et al<\/span>. studied changes in inflammatory markers with empagliflozin therapy in the same cohort of patients with MI from the EMMY trial.<span id=\"dd99d00d-4f5a-4926-946b-feda8c739bc9\" class=\"jrnlBibRef\" data-citation-string=\" R19 \"><sup id=\"32b7c965-7069-44da-8a97-fca626079653\">19<\/sup><\/span>\u00a0Therefore, the results from this article have been analysed under von Lewinski\u00a0<span id=\"20bff499-c757-4101-b010-86b2c737d5c9\" class=\"styrm cts-3\">et al<\/span><em id=\"c91d8309-4353-4adb-83ef-afe4c97ed530\" class=\"sty cts-2\">.<\/em>\u00a0in this SRM. Sourij\u00a0<span id=\"2ce69ab5-2b6b-4241-adf8-83280df6cf4b\" class=\"styrm cts-3\">et al<\/span><em id=\"cce3dec1-7bf3-4b61-8d40-89dcc7f0bfe7\" class=\"sty cts-2\">.<\/em>\u00a0analysed the gender differences in response to empagliflozin therapy after AMI in the cohort of patients of the EMMY trial.<span id=\"c20b7440-bbe7-41c1-8520-322d2ed05070\" class=\"jrnlBibRef\" data-citation-string=\" R20 \"><sup id=\"3e835775-e4e9-4f08-89e4-8201bfd867a4\">20<\/sup><\/span>\u00a0<span id=\"3c59b7ed-5061-49fb-967c-8cd82e6b9b8d\" class=\"styrm cts-3\"><\/span><em id=\"41925d65-df7f-451f-84c2-72c6e4582ab9\" class=\"sty cts-2\"><\/em>The study by Mozawa\u00a0<span id=\"175d6257-ba63-47f6-b1c9-7ffdaa5a61e7\" class=\"styrm cts-3\">et al<\/span><em id=\"7f7797cc-40d5-489c-a0aa-fbb49937d106\" class=\"sty cts-2\">.<\/em>\u00a0was a double-blinded RCT evaluating the impact of empagliflozin 10 mg\/day compared with placebo initiated within 2 weeks of AMI in Japanese patients (Effects of Empagliflozin versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus [EMBODY trial]: UMIN000030158]).<span id=\"e40d4438-7ae5-4103-a430-afb415ef2348\" class=\"jrnlBibRef\" data-citation-string=\" R21 \"><sup id=\"0c3632b5-c5a4-4736-a0f0-a4e32858fdc1\">21<\/sup><\/span>\u00a0The article by Hoshika\u00a0<span id=\"e116e8fe-7fde-4ba1-a803-4e05bd05daba\" class=\"styrm cts-3\">et al<\/span><em id=\"199fda23-d19d-4409-88dc-76e316ce00da\" class=\"sty cts-2\">.<\/em>\u00a0was from the same cohort of patients in the EMBODY trial.<span id=\"4224f272-7a5c-4a14-ade6-8b4afa31d059\" class=\"jrnlBibRef\" data-citation-string=\" R22 \"><sup id=\"538c7a79-25cd-41d4-8b35-b386226971be\">22<\/sup><\/span>\u00a0Therefore, the results from this study have been presented under Mozawa\u00a0<span id=\"a08368a6-e5da-4917-86a9-d7adbfbec65e\" class=\"styrm cts-3\">et al<\/span><em id=\"d6436885-75f3-4eae-9e9e-e95efc599ee7\" class=\"sty cts-2\">.<\/em>\u00a0in this SRM. The study by Adel\u00a0<span id=\"98b30241-b549-41e8-8787-7877e45e55bf\" class=\"styrm cts-3\">et al<\/span><em id=\"5ccdeea1-8d8a-48b6-960c-521b26f4c1ff\" class=\"sty cts-2\">.<\/em>\u00a0evaluated the impact of empagliflozin 10 mg\/day compared with placebo in improving CV outcomes in patients with diabetes with acute coronary syndrome (ACS) after PCI.<span id=\"ffff8a01-37bd-4955-b0da-30e8b5a8fadf\" class=\"jrnlBibRef\" data-citation-string=\" R23 \"><sup id=\"2de695c2-5742-4238-8a04-676098aec032\">23<\/sup><\/span>\u00a0The details of the studies included in this SRM have been elaborated in\u00a0<em><span class=\"jrnlTblRef\" data-citation-string=\" T1 \">Table 1<\/span><\/em>.<span id=\"783bbeea-db74-4ad3-baea-19d12fcdb55c\" class=\"jrnlBibRef\" data-citation-string=\" R6 R7 R8 R9 R19 R20 \"><sup id=\"8a93ef10-2425-48be-bac0-a284d1858d13\">6\u20139,19,20<\/sup><\/span><\/p>\n<div id=\"BLK_T1\" class=\"jrnlTblBlock\">\n<h2 id=\"T1\" class=\"jrnlTblCaption\"><span id=\"c6a7038e-f128-4a08-a73e-4c438ef08340\" class=\"label\">Table 1: <\/span>Baseline characteristics of patients in the randomized controlled trials analysed in this systematic review and meta-analysis<span id=\"e9dcf0b3-03ef-454d-a393-c651fce15fc7\" class=\"jrnlBibRef\" data-citation-string=\" R6 R7 R8 R9 R19 R20 \"><sup id=\"18a68a86-8edb-42aa-aa84-51cf390872c7\">6\u20139,19,20<\/sup><\/span><\/h2>\n<div class=\"jrnlTblContainer\">\n<table id=\"a9a380ce-71a9-4074-a944-0faf7144cd30\" class=\"jrnlTable\">\n<thead id=\"ddd74f63-a7bf-470c-897a-2f314fce9ca4\">\n<tr id=\"03a95eb1-ef1a-42c7-840f-2a5af4d6450c\">\n<td id=\"5e649729-a77d-4229-b957-3260a2c1692e\" class=\"\" colspan=\"2\" rowspan=\"2\">\n<p id=\"8c81b1ea-9897-46d8-a281-07ef4bfa88cc\" class=\"jrnlTblBody\">Parameter<\/p>\n<\/td>\n<td id=\"9cfeb704-43e5-43d9-8660-392376583add\" class=\"\" colspan=\"2\">\n<p id=\"f0a92dc1-f3bf-467f-9ad6-24901040ec57\" class=\"jrnlTblBody\">Adel 2022<span id=\"1f9d88ca-011c-4c2d-b2b1-5efca9565bfc\" class=\"jrnlBibRef\" data-citation-string=\" R20 \"><sup id=\"006aa8c5-8b43-4584-84d3-3d4ed8637d5d\">20<\/sup><\/span><\/p>\n<\/td>\n<td id=\"4dbf9fe3-96c6-4885-9a7e-d6c5da652502\" class=\"\" colspan=\"2\">\n<p id=\"4161718f-deee-49bc-9d65-0316b5cb8638\" class=\"jrnlTblBody\">Butler 2024 (EMPACT-MI\u00a0<span id=\"ca06b1c3-3c7b-4040-9606-58f68f5c6a56\" class=\"changeCase sty cts-3\">trial<\/span>)<span id=\"52744eb5-e885-4264-a907-3f9181313d9a\" class=\"jrnlBibRef\" data-citation-string=\" R7 \"><sup id=\"e5b74fe2-66ae-49e4-8fb8-5eb68f7745d2\">7<\/sup><\/span><\/p>\n<\/td>\n<td id=\"de35447b-004a-4d8e-9e48-f97f65617417\" class=\"\" colspan=\"2\">\n<p id=\"c606a25e-eb02-4635-92cc-d2dd5d124b43\" class=\"jrnlTblBody\"><span id=\"faf68f11-f3a0-4a07-8e66-5e69b55078af\">Dayem 2023<\/span>\u00a0(DACAMI\u00a0<span id=\"1171192b-6bd2-4059-aa2e-fdfd316874ff\" class=\"changeCase sty cts-3\">trial<\/span>)<span id=\"cb7c8e09-ba77-4714-9d03-344d1512b4df\" class=\"jrnlBibRef\" data-citation-string=\" R8 \"><sup id=\"e82ac5c4-f36a-4419-b937-a4be42a1fa04\">8<\/sup><\/span><\/p>\n<\/td>\n<td id=\"69e9257f-7429-4555-a21d-6add57bd2f7e\" class=\"\" colspan=\"2\">\n<p id=\"6f178a3f-1a00-491d-92b0-732b35107bd6\" class=\"jrnlTblBody\"><span id=\"d92ec1e6-299a-496c-a487-62307d153ff4\">James 2024<\/span>\u00a0(DAPA-MI\u00a0<span id=\"d73f82ed-ef9f-447a-a9ff-87fba5d79d8d\" class=\"changeCase sty cts-4\">trial<\/span>)<span id=\"040ea5bb-b751-48cf-b76e-a88c2a04d56f\" class=\"jrnlBibRef\" data-citation-string=\" R6 \"><sup id=\"590ef21f-563c-4902-bcaa-01195b079719\">6<\/sup><\/span><\/p>\n<\/td>\n<td id=\"1e31ac27-d3a7-404b-a729-3021355343ed\" class=\"\" colspan=\"2\">\n<p id=\"dac320c9-d14e-4f41-9659-eb3a6459e8a9\" class=\"jrnlTblBody\"><span id=\"ea788d0a-4ac0-4cd3-9e02-da27e8941a05\">Mozawa 2021<\/span>\u00a0(EMBODY\u00a0<span id=\"6aa51b89-ce3a-4945-b117-730b7524d098\" class=\"changeCase sty cts-4\">trial<\/span>)<span id=\"23b26f07-4b9a-4192-8674-ec5d8187b229\" class=\"jrnlBibRef\" data-citation-string=\" R19 \"><sup id=\"9bd0bfc9-8789-436b-bc54-4e1d56be6356\">19<\/sup><\/span><\/p>\n<\/td>\n<td id=\"54c50273-9d74-46af-b9d1-7852912d8a75\" class=\"\" colspan=\"2\">\n<p id=\"6c3936e1-754a-4b2b-bc86-d5a4c7414253\" class=\"jrnlTblBody\"><span id=\"f49f754d-1aac-4239-b050-7f229d2156c2\">von Lewinski 2022<\/span>\u00a0(EMMY\u00a0<span id=\"fd5e91cb-dd42-4e34-8509-b2b90ca54d54\" class=\"changeCase sty cts-4\">trial<\/span>)<span id=\"1476e33c-e694-4c69-b273-02f2de78e39d\" class=\"jrnlBibRef\" data-citation-string=\" R9 \"><sup id=\"c77b732a-6d5d-4dd5-9680-2909c9092ce4\">9<\/sup><\/span><\/p>\n<\/td>\n<\/tr>\n<tr id=\"a3bf776b-21e4-4dac-9ba4-427b86155b7a\">\n<td id=\"73f3562f-0b86-428b-b97d-9bb0a4cbdc24\" class=\"\">\n<p id=\"63a8cc34-9f85-4fea-a0f1-1fcb7db1dfe3\" class=\"jrnlTblBody\">Empagliflozin (n=45)<\/p>\n<\/td>\n<td id=\"4c44ae00-41b2-41bb-9282-35b7e9662c29\" class=\"\">\n<p id=\"e32f4fbc-d12d-462f-86e2-82a42264452c\" class=\"jrnlTblBody\">Control\/placebo (n=48)<\/p>\n<\/td>\n<td id=\"aa807093-6e45-49c6-9b0c-8b4654f84d52\" class=\"\">\n<p id=\"f2da3b85-8391-47ac-b003-f26d4a6c7d80\" class=\"jrnlTblBody\">Empagliflozin (n=3,260)<\/p>\n<\/td>\n<td id=\"8c5e8c98-e1fd-44a3-bec6-1575d106a708\" class=\"\">\n<p id=\"4a623720-952f-4876-8a51-15ae85d8b648\" class=\"jrnlTblBody\">Control\/placebo (n=3,262)<\/p>\n<\/td>\n<td id=\"d5719d0d-a548-4c4a-99ce-8200dcec1d4d\" class=\"\">\n<p id=\"fc5a7fb3-ff06-4a76-bd84-a3a5dfea7ed7\" class=\"jrnlTblBody\">Dapagliflozin (n=50)<\/p>\n<\/td>\n<td id=\"c2eb800e-7757-417a-8032-2796ec9b2b65\" class=\"\">\n<p id=\"68e1eaa8-f2d9-4a22-973a-8b00ece76ba8\" class=\"jrnlTblBody\">Control (n=50)<\/p>\n<\/td>\n<td id=\"e3b7d16a-bba2-4fb0-be55-27c8c3ce5016\" class=\"\">\n<p id=\"b3c8a633-a98e-4716-ba8e-abddc00ea01a\" class=\"jrnlTblBody\">Dapagliflozin (n=2,019)<\/p>\n<\/td>\n<td id=\"034229c5-4d12-43f7-bf7f-c9c7b16dc3fb\" class=\"\">\n<p id=\"5e0bf5a1-b2df-4de1-9228-247e149ed45f\" class=\"jrnlTblBody\">Control\/placebo (n=1,998)<\/p>\n<\/td>\n<td id=\"f682210f-c1e8-4890-938e-91ff7626f053\" class=\"\">\n<p id=\"deb9d8f8-4b51-4ff6-b248-97d31c7d30ee\" class=\"jrnlTblBody\">Empagliflozin (n=46)<\/p>\n<\/td>\n<td id=\"80f3d16e-f4e3-4e66-a759-cb49167b4732\" class=\"\">\n<p id=\"4bb9d173-4e26-4c42-9dcb-647ab7d1f52c\" class=\"jrnlTblBody\">Control\/placebo (n=50)<\/p>\n<\/td>\n<td id=\"a236ebff-e18c-40b4-9ff2-f9d6b1862ca8\" class=\"\">\n<p id=\"d4218cdf-17f9-4fac-8037-dfb08669c516\" class=\"jrnlTblBody\">Empagliflozin (n=237)<\/p>\n<\/td>\n<td id=\"4b762a54-a327-4917-9294-af8c8366ea62\" class=\"\">\n<p id=\"edc13152-1804-4705-9a8f-4a72adbf6da7\" class=\"jrnlTblBody\">Control\/placebo (n =239)<\/p>\n<\/td>\n<\/tr>\n<\/thead>\n<tbody id=\"554bd8f7-a23f-4cdb-a47a-a3dd14fd6ffc\">\n<tr id=\"fc011e36-f43a-4dd8-a587-d015e34fecb2\">\n<td id=\"789afa14-efba-43d4-94c1-455e8d7fa90f\" class=\"\" colspan=\"2\">\n<p id=\"970de38d-7ec9-441d-b0b7-49a3ed5d5f89\" class=\"jrnlTblBody\">Age (years)<\/p>\n<\/td>\n<td id=\"183d3234-9aef-453f-ae30-3ea5f6b2d00c\">\n<p id=\"fea32f13-2e9a-4ad4-9004-3ae1196d72ec\" class=\"jrnlTblBody\">55 (45.5\u201364)<\/p>\n<\/td>\n<td id=\"3327daf2-aa23-4e93-82bc-5cb36b3f2edb\" class=\"\">\n<p id=\"de2e54c4-6ee8-4eea-9271-3b460e0342ed\" class=\"jrnlTblBody\">57 (50\u201366.75)<\/p>\n<\/td>\n<td id=\"8d73bf56-bea1-4e9c-84af-07df5106d44e\" class=\"\">\n<p id=\"b6ca8548-5443-405f-85c7-20a651b3b4d7\" class=\"jrnlTblBody\">63.6 \u00b1 11.0<\/p>\n<\/td>\n<td id=\"786c2b77-5e11-48df-8441-0c8c3750b677\" class=\"\">\n<p id=\"2f8a02a0-9a83-4966-a329-0793d832ed4b\" class=\"jrnlTblBody\">63.7 \u00b1 10.8<\/p>\n<\/td>\n<td id=\"f6de5648-a1b6-4c0e-95ec-404346ec61b4\" class=\"\">\n<p id=\"8b2affad-54b1-431e-85e4-115e53b88957\" class=\"jrnlTblBody\">55.24 \u00b1 13.2<\/p>\n<\/td>\n<td id=\"acb604cf-2477-4fbc-853a-3c2a7c358b27\" class=\"\">\n<p id=\"33c58f59-158b-470c-a77b-dbd25c42a318\" class=\"jrnlTblBody\">56.70 \u00b1 11.5<\/p>\n<\/td>\n<td id=\"f390b3cd-e1ff-422c-9b66-7bd1fd08f83a\" class=\"\">\n<p id=\"c4a5228d-63e8-437f-80e8-e2c15f6cfec1\" class=\"jrnlTblBody\">63.0 \u00b1 11.06<\/p>\n<\/td>\n<td id=\"7600f44f-cfec-414b-86b2-7d656394879a\" class=\"\">\n<p id=\"8aed25e9-8504-4697-8590-989406a0d740\" class=\"jrnlTblBody\">62.8 \u00b1 10.64<\/p>\n<\/td>\n<td id=\"db48be61-0762-4f1d-a94e-6785550e3f46\">\n<p id=\"3b70882c-7050-43ab-b817-a69353d56fce\" class=\"jrnlTblBody\">63.9 (10.4)<\/p>\n<\/td>\n<td id=\"edb01e94-2dca-4866-b40d-2aa93d0fc4e9\" class=\"\">\n<p id=\"eaa597ba-67b6-48dc-9ef5-a7d4a5515d4e\" class=\"jrnlTblBody\">64.6 \u00b1 11.6<\/p>\n<\/td>\n<td id=\"05406467-d363-4587-8a32-798bd4164870\">\n<p id=\"48e1d563-02f1-4583-9ecb-a34cb5b96d27\" class=\"jrnlTblBody\">57 (52\u201364)<\/p>\n<\/td>\n<td id=\"7e9d4c2f-788b-4e09-9bee-62239c16046e\">\n<p id=\"a166911d-9160-488d-a11b-6962b0d41331\" class=\"jrnlTblBody\">57 (52\u201365)<\/p>\n<\/td>\n<\/tr>\n<tr id=\"8404bdbc-3f4b-4764-a552-504e9ec9bb74\">\n<td id=\"f53992a2-53f3-470b-b8d2-ff01ff3c27fe\" class=\"\" colspan=\"2\">\n<p id=\"c2819a17-609e-4675-bb57-40d1e3706c78\" class=\"jrnlTblBody\">Male sex (%)<\/p>\n<\/td>\n<td id=\"19b5dd52-3845-4f7e-956d-129ccb1dba2b\" class=\"\">\n<p id=\"258ead56-5e65-4ac5-a666-25f5c04ccb53\" class=\"jrnlTblBody\">60.0<\/p>\n<\/td>\n<td id=\"cb214459-d8b3-4274-8e7d-21fccc7e02d1\" class=\"\">\n<p id=\"818e5b24-5b3d-4976-bd77-701ff692dc62\" class=\"jrnlTblBody\">60.4<\/p>\n<\/td>\n<td id=\"09ba6fcc-109f-4966-a248-636d3cb17bb5\" class=\"\">\n<p id=\"b51567af-8a97-461b-8103-6fbf65537b98\" class=\"jrnlTblBody\">75.1<\/p>\n<\/td>\n<td id=\"774e7a96-fa73-4ee4-8699-b2ab4321d643\" class=\"\">\n<p id=\"c6dea9e6-45ea-43f0-bb1b-7423bb45d21b\" class=\"jrnlTblBody\">75.1<\/p>\n<\/td>\n<td id=\"5895df23-2cd4-4acf-bd7a-c39336912fb2\" class=\"\">\n<p id=\"a63ed960-f213-4a29-82d0-31ab3987e77f\" class=\"jrnlTblBody\">84<\/p>\n<\/td>\n<td id=\"a5b888e8-70bd-4f49-897c-ab7027957e9f\" class=\"\">\n<p id=\"aecbb549-9222-43f3-b05e-cadf20c9e648\" class=\"jrnlTblBody\">82<\/p>\n<\/td>\n<td id=\"8da217bd-662e-4af2-9497-16c339c2f63a\" class=\"\">\n<p id=\"3c4eb8b8-53fa-47e8-91bc-1fe8bdda921e\" class=\"jrnlTblBody\">80.8<\/p>\n<\/td>\n<td id=\"f293076f-f6a7-4a00-9318-adad3a15f6b0\" class=\"\">\n<p id=\"86e3e912-dff6-4fc9-9266-4f03c49f87c4\" class=\"jrnlTblBody\">79.0<\/p>\n<\/td>\n<td id=\"8f546eb8-b463-43f8-b882-0f7d8e136e01\" class=\"\">\n<p id=\"53d26da0-1f38-4940-a5c9-638e68e4bc21\" class=\"jrnlTblBody\">82.6<\/p>\n<\/td>\n<td id=\"0a30dd25-11fd-483f-9811-f156e1c45ce3\" class=\"\">\n<p id=\"8cf6f113-b4f7-4dd9-a0bf-09986e8f5d2a\" class=\"jrnlTblBody\">78<\/p>\n<\/td>\n<td id=\"5a0efbbd-574e-44f8-ba38-8baebeda3ecd\" class=\"\">\n<p id=\"1a30c7cc-ee07-4e4f-b13e-e3c6f429ce0d\" class=\"jrnlTblBody\">82<\/p>\n<\/td>\n<td id=\"b91add34-d706-4a5f-99a6-f8568d47bbdd\" class=\"\">\n<p id=\"67ac5329-f423-4966-b267-310ffd9ad6d1\" class=\"jrnlTblBody\">82<\/p>\n<\/td>\n<\/tr>\n<tr id=\"39759d0b-b783-48a7-ac30-58b1c9fd064b\">\n<td id=\"ae1ad46d-2e51-4892-870b-1ecaa756285c\" class=\"\" colspan=\"2\">\n<p id=\"0d314e59-1c1a-46db-841e-d7b7984fb8df\" class=\"jrnlTblBody\">Weight (kg)<\/p>\n<\/td>\n<td id=\"c5082f22-eee8-4809-85aa-7824541b748b\" class=\"\">\n<p id=\"5c443ec0-f1ab-47b6-83ff-ca05bb898627\" class=\"jrnlTblBody\">75 (67.5\u201384.5)<\/p>\n<\/td>\n<td id=\"ec6774d0-7879-448e-817e-10d5c05113c3\" class=\"\">\n<p id=\"bbcff53a-8fed-4db8-949f-3a656bb78623\" class=\"jrnlTblBody\">69.5 (65\u201383.75)<\/p>\n<\/td>\n<td id=\"695e30bd-d6fb-4617-b878-9443c9fb6fd5\" class=\"\">\n<p id=\"3c2b24f2-c6e7-4c1e-8c8d-0ea8f34a10cb\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"5dde485c-eaea-4277-9a3b-7df4e5a163d1\" class=\"\">\n<p id=\"225f14ee-9174-4aef-b2bd-dc1fa894e4b3\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"78b4ff3a-95f2-4f98-b219-c5403bc6097f\" class=\"\">\n<p id=\"5096c0a3-9449-4af4-91ae-f4f3b07169ce\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"d39ed9c3-9be2-4990-b632-d4d6f321cd02\" class=\"\">\n<p id=\"ea52f260-e7c1-4432-accb-34b8ea919fab\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"c815014c-a224-4e7f-9937-6a92affdead3\" class=\"\">\n<p id=\"300506ac-43ef-47e4-8a36-30218309d3b1\" class=\"jrnlTblBody\">85.5 \u00b1 15.87<\/p>\n<\/td>\n<td id=\"eadb6b35-8852-4393-9f52-acda1392fee3\" class=\"\">\n<p id=\"3884c604-a21e-4e40-bf6b-3a21061ea06f\" class=\"jrnlTblBody\">85.5 \u00b1 16.54<\/p>\n<\/td>\n<td id=\"8aaf6507-7e87-4511-bf94-8e250a9d4fc0\" class=\"\">\n<p id=\"79ef1d1c-9f05-4937-9e30-0cf0981bfa20\" class=\"jrnlTblBody\">70.1 \u00b1 13.7<\/p>\n<\/td>\n<td id=\"d65fee4d-3a24-4e3a-8efb-55794399c912\" class=\"\">\n<p id=\"e25ee64a-b404-4f39-b161-d463ec1ca5bf\" class=\"jrnlTblBody\">68.1 \u00b1 14.4<\/p>\n<\/td>\n<td id=\"9c554106-354b-4427-ae35-29f9958932d8\" class=\"\">\n<p id=\"8ca4059b-9bb4-4366-8f96-956862491899\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"1ab87d9a-50f1-4f93-a9e9-c9a8cded3231\" class=\"\">\n<p id=\"28978729-42dd-4e4d-bdfa-f3518cd00865\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<\/tr>\n<tr id=\"5684987b-e03e-4307-81e5-7be43b0a4ed3\">\n<td id=\"33bf068d-b9fd-48aa-b776-e12085e766b2\" class=\"\" colspan=\"2\">\n<p id=\"d9b017c0-529b-4840-92e1-e04b77c2ffd0\" class=\"jrnlTblBody\">BMI (kg\/m<sup id=\"b9196bde-792d-4ff6-863d-7c3007c8698a\" class=\"sty cts-2\">2<\/sup>)<\/p>\n<\/td>\n<td id=\"459d9c07-c0d0-4b64-a5bb-26752f8f8fa2\" class=\"\">\n<p id=\"6ee81130-28b0-4628-b407-39e873375d90\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"806b3f8b-7123-4165-b476-29956f1023ac\" class=\"\">\n<p id=\"08a9f495-422a-4aba-b947-53aff593b9b1\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"0bac87d1-1755-4eb3-bc49-6b6c64dc8178\" class=\"\">\n<p id=\"826a0ab5-2f64-4b41-a155-83fb3314cdad\" class=\"jrnlTblBody\">28.1 \u00b1 5<\/p>\n<\/td>\n<td id=\"25f8796f-f270-42e0-b703-47d17d87e0c6\" class=\"\">\n<p id=\"f40b641a-346f-410d-8a43-3950c6228aa1\" class=\"jrnlTblBody\">28.1 \u00b1 5<\/p>\n<\/td>\n<td id=\"1a43ac29-d002-4a64-8019-749fe17f5bdf\" class=\"\">\n<p id=\"b72f69ca-8ef0-4c46-9073-8bd06967cd93\" class=\"jrnlTblBody\">29.96 \u00b1 4.9<\/p>\n<\/td>\n<td id=\"d0acef88-470c-425b-a329-f13cb8cd68a9\" class=\"\">\n<p id=\"feaaa6bf-390f-43f3-90a3-3114e9c0843c\" class=\"jrnlTblBody\">30.13 \u00b1 4.6<\/p>\n<\/td>\n<td id=\"9fe7669e-15ab-459b-8670-a89f5b2e9770\" class=\"\">\n<p id=\"eaf1fe7a-06bc-40a7-ac55-a4c3ecacc758\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"34af5cd2-c5a1-42d0-8ad6-a688d5480061\" class=\"\">\n<p id=\"8f172129-97c2-4ea1-87ea-2eca2d61a678\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"9aa9387a-041c-4b56-ac35-3bde9fb07922\" class=\"\">\n<p id=\"53c8944e-9c05-4d3a-8ecd-a3dd9ff3d7b4\" class=\"jrnlTblBody\">25.2 \u00b1 3.7<\/p>\n<\/td>\n<td id=\"72f6cb98-f7df-4352-9d6b-ae7d0e5aab40\" class=\"\">\n<p id=\"cbd5f4cb-50e5-40a2-b080-c46c6cc716df\" class=\"jrnlTblBody\">25.2 \u00b1 4.1<\/p>\n<\/td>\n<td id=\"62a662ad-ad00-47d8-aa3b-51edba1aaaaa\" class=\"\">\n<p id=\"fc9207d5-4f78-4a21-85e8-53ec5d69d76e\" class=\"jrnlTblBody\">27.7 (25.3\u201330.3)<\/p>\n<\/td>\n<td id=\"f884fcf2-f4c4-42e0-9a77-ae77be62ef9d\">\n<p id=\"8f0614e9-3e54-4fb3-859e-0d2770f920bb\" class=\"jrnlTblBody\">27.2 (24.9\u201330.2)<\/p>\n<\/td>\n<\/tr>\n<tr id=\"3ced38b5-3629-4667-8afc-5a2f711e4798\">\n<td id=\"b2134d13-2554-43e7-826d-dd324b1d2589\" class=\"\" colspan=\"2\">\n<p id=\"7f710afc-7d34-4be9-afe9-cf4f4c8ab6c3\" class=\"jrnlTblBody\">SBP (mm Hg)<\/p>\n<\/td>\n<td id=\"6e5bbeaf-4cd8-4c3e-aa17-4304c75b26f9\" class=\"\">\n<p id=\"9d5f77bb-75e2-4881-810a-a8270100fa99\" class=\"jrnlTblBody\">130 (116.25\u2013150)<\/p>\n<\/td>\n<td id=\"37c3446c-16b3-41a6-8fa3-32ce2e9fbe46\" class=\"\">\n<p id=\"6d6f9828-738a-407e-958c-8ba598acabde\" class=\"jrnlTblBody\">130 (116.25\u2013140)<\/p>\n<\/td>\n<td id=\"30f49518-9159-4521-a7c0-9fbcddb85bc5\">\n<p id=\"607aa38a-0c30-460b-b0ea-341c389e2f22\" class=\"jrnlTblBody\">120.3 (14.6)<\/p>\n<\/td>\n<td id=\"8c36b4ec-eedb-4a04-a011-923f639878c3\">\n<p id=\"41752482-1f5f-40d0-89ca-73f74590b5c5\" class=\"jrnlTblBody\">120.5 (15.2)<\/p>\n<\/td>\n<td id=\"c2c0d97a-8f3a-4fd5-9a70-e0fd725cdce8\" class=\"\">\n<p id=\"f5cd1710-1596-4031-a0f9-e46f56e6239b\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"f9ddc870-b399-4301-9d57-6f925ccf937f\" class=\"\">\n<p id=\"c344a0fe-75d3-4740-a604-892f24489749\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"fdf36cc2-c91f-499d-999a-5dc5896ed487\" class=\"\">\n<p id=\"f9e5feb6-01d9-4fd8-ac5a-5b47486fcd4a\" class=\"jrnlTblBody\">119.1 \u00b1 16.23<\/p>\n<\/td>\n<td id=\"e08e7ec7-424e-4ff1-bfb7-c626168ecf4f\" class=\"\">\n<p id=\"bf670787-2d43-41a3-9cc5-d1a0feddf9ea\" class=\"jrnlTblBody\">118.7 \u00b1 16.62<\/p>\n<\/td>\n<td id=\"bac15945-53cd-4ec9-9008-0bb165faacce\" class=\"\">\n<p id=\"6c719ac1-0ef1-4e47-80ea-942e4601f773\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"89f762bb-abb3-496c-b018-6cb6098ebbec\" class=\"\">\n<p id=\"5f4b3965-1eeb-444e-9605-9a9ed423823d\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"9830df13-31d8-44f5-a1d2-49fb13c6ebd1\" class=\"\">\n<p id=\"87163bc4-b237-4135-8e76-556fda130c64\" class=\"jrnlTblBody\">125 (116\u2013131)<\/p>\n<\/td>\n<td id=\"54abbfa0-dd49-4e3d-b817-2cb1e91a7f2e\" class=\"\">\n<p id=\"adb51914-75dc-4817-9506-1fd19c40b928\" class=\"jrnlTblBody\">125 (118\u2013131)<\/p>\n<\/td>\n<\/tr>\n<tr id=\"7934b08c-0fad-4648-9649-05ff4ae46dd7\">\n<td id=\"9b333814-a0a2-4bb7-b5c6-2f6fab9c4cc6\" class=\"\" colspan=\"2\">\n<p id=\"f70c883e-526a-474d-bb99-51f87d7bd774\" class=\"jrnlTblBody\">eGFR<\/p>\n<p id=\"426bc73f-576c-46e5-91d2-05eb8c716d08\" class=\"jrnlTblBody\">(mL\/min\/1.73 m<sup id=\"8ea98225-ae3b-4c7d-868c-f706c8b8fa30\">2<\/sup>)<\/p>\n<\/td>\n<td id=\"43159437-070b-44dc-8814-e2691d90a97c\" class=\"\">\n<p id=\"197c149a-df9b-42f3-9bf7-bac0028bea2b\" class=\"jrnlTblBody\">72 (61\u201383)<\/p>\n<\/td>\n<td id=\"7b52cb1d-62e3-4a51-a59e-da6fd8ae2976\" class=\"\">\n<p id=\"93afd5ee-f524-466b-95f8-1df121c62ed1\" class=\"jrnlTblBody\">76 (61.25\u201381)<\/p>\n<\/td>\n<td id=\"c573b7b6-8422-44a9-93f1-964434b8299e\" class=\"\">\n<p id=\"5dd27599-e398-4872-a0eb-7acf2b094c80\" class=\"jrnlTblBody\">77.5 (62.2\u201391.0)<\/p>\n<\/td>\n<td id=\"ca8188f3-9ea9-48ef-a1e5-ec26e3755d35\" class=\"\">\n<p id=\"df727aee-6522-4e8d-b238-df5fd0698521\" class=\"jrnlTblBody\">78.0 (61.7\u201391.4)<\/p>\n<\/td>\n<td id=\"4c4ef193-22ec-42dd-88ce-cf073a9e235e\" class=\"\">\n<p id=\"2922b1ff-42b4-477f-ac0c-b6f4fbd10b0a\" class=\"jrnlTblBody\">82.61 \u00b1 14.31<\/p>\n<\/td>\n<td id=\"6ffda9f6-8604-434d-ae5d-f4fabebcffea\" class=\"\">\n<p id=\"d9566ee7-e082-4c2f-a171-1d5c4f2d3dcb\" class=\"jrnlTblBody\">85.49 \u00b1 13.49<\/p>\n<\/td>\n<td id=\"82217723-9fa4-4dbb-ad0b-ef522e582579\" class=\"\">\n<p id=\"98ad2c19-a458-4c8d-b8b9-dadbbd55a6c4\" class=\"jrnlTblBody\">83.5 \u00b1 17.12<\/p>\n<\/td>\n<td id=\"f274c406-a248-465a-bd4a-353a468140d0\" class=\"\">\n<p id=\"439ee724-03bf-4517-86f6-f3f0b1c62d00\" class=\"jrnlTblBody\">83.4 \u00b1 16.91<\/p>\n<\/td>\n<td id=\"4f1f1847-5067-424b-9356-0fe1d339fba2\" class=\"\">\n<p id=\"40839e93-e82a-4103-b8c9-6a013976c8fa\" class=\"jrnlTblBody\">64.60 \u00b1 14.95<\/p>\n<\/td>\n<td id=\"0d9f7b7f-c5a2-440c-8395-d38398ff223e\" class=\"\">\n<p id=\"b0787b9a-41a4-4822-95da-794c430ffe78\" class=\"jrnlTblBody\">66.14 \u00b1 15.72<\/p>\n<\/td>\n<td id=\"a1c539f6-5b64-484f-bc3b-7f184ca5a8f6\" class=\"\">\n<p id=\"2e2ecf08-6d26-487c-a5a8-eea144e54430\" class=\"jrnlTblBody\">92 (78\u2013101)<\/p>\n<\/td>\n<td id=\"d74609de-eaa0-459c-8aa8-4f700c291246\" class=\"\">\n<p id=\"f7339184-bc53-4d33-b357-9fef32bab3ef\" class=\"jrnlTblBody\">91 (78\u2013102)<\/p>\n<\/td>\n<\/tr>\n<tr id=\"64cff207-ba7e-4f6d-983f-4651776ca00b\">\n<td id=\"df500280-642e-4bb9-995b-8c06f692e0e9\" class=\"\" colspan=\"2\">\n<p id=\"8c6f6bbf-22da-4549-9847-e80ee55b13d3\" class=\"jrnlTblBody\">HbA1c (%)<\/p>\n<\/td>\n<td id=\"cc912107-3148-427d-baf0-a60ba2bdb4f4\" class=\"\">\n<p id=\"ec615c15-7653-446e-b5c5-4c190ff4e75c\" class=\"jrnlTblBody\">7.8 (7.2\u20138.45)<\/p>\n<\/td>\n<td id=\"124998c3-0470-4d71-abb4-db79251f6a16\" class=\"\">\n<p id=\"bb8a1509-4108-4fe0-be9b-f33ab3bbbb2c\" class=\"jrnlTblBody\">7.8 (7.1\u20138.05)<\/p>\n<\/td>\n<td id=\"1a4bb556-e121-49a0-a312-4ae7c63d2e07\" class=\"\">\n<p id=\"caf0f01b-4c44-44f4-9808-5e074b4338fe\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"e90de65a-c352-4903-9f29-a9a7d263a133\" class=\"\">\n<p id=\"07daf93c-d551-4a4c-8cf4-c8ba85f10ffa\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"43badbf5-165e-41a1-9d2d-82e614e0df01\" class=\"\">\n<p id=\"96eaf858-7433-4bba-9bb3-a27b7480b68a\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"72a34067-2722-41d8-af75-8805d8e638da\" class=\"\">\n<p id=\"b802ca00-6e75-48bb-9e05-bc1caf632b54\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"20d3a88c-b090-4225-b2bc-c6a1b400c04b\" class=\"\">\n<p id=\"059ecdc6-a087-4b0d-9a1d-8cbe4397fe85\" class=\"jrnlTblBody\">5.7 \u00b1 0.58<\/p>\n<\/td>\n<td id=\"34350fe3-5cc5-405c-b8a8-1b02112538fa\" class=\"\">\n<p id=\"4290c609-2191-4c04-8e35-2c864f8408f6\" class=\"jrnlTblBody\">5.7 \u00b1 0.51<\/p>\n<\/td>\n<td id=\"8eb1045e-5e94-4460-a5c4-20584306a4d8\" class=\"\">\n<p id=\"792ba744-3f5d-4a89-baac-42cb9b870766\" class=\"jrnlTblBody\">6.82 \u00b1 1.00<\/p>\n<\/td>\n<td id=\"d7cbcd4d-c63a-4541-839e-251f0d3ac592\" class=\"\">\n<p id=\"bf011d54-b502-4e20-bb1c-7baf1ef5c598\" class=\"jrnlTblBody\">6.89 \u00b1 0.92<\/p>\n<\/td>\n<td id=\"0d27b891-0474-45ce-921e-b269d1bee380\" class=\"\">\n<p id=\"fbab6ef6-f719-4f79-b049-bbe23031a438\" class=\"jrnlTblBody\">5.60 (5.40\u20136.00)<\/p>\n<\/td>\n<td id=\"7967c5da-bd9e-46a4-a548-64af1092ba85\" class=\"\">\n<p id=\"3b07c15e-fec7-464d-a955-d9df2705a646\" class=\"jrnlTblBody\">5.70 (5.40\u20136.00)<\/p>\n<\/td>\n<\/tr>\n<tr id=\"da9b5dc5-2c6d-4005-ada8-15f023bc649d\">\n<td id=\"168cb480-ef89-4382-8111-10da8e81b2fc\" class=\"\" rowspan=\"2\">\n<p id=\"07e69b23-611f-4abe-b325-051fdbcff210\" class=\"jrnlTblBody\">Index MI (%)<\/p>\n<\/td>\n<td id=\"ace5c1fb-1490-47f8-a1da-7becf67d93f5\" class=\"\">\n<p id=\"903de28f-8ba1-4fe1-abe1-213cce9d4fa9\" class=\"jrnlTblBody\">STEMI<\/p>\n<\/td>\n<td id=\"9b131304-2815-4445-a92a-2eab24315749\" class=\"\">\n<p id=\"8da1d87f-7224-433c-8c53-71086df4ac49\" class=\"jrnlTblBody\">60<\/p>\n<\/td>\n<td id=\"ff105989-6124-4035-ae5e-730ccc960e5a\" class=\"\">\n<p id=\"55f3ab73-ab63-4c55-9ef9-97fd29cc1fb0\" class=\"jrnlTblBody\">50<\/p>\n<\/td>\n<td id=\"df1f36ca-3ea8-4b09-b5df-0ae1ec2f1ba3\" class=\"\">\n<p id=\"1f8ca5ac-006e-4061-9bac-7a483417a93f\" class=\"jrnlTblBody\">75<\/p>\n<\/td>\n<td id=\"09009f71-1361-4bae-8b7c-749287426819\" class=\"\">\n<p id=\"01954ec2-3594-45a7-82f8-0518d8508686\" class=\"jrnlTblBody\">73.6<\/p>\n<\/td>\n<td id=\"afbbf4ec-774c-44bb-8762-c42563b3bddf\" class=\"\">\n<p id=\"7fafe9b2-23e6-4567-8eff-5f14df3af223\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"460b3589-c9a9-429d-9f5f-70a52d04ae23\" class=\"\">\n<p id=\"c9b9e571-dcfb-4f74-bb15-9fc4cb6f0940\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"ace129ec-bf5e-4b51-95f0-80181fbf8e50\" class=\"\">\n<p id=\"106a95ba-02b4-43a3-9501-aaa59fa23a93\" class=\"jrnlTblBody\">72.6<\/p>\n<\/td>\n<td id=\"ff7b2a27-4795-4570-b3e6-6a473c64b7f4\" class=\"\">\n<p id=\"54ff0658-7732-4eec-9e30-58ecb534c565\" class=\"jrnlTblBody\">71.5<\/p>\n<\/td>\n<td id=\"64cd137a-201b-4b64-9f5a-910a2739d724\" class=\"\">\n<p id=\"fec9c975-3d0a-4a9f-9f86-703325a250cc\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"32657452-e911-4cec-9d17-c6898079f535\" class=\"\">\n<p id=\"1872853f-0aa2-41e4-a4ca-436eff57bcb8\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"78d9c882-c742-4a5b-9fa3-5be0dd34e638\" class=\"\">\n<p id=\"3f18852d-84b4-49fc-8bb3-47b5394775f6\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"bf80c01d-bc26-4487-88b3-8dd6d2db1b23\" class=\"\">\n<p id=\"2faf7f41-1b6a-49e3-abb9-3d99be4bde5b\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<\/tr>\n<tr id=\"63c4f5a6-8b88-4ba2-94b0-66c64ded4ae1\">\n<td id=\"f58ba7c8-8f3e-4dd9-9f09-a375d5dab017\" class=\"\">\n<p id=\"7fa95dd9-bdab-4d50-9b0c-b0b6c0c62dc7\" class=\"jrnlTblBody\">NSTEMI<\/p>\n<\/td>\n<td id=\"89079ed1-aa5e-46cc-9399-7a2c547b1e4d\" class=\"\">\n<p id=\"e9c92c75-238e-4eff-a073-f6b046953eee\" class=\"jrnlTblBody\">4.4<\/p>\n<\/td>\n<td id=\"2c395826-ed52-4f3a-8684-d12eba5ebce3\" class=\"\">\n<p id=\"5008c6a3-58d6-41fe-9c86-3f5d16e79754\" class=\"jrnlTblBody\">8.3<\/p>\n<\/td>\n<td id=\"cbb7bb61-4b9f-4d5e-8ff8-0c55112b3393\" class=\"\">\n<p id=\"1336e3ac-31b0-41b7-9ef1-34e9073e074a\" class=\"jrnlTblBody\">25<\/p>\n<\/td>\n<td id=\"7a8a7def-228e-4aa1-8598-d358eadba11c\" class=\"\">\n<p id=\"0e3916fc-404c-4eb5-b0a5-6a6d1d3c566c\" class=\"jrnlTblBody\">26.4<\/p>\n<\/td>\n<td id=\"2ebfd272-547d-49f2-a892-2d5a4575b366\" class=\"\">\n<p id=\"f2cc5b21-0c0a-4eda-bfd2-36f024b7a94d\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"664f6029-22d7-48e0-a234-4f2d18ec191a\" class=\"\">\n<p id=\"c7c20dcd-f668-45fb-b502-355229e5bc67\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"75337bd4-5401-4484-8d9e-35ce9f244a48\" class=\"\">\n<p id=\"725edaf2-6fd9-45b6-817a-a332935d50ea\" class=\"jrnlTblBody\">27.4<\/p>\n<\/td>\n<td id=\"8fedc58e-ef38-4bbe-b32d-8f719e4effb0\" class=\"\">\n<p id=\"7cdbd85c-99e7-4ad7-880a-3361acd4bbaf\" class=\"jrnlTblBody\">28.5<\/p>\n<\/td>\n<td id=\"20162cbe-6c47-42ce-8863-83ceae737c6b\" class=\"\">\n<p id=\"f96ef6b1-79ac-41ce-b49a-d30a6edc6a06\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"2c7f3cf4-cc3f-453a-8a95-a39222c3a680\" class=\"\">\n<p id=\"6b80ff6f-f1da-4853-bac5-c49e37bb0a9f\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"e1c0f095-1a96-4142-9f59-de675071b57e\" class=\"\">\n<p id=\"9f2577d2-5696-401a-b6f4-3ce1733eedc2\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"c4b38793-edb0-4d7a-8c53-e19cff73f10e\" class=\"\">\n<p id=\"630e0cc8-420c-4001-b390-4d93c211b865\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<\/tr>\n<tr id=\"4f1bfc33-b66e-4c3d-bc57-923b789e9300\">\n<td id=\"0a811077-50ce-40c4-9ba0-c26ba2e762f9\" class=\"\" rowspan=\"6\">\n<p id=\"bb4bae56-be26-45e4-af2a-9237a802d94c\" class=\"jrnlTblBody\">Previous cardiovascular history (%)<\/p>\n<\/td>\n<td id=\"ed333f1c-1e89-49b0-8791-584d9c272694\" class=\"\">\n<p id=\"a6e71aa4-712e-417e-b58f-41a012f3443a\" class=\"jrnlTblBody\">MI<\/p>\n<\/td>\n<td id=\"ffbd0e53-a49b-4f85-8444-0fd55d5399f4\">\n<p id=\"ddb45152-d144-4cf5-91f8-7e2f6eac433b\" class=\"jrnlTblBody\">\n<\/td>\n<td id=\"cbae3ac3-3555-4da9-b03c-36fcc335d5dd\" class=\"\">\n<p id=\"e0ec4c7f-1b2e-4620-85fe-a576a0a9fd46\" class=\"jrnlTblBody\">\n<\/td>\n<td id=\"6ae7a54f-84d0-46cd-a935-7018f47a6bd2\" class=\"\">\n<p id=\"3808d6e2-c269-42bc-a556-c1d93abf7678\" class=\"jrnlTblBody\">11.9<\/p>\n<\/td>\n<td id=\"ee5312ab-45f8-40cf-adcf-69d3a0bb136b\" class=\"\">\n<p id=\"08dd0895-09cc-40fc-82ae-f9df51556cca\" class=\"jrnlTblBody\">14.1<\/p>\n<\/td>\n<td id=\"4fdb6bf3-3e36-4cc2-adff-a7e83b98a5d3\" class=\"\">\n<p id=\"abb0278d-8ecb-4bb5-ac75-ccc3a68a3624\" class=\"jrnlTblBody\">12<\/p>\n<\/td>\n<td id=\"77fc38ce-3f6c-4cc7-9cf6-a3eab24e7eec\" class=\"\">\n<p id=\"d89b9693-2413-44cb-9444-1c0a80a85df8\" class=\"jrnlTblBody\">14<\/p>\n<\/td>\n<td id=\"1c4e2455-4e08-42cc-9e95-8876c68e7e34\" class=\"\">\n<p id=\"b14abb98-3fd0-4140-b03d-af2281c7fbcb\" class=\"jrnlTblBody\">8.8<\/p>\n<\/td>\n<td id=\"29ef7b05-d408-4ff4-b461-449f84cdc4f8\" class=\"\">\n<p id=\"4fbae35b-fd0b-4b0a-a2be-79caec77d903\" class=\"jrnlTblBody\">9.5<\/p>\n<\/td>\n<td id=\"8d7907b9-19ea-4efb-8f6d-649651836ef4\" class=\"\">\n<p id=\"09260593-5bc2-451c-9adc-e945c7eaab7c\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"30dabbb2-d4fa-4ef2-afc9-7bdf5a059283\" class=\"\">\n<p id=\"92d1cb06-8731-440b-be9d-745443895014\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"c34bf4fa-5136-4911-b7ba-f851d4267275\" class=\"\">\n<p id=\"035fdc0d-4cc4-4009-95d9-eaf8d2023ca3\" class=\"jrnlTblBody\">5.9<\/p>\n<\/td>\n<td id=\"53590257-8b82-41c3-a0a8-da263ae23f96\" class=\"\">\n<p id=\"f5b7e018-8beb-4836-b079-e12d70f709ca\" class=\"jrnlTblBody\">3.8<\/p>\n<\/td>\n<\/tr>\n<tr id=\"d382f813-d433-42c8-8bd7-43c38881d2d3\">\n<td id=\"12319076-a548-434e-9f1e-1049c31feaa0\" class=\"\">\n<p id=\"4ed35d85-7769-4c94-b7ac-918cfe7328c5\" class=\"jrnlTblBody\">Stroke<\/p>\n<\/td>\n<td id=\"ebd9b042-f91a-44bb-8697-d2967045783f\" class=\"\">\n<p id=\"60259afa-3561-46a6-ad07-f56c0fc6b017\" class=\"jrnlTblBody\">2.2<\/p>\n<\/td>\n<td id=\"d630ef36-c876-49a1-8913-1ed74f504274\" class=\"\">\n<p id=\"b39659ae-993f-44b1-b5e0-d18e2f84b7e7\" class=\"jrnlTblBody\">4.2<\/p>\n<\/td>\n<td id=\"fffbe12e-49ee-47f5-a5aa-4c2c06ed6740\" class=\"\">\n<p id=\"2adae1fe-5a3c-40b7-a3f5-d08a5c728002\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"e6139115-11e9-4eee-94af-ad909a1c9c35\" class=\"\">\n<p id=\"2c6c5ce9-490e-4a15-a96e-c4aa4fd8b4e6\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"ee5331ae-14eb-4892-b773-6738ffed9b0a\" class=\"\">\n<p id=\"4d2dcf8a-46ef-404e-b2c2-7acba0d874b3\" class=\"jrnlTblBody\">0<\/p>\n<\/td>\n<td id=\"ce48d03e-cab7-4bc1-a0be-482192378c8b\" class=\"\">\n<p id=\"c400f83f-7b7f-43ff-be42-53329e5ccd96\" class=\"jrnlTblBody\">0<\/p>\n<\/td>\n<td id=\"27b75b39-b3c9-46f1-b62a-b415defac7d6\" class=\"\">\n<p id=\"7cda6d2e-264f-4d71-b872-7894413e0a6b\" class=\"jrnlTblBody\">2.3<\/p>\n<\/td>\n<td id=\"1854c21c-42fa-4078-9677-eeef0b7f3317\" class=\"\">\n<p id=\"c2a7e4ef-bd90-4ef3-a7c6-d157c519fe4b\" class=\"jrnlTblBody\">2.5<\/p>\n<\/td>\n<td id=\"a31672a1-be7f-492d-b071-5121839af131\" class=\"\">\n<p id=\"3b958307-8d57-480f-8b0b-92ebc75a75e1\" class=\"jrnlTblBody\">15.2<\/p>\n<\/td>\n<td id=\"4353ba63-50b8-417c-85a6-50b7965784e5\" class=\"\">\n<p id=\"fa5fa54f-90a4-4f69-8b00-22631c776e08\" class=\"jrnlTblBody\">22<\/p>\n<\/td>\n<td id=\"9e4a0362-a8cb-4bfc-a954-4bbc48288536\" class=\"\">\n<p id=\"97fbf72c-e714-40d9-9b61-cd6797d443a6\" class=\"jrnlTblBody\">2.1<\/p>\n<\/td>\n<td id=\"a996d81d-f220-484d-bff5-08b4c3c4a7dd\" class=\"\">\n<p id=\"770ba6bb-ed45-436e-b63d-4d533101358d\" class=\"jrnlTblBody\">0.4<\/p>\n<\/td>\n<\/tr>\n<tr id=\"8e8cdda2-edf5-4a4b-958b-1ba8008b0070\">\n<td id=\"c45cdd2e-1576-4897-bfbf-d9f6c07d8e7f\" class=\"\">\n<p id=\"bba3824a-9960-4053-b584-e6bbf64b50be\" class=\"jrnlTblBody\">AF<\/p>\n<\/td>\n<td id=\"c0a3c0d2-ad43-4033-8b68-11e070df0025\" class=\"\">\n<p id=\"fae3d22c-d933-465a-878e-7afc1ab11cd4\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"e9c1d489-8099-4d37-be0f-a98c2b2c3842\" class=\"\">\n<p id=\"5ddeb844-9dcd-4678-8d2a-30ff0d929c95\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"6da85535-fd0d-4172-863e-fd513ce3c3c4\" class=\"\">\n<p id=\"93557222-e50b-4ee2-a8fd-9687f74852e9\" class=\"jrnlTblBody\">11.0<\/p>\n<\/td>\n<td id=\"160a9124-0d30-43a4-b92d-1dc69b43cab2\" class=\"\">\n<p id=\"6969bb2a-2a90-4660-be9b-c811da2a34a8\" class=\"jrnlTblBody\">11.1<\/p>\n<\/td>\n<td id=\"f27fee23-9138-4891-ad31-d1af73e71582\" class=\"\">\n<p id=\"e22d1319-9822-494e-be9e-9f2f235278a1\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"a6ae23b2-c5f8-4ae3-aaae-94e23c3c5360\" class=\"\">\n<p id=\"2ab9af91-4dee-43b3-b10e-72dbd1387880\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"fc8c784e-e5a7-450e-9576-a2242c9eed68\" class=\"\">\n<p id=\"a930af59-6528-4d4d-a611-6125dbb6ae5e\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"7ea2469d-475b-4329-8d1d-1cccdb69a237\" class=\"\">\n<p id=\"e6525d1f-cd14-4b15-a657-078e9fa585a1\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"2a7a05e1-d210-40ee-9a4c-5f62d5c6b9e7\" class=\"\">\n<p id=\"d3b03061-fa7f-473d-bab4-2964a845b479\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"3b4993f7-6b35-4667-911a-535cbc344b0e\" class=\"\">\n<p id=\"66ebada2-c230-4a48-a955-f98f5c06180c\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"d5b4a2f9-3aa6-4e3a-a380-6d06b39c7c9b\">\n<p id=\"9d4ca6a9-1134-4a35-b434-d9933d907fe2\" class=\"jrnlTblBody\">\n<\/td>\n<td id=\"ed742350-37d6-4dfe-aaac-c00f52bd728f\">\n<p id=\"50b0f53a-ecb9-45b3-8bae-72dedb757f09\" class=\"jrnlTblBody\">\n<\/td>\n<\/tr>\n<tr id=\"6d55ba66-5179-4e9b-a8d6-98f6c2c4b593\">\n<td id=\"622c831b-6104-46db-8fc0-86c18b181124\" class=\"\">\n<p id=\"41a873df-1a2a-4e3d-bd7d-21bb58298567\" class=\"jrnlTblBody\">T2D<\/p>\n<\/td>\n<td id=\"78878237-75b1-4bc3-86f0-57e1d457c193\" class=\"\">\n<p id=\"352edefd-bfe3-43a3-88da-afbac2732326\" class=\"jrnlTblBody\">100<\/p>\n<\/td>\n<td id=\"f43c527e-69ca-426b-aca6-18280962a1c3\" class=\"\">\n<p id=\"24bb683d-9384-4808-b68e-2ff8733d0599\" class=\"jrnlTblBody\">100<\/p>\n<\/td>\n<td id=\"8fc11649-3ef7-4aef-bc66-c069991c0ef2\" class=\"\">\n<p id=\"458fa5fc-6ebc-49a4-9d9d-8f78431d3cf6\" class=\"jrnlTblBody\">31.7<\/p>\n<\/td>\n<td id=\"8ec2b9ca-1112-4976-bc6d-65cc03a3fd2e\" class=\"\">\n<p id=\"d3ebc58c-9f0b-4b17-a22b-0f48ee1ce6d8\" class=\"jrnlTblBody\">32.1<\/p>\n<\/td>\n<td id=\"853a6e1c-646e-4c7a-a35e-f8f93634e33f\" class=\"\">\n<p id=\"89e678b7-c181-4c97-92fb-9fe913db477a\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"888fddf5-0b28-4bca-91bf-7914d4ad86ee\" class=\"\">\n<p id=\"0a74e40f-9f9b-4ff4-a39a-186bcc5b1e71\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"69e6f458-dece-4d9f-bb86-41764aeda142\" class=\"\">\n<p id=\"7f12cd66-ad66-4f3e-9f35-83d8ede1eafb\" class=\"jrnlTblBody\">0<\/p>\n<\/td>\n<td id=\"59e0cec6-ba0e-4522-a47e-d05f357f7492\" class=\"\">\n<p id=\"5cf0c0d5-90aa-4bc1-9bc1-405a58b643ab\" class=\"jrnlTblBody\">0<\/p>\n<\/td>\n<td id=\"d853bfea-73d9-46f8-a402-ccb5b45be951\" class=\"\">\n<p id=\"0912918b-4775-48a6-80c9-b2bbd714df0c\" class=\"jrnlTblBody\">100<\/p>\n<\/td>\n<td id=\"f5684545-7b8f-4475-9c1c-c9b13b04ffc5\" class=\"\">\n<p id=\"6e4f55f4-f9c3-4c73-ba7f-16e13c10d6f3\" class=\"jrnlTblBody\">100<\/p>\n<\/td>\n<td id=\"58eb21a4-a9d6-44be-a406-13548604a2c9\" class=\"\">\n<p id=\"7e82bbda-53cb-405e-bce7-dc59ff894cea\" class=\"jrnlTblBody\">13<\/p>\n<\/td>\n<td id=\"8cf7e5f9-cae6-451b-bf18-51131a0a3dc0\" class=\"\">\n<p id=\"f277283d-11ca-4803-8852-89552add1b0a\" class=\"jrnlTblBody\">14<\/p>\n<\/td>\n<\/tr>\n<tr id=\"7faf9f5e-4640-41c0-b11c-186adc8da9d2\">\n<td id=\"35c12c86-badc-420c-841e-058f99a64272\" class=\"\">\n<p id=\"fd47f9fd-a0a9-43db-ac96-3aa5137fa757\" class=\"jrnlTblBody\">HT<\/p>\n<\/td>\n<td id=\"04070420-dfad-487d-8535-5e049d9fc68b\" class=\"\">\n<p id=\"54fe61ab-4cc4-490a-b046-588fbfb49fd8\" class=\"jrnlTblBody\">57.8<\/p>\n<\/td>\n<td id=\"dec6e132-1290-482a-84d7-0f5cd88f8604\" class=\"\">\n<p id=\"469c80af-8c8c-4da8-9800-9c62e3689834\" class=\"jrnlTblBody\">66.7<\/p>\n<\/td>\n<td id=\"836fe77d-4dcb-41e0-b97d-6b8c627eafe8\" class=\"\">\n<p id=\"66db2c17-8820-4068-850f-fe547c7ec621\" class=\"jrnlTblBody\">69.4<\/p>\n<\/td>\n<td id=\"5f5452de-50b1-4b10-b067-51ccb1fe8917\" class=\"\">\n<p id=\"62434ecf-20e6-4e71-b694-5d46436146bf\" class=\"jrnlTblBody\">69.8<\/p>\n<\/td>\n<td id=\"e4e0a99a-cd28-40fc-9b0b-5bca95967e3a\" class=\"\">\n<p id=\"35edc198-2cc4-4ae9-a915-23ab42e4c2ea\" class=\"jrnlTblBody\">64<\/p>\n<\/td>\n<td id=\"a3bd7822-aca6-4616-bcf4-a30a69f94673\" class=\"\">\n<p id=\"90033020-2428-497d-a4ea-5f0f32b768e6\" class=\"jrnlTblBody\">58<\/p>\n<\/td>\n<td id=\"61ef676b-efd4-446b-965e-a233359c88c6\" class=\"\">\n<p id=\"bd83e7df-9e20-44d4-9831-6407280e9d03\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"b0a5e973-97b5-409e-a0b5-4d7ca95f04d3\" class=\"\">\n<p id=\"cf01156b-264a-4410-a1ec-0db19e3652fa\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"7c3946d6-c33c-4a69-a5d7-59f001cbefb9\" class=\"\">\n<p id=\"58f64e83-24cb-4d56-88e9-95ca259b05ca\" class=\"jrnlTblBody\">82.6<\/p>\n<\/td>\n<td id=\"5f83d1d2-d89d-49a6-ad66-009a34356d99\" class=\"\">\n<p id=\"0347a8ce-88a5-49b8-b6ae-c486827130f8\" class=\"jrnlTblBody\">78.0<\/p>\n<\/td>\n<td id=\"209e12f4-5a1b-428f-bfae-3fc7c0bb27a3\" class=\"\">\n<p id=\"1f5628e4-2a0b-47cb-b4b6-cfa4735b6ce3\" class=\"jrnlTblBody\">39<\/p>\n<\/td>\n<td id=\"6ef52dc0-0d27-4c7a-affa-8db1037380ff\" class=\"\">\n<p id=\"fb4fe95a-a0fa-4c19-ad4a-aab7cf19b0b9\" class=\"jrnlTblBody\">45<\/p>\n<\/td>\n<\/tr>\n<tr id=\"e283096d-964a-4c0f-88ef-09b48e69e9fd\">\n<td id=\"8f009770-1978-4b2b-868a-58c9f4fb1f0d\" class=\"\">\n<p id=\"eae05a60-6d0e-453c-b3c3-acb2c1e5e5ce\" class=\"jrnlTblBody\">PAD<\/p>\n<\/td>\n<td id=\"270894d2-93cc-449b-ab80-b3c3081aaa28\" class=\"\">\n<p id=\"4427fc9d-92d9-4ed7-96a0-8c1d39de67b0\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"0e0ba25f-e2fa-4816-b187-7c2eb48d0344\" class=\"\">\n<p id=\"10652f32-68aa-4621-8080-ddba8a297aad\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"132f825b-4b1d-4b31-82c7-7fe778011468\" class=\"\">\n<p id=\"2b872f6e-bf8f-4972-a66e-86c2a252ad45\" class=\"jrnlTblBody\">5.3<\/p>\n<\/td>\n<td id=\"270bc778-4fb0-462e-90d9-8ec4919013c8\" class=\"\">\n<p id=\"6e4ee42b-de0c-422c-a307-7521f80005e0\" class=\"jrnlTblBody\">5.5<\/p>\n<\/td>\n<td id=\"5b83828f-9b8b-4dc3-977b-b5aae8fb360b\" class=\"\">\n<p id=\"4393b812-45c6-439d-a3f3-496e6b3a0eb7\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"6acab846-c8e4-4562-be84-0fa3b8365847\" class=\"\">\n<p id=\"a394228f-af6a-4190-8184-8e6918159003\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"5e38ceff-8013-46bb-b755-a1654b29fe77\" class=\"\">\n<p id=\"6273ddd4-6419-4786-b438-58da471d7662\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"73a785b6-5ada-43a2-8910-8eb701e225eb\" class=\"\">\n<p id=\"2e015bb6-f9ad-485b-82cd-888a6caf466b\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"d6052b99-3b24-4bac-8cc0-7abb2969669c\" class=\"\">\n<p id=\"975bf155-17bb-499e-8cfa-ea331db390d3\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"c35613ef-e527-46fb-ac62-81870e504024\" class=\"\">\n<p id=\"41baa05b-caa4-44a9-80b2-26357685b7fe\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"93bd3d82-2fd7-4d3b-a6f0-f94357ff078a\" class=\"\">\n<p id=\"11706a67-e3c1-429b-9ced-6f85640e3823\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"f194d6ce-3017-488c-8008-da3eacf37374\" class=\"\">\n<p id=\"860411fa-d74d-4814-aeae-87083eb93890\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<\/tr>\n<tr id=\"52e26ecc-cea9-49a7-bf78-5786ed1d5b21\">\n<td id=\"ad1519bf-63c5-49ad-bc0b-e7cd919f2d22\" class=\"\" colspan=\"2\">\n<p id=\"703c718d-0b95-4c4f-8379-382e3a0fc96b\" class=\"jrnlTblBody\">Unstable angina (%)<\/p>\n<\/td>\n<td id=\"a9c462cc-ea2a-4c16-8847-fcfc28bc8626\" class=\"\">\n<p id=\"c3394088-9c70-40fe-89ff-75178b4d097f\" class=\"jrnlTblBody\">35.6<\/p>\n<\/td>\n<td id=\"9dd29783-409a-47a2-922c-2e3ead5b4366\" class=\"\">\n<p id=\"7bb843b7-cebb-45c6-9de4-ed6f35031643\" class=\"jrnlTblBody\">43.8<\/p>\n<\/td>\n<td id=\"6cdd465b-cac1-4abf-8140-ea325d8b19b1\" class=\"\">\n<p id=\"3a7f2cf9-5b0d-4193-be64-3eb75ac10451\" class=\"jrnlTblBody\">0<\/p>\n<\/td>\n<td id=\"8dcd489b-3d6b-49f6-875c-4fdd7d56fa5f\" class=\"\">\n<p id=\"86efa3cd-7c37-4983-860e-4ba02a03654e\" class=\"jrnlTblBody\">0<\/p>\n<\/td>\n<td id=\"a454bed3-3f25-4abf-97ee-ec7aaecb484a\" class=\"\">\n<p id=\"80b2352a-7a3a-421e-81ec-18a8dcac9370\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"a5f67022-a5ea-43cf-846c-bc70cd8176cd\" class=\"\">\n<p id=\"48590eeb-afcd-4edc-bdcf-45b9c4eeff12\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"0cbd5aab-5ad6-4026-aee2-0e88e53c2d0a\" class=\"\">\n<p id=\"02794c1c-92b1-4141-a6de-30ab67234fd8\" class=\"jrnlTblBody\">0<\/p>\n<\/td>\n<td id=\"16537978-c003-4536-80ae-ae6d7de209d0\" class=\"\">\n<p id=\"4ca9f23e-efe0-4dfc-ae82-e00bef4423de\" class=\"jrnlTblBody\">0<\/p>\n<\/td>\n<td id=\"958f8084-6bda-47ad-937e-99eab6076a85\" class=\"\">\n<p id=\"d24d1406-5c9c-44a1-9b7a-c09c872ac05d\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"8f5304e3-f203-4dcf-a46d-82287d0089ef\" class=\"\">\n<p id=\"8ff38561-b683-416e-a57d-3c5ab7beaff2\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"9894bd1f-4206-498d-acb1-a62dde51425f\" class=\"\">\n<p id=\"ffac9563-4553-427a-a5e7-e1759c118d19\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"eb390dd4-1076-4132-816a-adad335b25f4\" class=\"\">\n<p id=\"df8d23e8-c1bc-4d9c-a21c-4df290ab8ef7\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<\/tr>\n<tr id=\"5bbc0134-e67a-40af-8f27-b8c3774f2973\">\n<td id=\"9e8c9862-2fea-4356-822d-0ba80a31db30\" class=\"\" colspan=\"2\">\n<p id=\"5d6fc927-ca09-42d6-a7fb-bb7331b556d8\" class=\"jrnlTblBody\">Patient characteristics<\/p>\n<\/td>\n<td id=\"672261b4-612a-44f5-a85d-b6e2c405ae67\" class=\"\" colspan=\"2\">\n<p id=\"134eb87d-7159-417b-b53b-660d577ad8aa\" class=\"jrnlTblBody\">Inclusion criteria: adults over 18 years with a prior diagnosis of T2D and ACS, including ST elevation MI, non-ST elevation MI or unstable angina. Exclusion criteria: DKA, urinary and genital infections, T1D, severe liver failure, malignancy, eGFR &lt;30 mL\/min\/1.73 m<sup id=\"eb302374-3970-462e-8528-fae25d24a92d\" class=\"sty cts-3\">2<\/sup>\u00a0and non-adherence<\/p>\n<\/td>\n<td id=\"b06c5ea0-c28f-49a3-8495-4ba9c747e0b5\" class=\"\" colspan=\"2\">\n<p id=\"13e1e1d0-e0b0-485f-ae4a-c7c7d180278f\" class=\"jrnlTblBody\">Inclusion criteria: adults over 18 years hospitalized with acute MI within 14 days before randomization, presenting evidence of either a newly developed LVEF &lt;45% or signs\/symptoms of congestion necessitating treatment. Exclusion criteria: previous heart failure diagnosis and use of SGLT2i<\/p>\n<\/td>\n<td id=\"d75eab7b-bd14-42ff-8f2b-3b2bef96675c\" class=\"\" colspan=\"2\">\n<p id=\"00d16d36-66cb-4047-a980-7d2080513c31\" class=\"jrnlTblBody\">Inclusion criteria: patients with anterior STEMI, LVEF &lt;50% and successful pPCI. Exclusion criteria: patients with diabetes, prior HF, cardiotoxic medication, haemoglobinopathies, chronic organ damage, existing SGLT2i use, need for additional anticoagulation or contraindications for dapagliflozin<\/p>\n<\/td>\n<td id=\"4b03deaf-f7d7-45cb-85cf-045b72f94a26\" class=\"\" colspan=\"2\">\n<p id=\"c431f53b-b332-45f5-a153-523a13a557d6\" class=\"jrnlTblBody\">Inclusion criteria: stable adults over 18 years hospitalized for acute MI and with LV systolic dysfunction or Q-wave MI on ECG. Exclusion criteria: established diabetes, symptomatic HF with reduced LVEF \u226440% and current SGLT2i treatment<\/p>\n<\/td>\n<td id=\"b651cdad-9510-45e8-bed1-604b459bdc05\" class=\"\" colspan=\"2\">\n<p id=\"fdd97fcb-a43b-4153-8ac1-8d4fc8d33b0e\" class=\"jrnlTblBody\">Inclusion criteria: adults over 20 years with diagnosed T2D according to Japanese guidelines and patients within 2\u201312 weeks after the onset of acute MI. Exclusion criteria: T1D, persistent AF, use of insulin, GLP1RA or high-dose sulfonylurea, HbA1C &gt;10%, recent DKA or coma, renal dysfunction (eGFR &lt;45 mL\/min\/1.73 m<sup id=\"b2cf173e-5e4c-456b-90b1-c22936d13d90\" class=\"sty cts-3\">2<\/sup>), NYHA functional class IV heart failure, pregnancy or breastfeeding and contraindications to empagliflozin<\/p>\n<\/td>\n<td id=\"68b09520-4d48-408d-98b2-16d88ab855ca\" class=\"\" colspan=\"2\">\n<p id=\"a4cbd7c2-f6cc-4a6e-ba80-a5b03606a7b5\" class=\"jrnlTblBody\">Inclusion criteria: patients aged 18\u201380 years with confirmed acute large MI (CK &gt;800 IU\/L), high troponin T (or I) &gt;10\u00d7 upper limit, and eGFR &gt;45 mL\/min\/1.73 m<sup id=\"d484d71a-d481-4460-851e-975de24f05d2\">2<\/sup>. Exclusion criteria: patients with non T2D, pH &lt;7.32, haemodynamic instability, acute UTI or genital infection, current or recent SGLT2i treatment<\/p>\n<\/td>\n<\/tr>\n<tr id=\"c1c422b4-6587-46c7-8acd-052b24d6da90\">\n<td id=\"b7b8c4eb-d98c-448d-8c01-20c07ebc61d1\" class=\"\" colspan=\"2\">\n<p id=\"aa379ffa-fdb7-43f4-a11b-9bd5122449db\" class=\"jrnlTblBody\">Duration of study<\/p>\n<p id=\"6733a221-217c-4f3a-a57c-db14f90b3eb1\" class=\"jrnlTblBody\">(weeks)<\/p>\n<\/td>\n<td id=\"c43226dc-c083-4be5-827c-ccefe4026535\" class=\"\" colspan=\"2\">\n<p id=\"9b740410-dca8-420a-a98f-ae53d91dd615\" class=\"jrnlTblBody\">24<\/p>\n<\/td>\n<td id=\"08a4dcf7-fffc-47ca-ace9-9dd4e3ade7cb\" class=\"\" colspan=\"2\">\n<p id=\"b7a8085d-e076-4057-bdb5-b63ffa3e8457\" class=\"jrnlTblBody\">24<\/p>\n<\/td>\n<td id=\"86d7cb62-b8bf-4c28-a856-49cea6abe93d\" colspan=\"2\">\n<p id=\"f23e542c-9362-4736-840f-1a24cb952f9f\" class=\"jrnlTblBody\">12<\/p>\n<\/td>\n<td id=\"ce611114-571d-4580-8ec6-0905fb71521e\" class=\"\" colspan=\"2\">\n<p id=\"990aae41-2510-44d7-981a-2b13ab80decc\" class=\"jrnlTblBody\">48<\/p>\n<\/td>\n<td id=\"748da772-ba01-4b2e-99f4-a8af75c2c344\" colspan=\"2\">\n<p id=\"5b537306-62d3-46a7-9968-d6174fe94741\" class=\"jrnlTblBody\">24<\/p>\n<\/td>\n<td id=\"527af0d2-1b95-4740-a91f-45fc1fea8b5f\" class=\"\" colspan=\"2\">\n<p id=\"6929f6df-4150-44ce-bc9d-4251dd81652d\" class=\"jrnlTblBody\">26<\/p>\n<\/td>\n<\/tr>\n<tr id=\"e2868c79-6425-47b2-aa93-3568a27d0381\">\n<td id=\"61bc89f1-5009-4cff-bff2-3018f4811e84\" class=\"\" colspan=\"2\">\n<p id=\"3ee572b2-7ce9-4507-8235-a311abf1def7\" class=\"jrnlTblBody\">Key outcomes<\/p>\n<\/td>\n<td id=\"44c36ae3-cfff-4ecd-acf8-a8c18a00c714\" class=\"\" colspan=\"2\">\n<p id=\"5907e942-5eb9-4e3c-ae9a-667f29132480\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"8a4c4f22-ef41-4138-9f74-d4c661ff48fe\" class=\"\" colspan=\"2\">\n<p id=\"3482dec6-4687-442d-83ce-ab033eb83f57\" class=\"jrnlTblBody\">There was no difference in the incidence of hypoglycaemia or lower limb amputations<\/p>\n<\/td>\n<td id=\"a3b110f3-48ce-4d5e-9682-399cd2fc1e55\" class=\"\" colspan=\"2\">\n<p id=\"a20e90b9-f231-4eb8-b852-c5b85dc492e0\" class=\"jrnlTblBody\">None of the patients in the study group receiving dapagliflozin encountered genitourinary infections or hypoglycaemic episodes<\/p>\n<\/td>\n<td id=\"8d3ab862-60ae-4db2-80b5-59cf5bfa96b8\" class=\"\" colspan=\"2\">\n<p id=\"fcd1263b-15d2-4cc6-a774-a10c2d6b2fed\" class=\"jrnlTblBody\">There was no increase in serious adverse events related to adverse<\/p>\n<p id=\"f2a0f72f-c3d6-4915-bc6d-56b512b624f3\" class=\"jrnlTblBody\">reactions that could potentially be associated with SGLT2i, such as hypovolaemia, hypotension, amputations or genital infections<\/p>\n<\/td>\n<td id=\"11d2aaa1-8b93-449b-8e2f-8f5321f11618\" class=\"\" colspan=\"2\">\n<p id=\"8c708d3c-cdea-4d8a-a8fe-f8c2fbbb61c3\" class=\"jrnlTblBody\">\u2013<\/p>\n<\/td>\n<td id=\"e4723340-b46d-4519-9ebd-4a9f60b99daa\" class=\"\" colspan=\"2\">\n<p id=\"f683cd96-34c3-4103-8af1-b303a9544666\" class=\"jrnlTblBody\">Incidence of genital infections and showed no significant difference between the empagliflozin and placebo. No amputations or severe hypoglycaemic episodes were reported. While beta-hydroxybutyrate concentrations increased significantly more in the empagliflozin group compared with placebo, there was no difference in the occurrence of DKA<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div id=\"c5f940f0-15d3-4551-90f0-356f0fae8ae6\" class=\"jrnlTblFootGroup\">\n<div id=\"T1_FN1\" class=\"jrnlTblFoot\">\n<p class=\"jrnlTblFootText\"><em>All continuous variables have been expressed either as mean \u00b1 standard deviation or median (interquartile range).<\/em><\/p>\n<\/div>\n<div id=\"61c50e05-996f-4e55-a94b-b3adff7079d5\" class=\"jrnlTblFoot\">\n<p class=\"jrnlTblFootText\"><em><span id=\"c8281766-8946-4b70-aa2b-2ce74fad701e\" class=\"jrnlTblDefItem\"><span id=\"159487b5-b2fc-4c22-8c44-08f982c0f551\" class=\"jrnlAbbrevTerm\">ACS<\/span>\u00a0=\u00a0<span id=\"c48de2fd-09fb-48d4-ac89-05654b41d3d2\" class=\"jrnlFootDefinition\">acute coronary syndrome<\/span>; <\/span><span id=\"c0b3b88f-2050-4502-87e4-c1c44226a2ef\" class=\"jrnlTblDefItem\"><span id=\"0addb2ef-e26b-4201-9a27-53e0a2fe03af\" class=\"jrnlAbbrevTerm\">AF<\/span>\u00a0=\u00a0<span id=\"ba50da8d-93c2-43d1-8367-0dcf2b133828\" class=\"jrnlFootDefinition\">atrial fibrillation<\/span>; <\/span><span id=\"e3857991-8a2d-43d2-9d2d-ca464af0eadd\" class=\"jrnlTblDefItem\"><span id=\"2a2d9f93-1ba2-442d-b6b9-0047b07c190f\" class=\"jrnlAbbrevTerm\">BMI<\/span>\u00a0=\u00a0<span id=\"a7d87354-0f05-429e-b85f-d9d860bd2587\" class=\"jrnlFootDefinition\">body mass index<\/span>; <\/span><span id=\"8d1cb66f-b6c5-4b19-b9af-89c06bd7ecd8\" class=\"jrnlTblDefItem\"><span id=\"b7ac5d1d-4787-43e2-88ce-2d06936e1936\" class=\"jrnlAbbrevTerm\">CK<\/span>\u00a0=\u00a0<span id=\"43e74a07-57ec-4efe-82cb-4b597dd8e484\" class=\"jrnlFootDefinition\">creatine kinase<\/span>; <\/span><span id=\"d1f2645f-1746-4965-bfb9-4a9885b94c25\" class=\"jrnlTblDefItem\"><span id=\"d8a7141a-b7a1-44d0-825a-c0fca979d406\" class=\"jrnlAbbrevTerm\">DKA<\/span>\u00a0=\u00a0<span id=\"2512188e-94d6-4dbb-afbc-9a41d3a9bd81\" class=\"jrnlFootDefinition\">diabetic ketoacidosis<\/span>; <\/span><span id=\"ded69de1-1b03-482b-9168-8315233c224b\" class=\"jrnlTblDefItem\"><span id=\"c6d80e2c-6d23-4051-9f0c-24549d0c2d7f\" class=\"jrnlAbbrevTerm\">ECG<\/span>\u00a0=\u00a0<span id=\"320757f0-e713-4481-b9d4-b732e0f500fe\" class=\"jrnlFootDefinition\">electrocardiogram<\/span>; <\/span><span id=\"b5fa99f2-4983-482e-b87c-47ef28dec351\" class=\"jrnlTblDefItem\"><span id=\"ebe2d2b0-5859-44ed-b17d-3d0c1698447e\" class=\"jrnlAbbrevTerm\">eGFR<\/span>\u00a0=\u00a0<span id=\"88cc3ffa-58b2-49de-8445-5abc241694c1\" class=\"jrnlFootDefinition\">estimated glomerular filtration rate<\/span>; <\/span><span id=\"edb6015f-baba-4343-ba67-f89b80f5d86e\" class=\"jrnlTblDefItem\"><span id=\"84636e9a-ec64-4444-9fce-c96f055d4438\" class=\"jrnlAbbrevTerm\">GLP1RA<\/span>\u00a0=\u00a0<span id=\"be9a001b-4466-428a-96e3-b10cb2e8d5b2\" class=\"jrnlFootDefinition\">glucagon-like peptide-1 receptor agonist<\/span>; <\/span><span id=\"26359daf-55d0-4d52-a5af-e404b9e29a4c\" class=\"jrnlTblDefItem\"><span id=\"dbaeea1d-5f0f-4076-86a4-8d2781039075\" class=\"jrnlAbbrevTerm\">HbA1C<\/span>\u00a0=\u00a0<span id=\"b0431bf6-c120-4f92-a564-b2cedb96739c\" class=\"jrnlFootDefinition\">haemoglobin A1C<\/span>; <\/span><span id=\"e1e07b23-71fa-4bd3-811f-490b629634e5\" class=\"jrnlTblDefItem\"><span id=\"7436e47a-241f-4eb1-bdf3-1c82439c45ce\" class=\"jrnlAbbrevTerm\">HF<\/span>\u00a0=\u00a0<span id=\"a961045f-cc1f-436f-8eed-f892769a3b3c\" class=\"jrnlFootDefinition\">heart failure<\/span>; <\/span><span id=\"f86f2209-101e-47c6-9c91-08732e1968cc\" class=\"jrnlTblDefItem\"><span id=\"2b7d17c1-d5ad-4af3-9803-bf017d29733a\" class=\"jrnlAbbrevTerm\">HT<\/span>\u00a0=\u00a0<span id=\"d27f551a-c082-4446-9b73-aa7e93815df9\" class=\"jrnlFootDefinition\">hypertension<\/span>; <\/span><span id=\"ee0f3322-c6ee-41b1-a3fd-b1c6869973e2\" class=\"jrnlTblDefItem\"><span id=\"6a2d5b2b-a400-46f2-903f-233d607c517b\" class=\"jrnlAbbrevTerm\">LV<\/span>\u00a0=\u00a0<span id=\"1e61ae1f-3558-489c-81b7-b8d5a9c5b608\" class=\"jrnlFootDefinition\">left ventricular<\/span>; <\/span><span id=\"12d62185-16b8-450b-a4e6-4b8f142a2668\" class=\"jrnlTblDefItem\"><span id=\"d401be1d-ddaf-4172-b292-ee4d8ece11cc\" class=\"jrnlAbbrevTerm\">LVEF<\/span>\u00a0=\u00a0<span id=\"06eb8fb3-d1bf-4734-91d3-33de68dc5d3b\" class=\"jrnlFootDefinition\">left ventricular ejection fraction<\/span>; <\/span><span id=\"dd857ab1-1cb4-4a4e-a830-423a04922693\" class=\"jrnlTblDefItem\"><span id=\"c09e9280-1e7a-45fd-ab77-10a50da9768e\" class=\"jrnlAbbrevTerm\">MI<\/span>\u00a0=\u00a0<span id=\"992f22e6-4857-4ccb-9386-799a9053b9b0\" class=\"jrnlFootDefinition\">myocardial infarction<\/span>; <\/span><span id=\"33f2cbda-d7ae-47a3-8979-4f0d62c86589\" class=\"jrnlTblDefItem\"><span id=\"c4131891-50fa-4556-9052-6d968f07703c\" class=\"jrnlAbbrevTerm\">NSTEMI<\/span>\u00a0=\u00a0<span id=\"b46762c7-3d68-46df-b31a-0b7c98f5432a\" class=\"jrnlFootDefinition\">non-ST elevation myocardial infarction<\/span>; <\/span><span id=\"e3529dd5-ec08-4bff-881f-bdf99bc7546a\" class=\"jrnlTblDefItem\"><span id=\"d87303ff-f6b9-46ae-adc8-f208752dc2dd\" class=\"jrnlAbbrevTerm\">NYHA<\/span>\u00a0=\u00a0<span id=\"9804dff0-cc29-4e5b-9f39-36a498b79f1e\" class=\"jrnlFootDefinition\">New York Heart Association<\/span>; <\/span><span id=\"483bcca4-698b-48c9-aaa5-719d8ce081b1\" class=\"jrnlTblDefItem\"><span id=\"ee8e0671-926a-4788-9d56-dc173e746290\" class=\"jrnlAbbrevTerm\">PAD<\/span>\u00a0=\u00a0<span id=\"375b11ec-c349-42f2-899e-331370d402b0\" class=\"jrnlFootDefinition\">peripheral artery disease<\/span>; <\/span><span id=\"76421b21-f6a0-4a6a-b846-5f6707553409\" class=\"jrnlTblDefItem\"><span id=\"405df566-21f6-4280-8842-fb9667b01f4a\" class=\"jrnlAbbrevTerm\">pPCI<\/span>\u00a0=\u00a0<span id=\"cd9c0acf-2e65-432e-a707-f179468125d9\" class=\"jrnlFootDefinition\">primary percutaneous coronary intervention<\/span>; <\/span><span id=\"f4f7ef8c-5742-43e6-83e1-81df238e595e\" class=\"jrnlTblDefItem\"><span id=\"67805f10-2865-4908-8970-cbd8f76a4f93\" class=\"jrnlAbbrevTerm\">SBP<\/span>\u00a0=\u00a0<span id=\"7a2ec3b8-5ee6-4795-bd2c-2742903169a5\" class=\"jrnlFootDefinition\">systolic blood pressure<\/span>; <\/span><span id=\"a90949bb-2c82-42a8-8d86-cee5a9216473\" class=\"jrnlTblDefItem\"><span id=\"c2e54b33-9f42-4c57-a413-9fbf42516545\" class=\"jrnlAbbrevTerm\">SGLT2i<\/span>\u00a0=\u00a0<span id=\"8624320c-3dc8-4793-8400-b32bb55ee25f\" class=\"jrnlFootDefinition\">sodium\u2013glucose co-trasnporter-2 inhibitors<\/span>; <\/span><span id=\"2d8de7d6-afdf-445a-9664-b825bfde663e\" class=\"jrnlTblDefItem\"><span id=\"b4fabfd1-83c0-403d-80cb-913ce4545427\" class=\"jrnlAbbrevTerm\">STEMI<\/span>\u00a0=\u00a0<span id=\"f0361910-eeaf-48b1-b912-d520c9099c7c\" class=\"jrnlFootDefinition\">ST elevation myocardial infarction<\/span>; <\/span><span id=\"51fcd9d2-dc87-4f7a-94dd-d0585615fbf1\" class=\"jrnlTblDefItem\"><span id=\"f3230a19-8a74-4e00-bfab-77cf6914ce9b\" class=\"jrnlAbbrevTerm\">T1D<\/span>\u00a0=\u00a0<span id=\"e1661756-e65f-409c-b205-f6343a420350\" class=\"jrnlFootDefinition\">type 1 diabetes<\/span>; <\/span><span id=\"0c935df7-55ba-445f-9920-8833a69554ec\" class=\"jrnlTblDefItem\"><span id=\"bf9225fc-6a64-4ff3-bd75-734b93531043\" class=\"jrnlAbbrevTerm\">T2D<\/span>\u00a0=\u00a0<span id=\"ad43bb87-f3da-4084-839c-bf25797f74fa\" class=\"jrnlFootDefinition\">type 2 diabetes<\/span>; <\/span><span id=\"7f426762-e5d9-4249-8c15-c76355f7447f\" class=\"jrnlTblDefItem\"><span id=\"8bbda571-d22d-433b-8720-1cf960856c74\" class=\"jrnlAbbrevTerm\">UTI<\/span>\u00a0=\u00a0<span id=\"5509081b-7acc-4cbb-9442-075bc034de65\" class=\"jrnlFootDefinition\">urinary tract infection<\/span>.<\/span><\/em><\/p>\n<\/div>\n<\/div>\n<\/div>\n<p id=\"2d910381-b9c4-44e2-bda6-b476fa89b7bb\" class=\"jrnlSecPara\">SOdium\u2013glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities and a recent Myocardial Infarction\u00a0<span id=\"27caad8d-d1db-40f9-be22-4bc1ca926a7c\">(SOCOGAMI<\/span>, EudraCT number: 2015-004571-73) was a randomized, double-blind, placebo-controlled trial, which was excluded from this SRM, as it involved patients with AMI or unstable angina pectoris in the last 6 months.<span id=\"699207a8-e623-42ea-95b9-c11decaf7513\" class=\"jrnlBibRef\" data-citation-string=\" R24 R25 \"><sup id=\"e2c6a59b-3937-4521-9a2c-537dd0ab5765\">24,25<\/sup><\/span>\u00a0The study by Khiali\u00a0<span id=\"cb5c0f3d-0aad-4b97-bc7f-ad7a6d44dcda\" class=\"styrm cts-3\">et al<\/span><em id=\"b0ac893e-1f45-4d79-9520-245e1509e750\" class=\"sty cts-2\">.<\/em>\u00a0was excluded from this analysis, although they initiated empagliflozin alone or in combination with colchicine, within 72<span id=\"cc346e55-b322-446b-8b66-39127ea4722f\" class=\"nonBreakingSpace\">\u00a0<\/span>h of MI, as they did not evaluate the primary and secondary outcomes evaluated in this SRM.<span id=\"08a63ad3-ce4b-4388-a72e-0432b61d32a8\" class=\"jrnlBibRef\" data-citation-string=\" R26 \"><sup id=\"ec403ac7-4527-4aa6-a670-f2aec6c02825\">26<\/sup><\/span>\u00a0They looked at changes in echocardiographic parameters and systemic inflammatory markers after 12 weeks of empagliflozin and\/or colchicine use following AMI.<span id=\"9ab85dcf-8873-4d0e-b728-f6a5cd185c2e\" class=\"jrnlBibRef\" data-citation-string=\" R26 \"><sup id=\"50717aa1-b8b8-4650-9846-5db3bc287d8b\">26<\/sup><\/span>\u00a0The RCT by Karetnikova\u00a0<span id=\"ab7eeb8d-19ac-4bd7-bad7-91e7ef0bea5f\" class=\"styrm cts-3\">et al<\/span><em id=\"7aef4066-f35a-47cb-8be1-ac3e21a62a47\" class=\"sty cts-2\">.<\/em>\u00a0evaluated the role of empagliflozin in patients undergoing PCI for coronary artery disease (CAD).<span id=\"08f8c1ea-b886-4b80-8faf-2c6579ad6299\" class=\"jrnlBibRef\" data-citation-string=\" R27 \"><sup id=\"4eaf3d70-f3ce-49da-b10e-975891404aff\">27<\/sup><\/span>\u00a0However, this RCT was excluded from our analysis because the elective PCI was done in stable patients with CAD rather than in the setting of AMI.<span id=\"4fa828e3-8b61-4fca-aca2-030c99030820\" class=\"jrnlBibRef\" data-citation-string=\" R27 \"><sup id=\"bb52300b-e7a7-4f4d-b2c0-f086a98ffbb7\">27<\/sup><\/span>\u00a0In addition, empagliflozin was initiated 1 month before the elective PCI.<span id=\"df84cd9f-68ef-400e-9a2a-05362e19c0ac\" class=\"jrnlBibRef\" data-citation-string=\" R27 \"><sup id=\"9eaae0a7-ecec-4bbb-8e20-35587464a8eb\">27<\/sup><\/span>\u00a0Therefore, this RCT did not fulfil our inclusion and exclusion criteria.<\/p>\n<h2 id=\"98707f84-189d-45e5-8b9d-88729d489a5a\" class=\"jrnlHead2\">Risk of bias in the included studies<\/h2>\n<p id=\"1fddb80a-0db8-495b-ba72-003cbfe71d4c\" class=\"jrnlSecPara\">The summaries of ROB of the six RCTs included in this SRM have been elaborated in\u00a0<span class=\"jrnlSupplRef\" data-citation-string=\" SM2 \"><em id=\"96fbce82-dab6-4d96-a363-36008b6a08a2\" class=\"sty cts-6\">Supplementary Material 2<\/em><\/span><em id=\"b8c3c490-8073-416c-853c-0443e92aebe9\" class=\"sty cts-6\">a and b<\/em><em id=\"dc9eef5b-c7a4-4648-baee-3f54c2502952\" class=\"sty cts-6\">.<\/em>\u00a0Random sequence generation, allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), attrition bias and reporting bias were judged to be at low ROB in all six studies (100%). Source of funding, especially pharmaceutical, authors from the pharmaceutical organizations and conflict of interests were looked into the \u2018other bias\u2019 section. Other bias was judged to be at low risk in two out of six RCTs (33.33%) (<span class=\"jrnlSupplRef\" data-citation-string=\" SM2 \"><em id=\"7e1f1940-57da-4412-95a4-499226537f82\" class=\"sty cts-6\">Supplementary Material 2<\/em><\/span><em id=\"4be0edb3-616b-4ff2-b26e-565aa26558da\" class=\"sty cts-6\">a and b<\/em>).<\/p>\n<h2 id=\"4622a21b-bd5b-40e7-9733-28e5ef8315d0\" class=\"jrnlHead2\">Effect of\u00a0<span id=\"d7b27af6-a93b-4a70-8fa6-e0a39f02232d\">sodium\u2013glucose co-trasnporter-2 inhibitors<\/span>\u00a0on primary outcomes<\/h2>\n<h3 id=\"bbc75bd6-ffa0-4277-af4e-ae8eda5c0abc\" class=\"jrnlHead3\">Cardiovascular death, all-cause death\/mortality and hospitalization for heart failure<\/h3>\n<p id=\"1e82d9ca-6622-45a0-a8a1-97d0e6a7b60d\" class=\"jrnlSecPara\">Data from four studies involving 11,108 patients with AMI were analysed to find out the impact of early initiation of SGLT2i following MI on CV death, all-cause death and HHF. CV deaths following AMI were similar in patients initiated on SGLT2i compared with placebo (odds ratio [OR]: 1.04; 95% confidence interval [CI]: 0.83\u20131.30; p=0.76;\u00a0<em id=\"e2aae821-102c-4144-b54a-31863876a3d3\" class=\"sty cts-3\">I<\/em><sup id=\"309753cd-1a4a-4141-a20a-d4add009677a\">2<\/sup>=0% [low heterogeneity];\u00a0<em><span class=\"jrnlFigRef\" data-citation-string=\" F1 \">Figure 1a<\/span><\/em>). All-cause mortality was also similar in patients receiving SGLT2i compared with placebo, following AMI (OR: 1.00; 95% CI: 0.82\u20131.21;\u00a0<em id=\"60f5d918-6cb9-4c6e-a9e4-ece798ae0d72\"><\/em>p=0.98;\u00a0<em id=\"9ef55eb4-0477-4f2c-a3ea-a7af79d15de0\" class=\"sty cts-3\">I<\/em><sup id=\"98fdb3c4-a756-48cd-8d9b-c3cb4022e712\">2<\/sup>=0% [low heterogeneity];\u00a0<em><span class=\"jrnlFigRef\" data-citation-string=\" F1 \">Figure 1b<\/span><\/em>). HHF was significantly lower in patients who had early initiation of SGLT2i following MI compared with placebo (OR: 0.75; 95% CI: 0.62\u20130.90;\u00a0<em id=\"152c7a68-a221-457f-aa66-07e97182f6e1\"><\/em>p=0.002;\u00a0<em id=\"6c3b9d0a-ab78-48d8-bd35-a1c90a5f0e7c\" class=\"sty cts-3\">I<\/em><sup id=\"642fe34d-86fd-4d43-817a-a7eeeeb94516\">2<\/sup>=0% [low heterogeneity];\u00a0<em><span class=\"jrnlFigRef\" data-citation-string=\" F1 \">Figure 1c<\/span><\/em>).<\/p>\n<h2 id=\"db52bd81-f90d-4d78-abd6-53849185917d\" class=\"jrnlHead2\">Effect of\u00a0<span id=\"cc88b19d-e03c-484f-abc5-1b2973afc5c8\">sodium\u2013glucose co-trasnporter-2 inhibitors<\/span>\u00a0on secondary outcomes<\/h2>\n<h3 id=\"c8dbb0bb-3684-4149-80bf-b9bf59a43a7e\" class=\"jrnlHead3\">Left ventricular ejection fraction<\/h3>\n<p id=\"2bb1fb59-967a-40d1-aa20-888f9a76d21e\" class=\"jrnlSecPara\">Data from three studies involving 669 patients with AMI were analysed to find out the impact of early initiation of SGLT2i following MI on LVEF in echocardiography. Patients initiated on SGLT2i had significantly higher LVEF compared with those on placebo (MD: 1.65%; 95% CI: 0.34\u20132.96;\u00a0<em id=\"0748f595-835a-4855-a7fc-eb4b7a3e4f17\"><\/em>p=0.01;\u00a0<em id=\"f0a76d4f-8c2b-4a1a-b0ce-48fe3cbf88fd\" class=\"sty cts-3\">I<\/em><sup id=\"16a0b11a-c85e-4902-96d0-0d8c36ed5700\">2<\/sup>=0% [low heterogeneity];\u00a0<em><span class=\"jrnlFigRef\" data-citation-string=\" F1 \">Figure 1d<\/span><\/em>).<\/p>\n<h2 id=\"adf0f8cc-aa7f-422b-ac5b-0a4ae6bf66e0\" class=\"jrnlHead2\">N-terminal pro-b-type natriuretic peptide<\/h2>\n<p id=\"2043b053-6395-4fb5-af5f-774d05b3d0bc\" class=\"jrnlSecPara\">Data from two studies (165 patients) on AMI were analysed to find out the impact of SGLT2i on circulating NT-proBNP levels. Changes in the absolute value of NT-proBNP (MD: -42.96 ng\/L; 95% CI: -122.28 to 36.37;\u00a0<em id=\"76adaba2-bd93-4861-a264-7e9d997a70fb\"><\/em>p=0.29;\u00a0<em id=\"c6df9f81-19a9-4ac3-9718-b10dac3c1271\" class=\"sty cts-3\">I<\/em><sup id=\"241d06e9-9905-47e1-a2bf-98ffd16e25b0\">2<\/sup>=0% [low heterogeneity];\u00a0<em><span class=\"jrnlFigRef\" data-citation-string=\" F1 \">Figure 1e<\/span><\/em>) were similar in patients receiving SGLT2i compared with those receiving placebo. Data from two studies (576 patients) on AMI were analysed to find out the impact of SGLT2i on the percentage change in circulating levels of NT-proBNP compared with baseline. Percentage change in NT-proBNP was similar in patients receiving SGLT2i compared with placebo (MD: 1.18%; 95% CI: -9.78 to 12.14;\u00a0<em id=\"47e982e6-cdf0-4210-bbb4-0ac600c7d56e\"><\/em>p=0.83;\u00a0<em id=\"22a7a528-f17d-4e90-ba4c-b310911bfbae\" class=\"sty cts-3\">I<\/em><sup id=\"2aad8f9b-4fed-4313-9758-14235523ae3d\">2<\/sup>=52% [moderate heterogeneity];\u00a0<em><span class=\"jrnlFigRef\" data-citation-string=\" F1 \">Figure 1f<\/span><\/em>).<\/p>\n<h2 id=\"540a4eda-1dd5-4eb4-b8fc-768ac271b8c3\" class=\"jrnlHead2\">High-sensitivity C-reactive protein<\/h2>\n<p id=\"b9423330-b5bb-4060-a68f-b338f7453665\" class=\"jrnlSecPara\">Data from two studies having 533 patients with AMI were analysed to find out the impact of SGLT2i on circulating inflammatory marker hs-CRP. hs-CRP levels were similar in patients receiving SGLT2i compared with those receiving placebo (MD: -0.08 mg\/L; 95% CI: -0.29 to 0.14;\u00a0<em id=\"0e612f9b-4b13-4fcf-8e5e-caebda3443e5\"><\/em>p=0.48;\u00a0<em id=\"9b2738e3-43c6-4cd1-94bf-8d9a8972b5d0\" class=\"sty cts-3\">I<\/em><sup id=\"68838a25-cd6b-4470-b608-39d7ff32f1a3\">2<\/sup>=0% [low heterogeneity];\u00a0<em><span class=\"jrnlFigRef\" data-citation-string=\" F2 \">Figure 2a<\/span><\/em>).<\/p>\n<div id=\"BLK_F2\" class=\"jrnlFigBlock\">\n<h2 id=\"F2\" class=\"jrnlFigCaption\"><span class=\"label\">Figure 2: <\/span>Forest plot highlighting the impact of early initiation of sodium<span id=\"d4763a29-dcbd-42cb-ba64-ac68d82dfc8f\">\u2013<\/span>glucose co-transporter-2 inhibitors in patients with myocardial infarction<\/h2>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-104777 size-full\" src=\"https:\/\/touchendocrinology.com\/wp-content\/uploads\/sites\/5\/2025\/02\/Screenshot-2025-02-07-150359.png\" alt=\"Figure 2: Forest plot highlighting the impact of early initiation of sodium\u2013glucose co-transporter-2 inhibitors in patients with myocardial infarction\" width=\"697\" height=\"481\" srcset=\"https:\/\/touchendocrinology.com\/wp-content\/uploads\/sites\/5\/2025\/02\/Screenshot-2025-02-07-150359.png 697w, https:\/\/touchendocrinology.com\/wp-content\/uploads\/sites\/5\/2025\/02\/Screenshot-2025-02-07-150359-300x207.png 300w, https:\/\/touchendocrinology.com\/wp-content\/uploads\/sites\/5\/2025\/02\/Screenshot-2025-02-07-150359-50x35.png 50w\" sizes=\"(max-width: 697px) 100vw, 697px\" \/><\/p>\n<p class=\"jrnlFigFoot\"><em>(<span id=\"0c2f2f92-4750-4bb8-a5f3-c6581ad36ced\" class=\"partLabel\">a<\/span>)<span id=\"74266bc3-f347-432c-894b-e97d4acf9353\" class=\"nonBreakingSpace\">\u00a0<\/span>hs-CRP; (<span id=\"91f2ccec-e288-46cf-b8e2-db7e4bfd15b0\" class=\"partLabel\">b<\/span>)<span id=\"8364e047-373f-4a7f-846e-4fddd5743c8d\" class=\"nonBreakingSpace\">\u00a0<\/span>stroke and (<span id=\"15666bd5-2b0d-4c33-becb-64f3000c26d2\" class=\"partLabel\">c<\/span>)<span id=\"aad0adbf-c02b-4ffb-9e99-278043304737\" class=\"nonBreakingSpace\">\u00a0<\/span>all-cause hospitalization.<\/em><\/p>\n<p class=\"jrnlFigFoot\"><em><span id=\"b9938018-d300-4a8c-9309-62fef1bcc9e5\"><span id=\"7fe607d7-d588-4123-b85e-ab5fe1bcb8cf\">CI = confidence interval<\/span>; df = degrees of freedom<\/span>; hs-CRP = high-sensitivity C-reactive protein; IV = inverse variance;\u00a0<span id=\"7b9685e0-1afc-47d3-a60b-89f7f5b9f28c\">SD = standard deviation;\u00a0<span id=\"ed7297b1-6576-4b85-bd1e-3127bbb6f5ed\">SGLT2i = s<\/span><span id=\"e4bf8b7f-7074-4eb8-8a28-297c28a89cb8\">odium\u2013glucose co-trasnporter-2 inhibitors<\/span><\/span>.<\/em><\/p>\n<\/div>\n<h2 id=\"d6386bdb-9609-4e3b-8324-4c7dd6c8bd36\" class=\"jrnlHead2\">Stroke, all-cause hospitalization and myocardial infarction<\/h2>\n<p id=\"bf40ed70-f800-4ace-85f4-c72fe3057ebe\" class=\"jrnlSecPara\">Data from two studies involving 4,110 patients with AMI were analysed to find out the impact of early initiation of SGLT2i following MI on the occurrence of stroke and all-cause hospitalization. Stroke (OR: 0.58; 95% CI: 0.26\u20131.27;\u00a0<em id=\"5ba961ae-8177-4f0d-85ea-643d9a6fd209\"><\/em>p=0.17;\u00a0<em><span class=\"jrnlFigRef\" data-citation-string=\" F2 \">Figure 2b<\/span><\/em>) and all-cause hospitalization (OR: 1.13; 95% CI: 0.97\u20131.32;\u00a0<em id=\"e9a37c95-d958-41ac-9430-2c2a1b646c83\"><\/em>p=0.11;\u00a0<em id=\"3bc0ccbb-0df4-4d76-a014-e7caefdef549\" class=\"sty cts-3\">I<\/em><sup id=\"dae63d8d-93a8-4999-bf9c-c623da790039\">2<\/sup>=0% [low heterogeneity];\u00a0<em><span class=\"jrnlFigRef\" data-citation-string=\" F2 \">Figure 2c<\/span><\/em>) following AMI were similar in patients on SGLT2i compared with placebo. Data from one study were available analysing the occurrence of a recurrent event of MI following the use of SGLT2i after an index AMI. Recurrence of MI following AMI was similar in patients on SGLT2i compared with placebo (OR: 1.12; 95% CI: 0.72\u20131.73;\u00a0<em id=\"c4183539-534d-4922-afe0-01a3e76400c2\"><\/em>p=0.61;\u00a0<em id=\"53929c8c-cb6a-493e-805d-4658368a1f78\" class=\"sty cts-3\">I<\/em><sup id=\"bec11b18-2bb7-460b-bf72-6db0ae4493b2\">2<\/sup>=0%;\u00a0<span id=\"11c84bf0-7d25-462b-82b1-7b7b1cdd0086\" class=\"styrm cts-3\"><\/span><em id=\"f40bfc7c-208f-4565-ae4d-0aee820278a1\" class=\"sty cts-2\"><\/em>DAPA-MI trial).<span id=\"0af86351-79e9-4e2f-bade-bd086e9d666a\" class=\"jrnlBibRef\" data-citation-string=\" R6 \"><sup id=\"eb8debb5-e6a4-4e45-b11a-4e12e2fd207c\">6<\/sup><\/span><\/p>\n<h2 id=\"c153642e-a0e3-4092-b6b9-7e12791baa7a\" class=\"jrnlHead2\">Safety<\/h2>\n<h3 id=\"2c3daeaf-7af1-4525-ba74-1cd0c47ee571\" class=\"jrnlHead3\">Weight<\/h3>\n<p id=\"cb6514e6-2a9e-471d-acf9-c2639d678c30\" class=\"jrnlSecPara\">Data from three studies involving 4,206 patients with AMI were analysed to find out the impact of early initiation of SGLT2i following MI on body weight. Patients receiving SGLT2i had significantly lower body weight compared with placebo (MD: -1.76 kg; 95% CI: -2.19 to -1.32];\u00a0<em id=\"301b21bd-22df-43c6-aaeb-c8eb27bac759\"><\/em>p&lt;0.001;\u00a0<em id=\"73f7642c-4e31-4c11-8afe-d944dd9a788c\" class=\"sty cts-3\">I<\/em><sup id=\"46bc19b6-8802-4159-92e4-868151f29be5\">2<\/sup>=0% [low heterogeneity];\u00a0<em><span class=\"jrnlFigRef\" data-citation-string=\" F3 \">Figure 3a<\/span><\/em>).<\/p>\n<div id=\"BLK_F3\" class=\"jrnlFigBlock\">\n<h2 id=\"F3\" class=\"jrnlFigCaption\"><span class=\"label\">Figure 3: <\/span>Forest plot highlighting the impact of early initiation of sodium<span id=\"9a656c25-1205-48b9-a561-dd38d4b2f93f\">\u2013<\/span>glucose co-transporter-2 inhibitors in patients with myocardial infarction<\/h2>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-104782 size-full\" src=\"https:\/\/touchendocrinology.com\/wp-content\/uploads\/sites\/5\/2025\/02\/Screenshot-2025-02-07-150502.png\" alt=\"Figure 3: Forest plot highlighting the impact of early initiation of sodium\u2013glucose co-transporter-2 inhibitors in patients with myocardial infarction\" width=\"618\" height=\"592\" srcset=\"https:\/\/touchendocrinology.com\/wp-content\/uploads\/sites\/5\/2025\/02\/Screenshot-2025-02-07-150502.png 618w, https:\/\/touchendocrinology.com\/wp-content\/uploads\/sites\/5\/2025\/02\/Screenshot-2025-02-07-150502-300x287.png 300w, https:\/\/touchendocrinology.com\/wp-content\/uploads\/sites\/5\/2025\/02\/Screenshot-2025-02-07-150502-50x48.png 50w\" sizes=\"(max-width: 618px) 100vw, 618px\" \/><\/p>\n<p class=\"jrnlFigFoot\"><em>(<span id=\"d6033de5-ef1a-4eca-9b81-2ea2c3cb2a1d\" class=\"partLabel\">a<\/span>)<span id=\"b8b7f1f6-e3da-4672-bf67-e752272b8c8b\" class=\"nonBreakingSpace\">\u00a0<\/span>Body weight; (<span id=\"a619724f-5341-407f-9e28-8452323560c8\" class=\"partLabel\">b<\/span>)<span id=\"272438d2-b688-4246-8a6a-bc76affa9a27\" class=\"nonBreakingSpace\">\u00a0<\/span>ketoacidosis; (<span id=\"846d8a15-3286-448e-8ace-314451fe05c0\" class=\"partLabel\">c<\/span>)<span id=\"e92fbbb7-2021-41d9-988a-3f67fb9242b2\" class=\"nonBreakingSpace\">\u00a0<\/span>acute kidney injury and (<span id=\"9a455e3c-233f-4aca-96a0-105a446f1c76\" class=\"partLabel\">d<\/span>) hepatic injury.<\/em><\/p>\n<p class=\"jrnlFigFoot\"><em><span id=\"5338b1f4-dd44-4a90-a5d1-e9a530da7083\"><span id=\"0c141b99-a7c5-4753-937e-ae32f0b211b8\">CI = confidence interval<\/span>; df = degrees of freedom<\/span>; IV = inverse variance;\u00a0<span id=\"ee1c5e27-2713-4237-b90c-be7ef4794678\">SD = standard deviation;\u00a0<span id=\"b1366e4a-62ed-4968-a386-73dc542512b7\">SGLT2i = s<\/span><span id=\"c9477b8b-d1dd-45d6-94fe-b16e3ae809d3\">odium\u2013glucose co-trasnporter-2 inhibitors<\/span><\/span>.<\/em><\/p>\n<\/div>\n<h2 id=\"6d911bac-9a10-47ac-bdda-bec98f4280a5\" class=\"jrnlHead2\">Ketoacidosis, acute renal failure and hepatic injury<\/h2>\n<p id=\"13bd2ee8-6484-4aae-9721-c5cd0a53b4b9\" class=\"jrnlSecPara\">Data from two studies involving 6,939 patients with AMI were analysed to find out the impact of early initiation of SGLT2i following MI on the occurrence of ketoacidosis, acute renal failure and hepatic injury. The occurrence of ketoacidosis (OR: 2.00; 95% CI: 0.18\u201322.04;\u00a0<em id=\"1a6281b0-641a-4612-8a91-d7b4d7c9f451\"><\/em>p=0.57;\u00a0<em><span class=\"jrnlFigRef\" data-citation-string=\" F3 \">Figure 3b<\/span><\/em>), acute renal failure (OR: 0.72; 95% CI: 0.49\u20131.08;\u00a0<em id=\"fa336c9c-24dd-4516-a440-dcc3ee5ad5fb\"><\/em>p=0.11;\u00a0<em><span class=\"jrnlFigRef\" data-citation-string=\" F3 \">Figure 3c<\/span><\/em>) and hepatic injury (OR: 2.88; 95% CI: 0.74\u201311.17;\u00a0<em id=\"ad0870b9-3046-44af-b029-753411d19430\"><\/em>p=0.13;\u00a0<em id=\"57c72185-5602-4007-8181-e641f544ee85\" class=\"sty cts-3\">I<\/em><sup id=\"f8db82cb-47ec-4eb1-94fb-9345eeaf865e\">2<\/sup>=0% [low heterogeneity];\u00a0<em><span class=\"jrnlFigRef\" data-citation-string=\" F3 \">Figure 3d<\/span><\/em>) was similar in patients receiving SGLT2i compared with placebo.<\/p>\n<p id=\"b36a332f-3b64-498d-8140-5451207a3db9\" class=\"jrnlSecPara\">Funnel plots were plotted to evaluate the presence of publication bias and have been elaborated in\u00a0<span class=\"jrnlSupplRef\" data-citation-string=\" SM3 \"><em id=\"93f00c9a-01b8-4439-bd46-58c18f9846a3\" class=\"sty cts-6\">Supplementary Material 3<\/em><\/span><em id=\"13098b47-bd8c-47ca-95a3-f23c8bd2d40f\" class=\"sty cts-6\">.<\/em>\u00a0All the key outcomes had low publication bias. The SoF of some of the major outcomes of this SRM has been elaborated in\u00a0<em><span class=\"jrnlTblRef\" data-citation-string=\" T2 \">Table 2<\/span><\/em>. All the key outcomes of this SRM had a high grade of evidence.<\/p>\n<div id=\"BLK_T2\" class=\"jrnlTblBlock\">\n<h2 id=\"T2\" class=\"jrnlTblCaption\"><span id=\"f51496a4-c9bf-4214-b8b3-fc321a2d258e\" class=\"label\">Table 2: <\/span>Summary of the findings of the key outcomes of this systematic review and meta-analysis evaluating the role of sodium<span id=\"a9a69ffd-9523-4910-9392-836064cef089\">\u2013<\/span>glucose co-transporter-2 inhibitors in acute myocardial infarction<\/h2>\n<div class=\"jrnlTblContainer\">\n<table id=\"be6921f4-47f1-40fa-8834-720c25a7e6b9\" class=\"jrnlTable\">\n<thead id=\"f250f70c-dabe-4f2d-9708-2a5c7b71373a\">\n<tr id=\"35e9666b-bd91-4d9a-a9ce-bcf8a259763f\">\n<td id=\"71752a04-82d2-415e-807a-31fa39dddc7a\" class=\"\" rowspan=\"2\">\n<p id=\"4332d601-7e1c-486f-b811-23ea340646a7\" class=\"jrnlTblBody\"><b id=\"edbbab52-5340-4317-b6d2-1b1875cf96d8\">Outcomes<\/b><\/p>\n<\/td>\n<td id=\"31236c5c-ae44-47c3-b598-efa16631220c\" class=\"\" colspan=\"2\">\n<p id=\"1ad9971d-a08f-4a81-bd08-4869a7cb8146\" class=\"jrnlTblBody\"><b id=\"2df956a0-5238-451f-b4cb-742bcccd44c1\">Anticipated absolute effects<sup id=\"b1aa2d6b-a291-4e24-b4e9-536a9170b884\">*<\/sup><\/b>\u00a0(95% CI)<\/p>\n<\/td>\n<td id=\"f249342b-8a0d-4a2f-a5d5-225723e118a1\" class=\"\" rowspan=\"2\">\n<p id=\"2b73b13e-ac07-4f5b-86ca-acf502ce743b\" class=\"jrnlTblBody\">Relative effect (95% CI)<\/p>\n<\/td>\n<td id=\"b8a3aaa5-ea7d-45ce-9290-17d7c4175d25\" class=\"\" rowspan=\"2\">\n<p id=\"aebcfc91-3bf3-453c-bf6a-aee7f801f391\" class=\"jrnlTblBody\">No. of participants (studies)<\/p>\n<\/td>\n<td id=\"b4c275d8-d464-4216-92e5-a5ad71cd7132\" class=\"\" rowspan=\"2\">\n<p id=\"2ef7a124-c001-49dc-90c3-cd4b298f1802\" class=\"jrnlTblBody\">Certainty of the evidence (GRADE)<\/p>\n<\/td>\n<\/tr>\n<tr id=\"47378dd6-51d0-4b1f-8828-a9278af4c758\">\n<td id=\"3591e59e-eb0e-44c8-b798-404b7b747be3\" class=\"\">\n<p id=\"259924ec-9951-4648-970e-1533b436b63c\" class=\"jrnlTblBody\"><b id=\"b1052f6d-4b4b-4c89-9ba8-1c72135a3fb2\">Risk with placebo in the MI group<\/b><\/p>\n<\/td>\n<td id=\"f6f1633b-17a3-4b5b-8f5e-0b98852730d4\" class=\"\">\n<p id=\"deb8b865-dc75-476c-8f0f-7a697be5b971\" class=\"jrnlTblBody\"><b id=\"28f5a8ce-30bc-4264-90b1-72138fed9669\">Risk with SGLT2i in the MI group<\/b><\/p>\n<\/td>\n<\/tr>\n<\/thead>\n<tbody id=\"ee6fbc28-a1d3-4752-9593-6ad9f062817c\">\n<tr id=\"fb3ba3e6-7dba-41f2-b75a-da5d65e06704\">\n<td id=\"4addaaf1-c26b-44c1-bf56-112a1cf4db79\" class=\"\">\n<p id=\"4f4b5c3c-0126-43ca-9354-9aecc20f823c\" class=\"jrnlTblBody\"><b id=\"0132b500-b81d-4cd5-b275-e4e44f3502e3\">CV death<\/b><\/p>\n<\/td>\n<td id=\"62e3abde-0348-410e-902c-0caacaf3eaf3\" class=\"\">\n<p id=\"3cb69acf-420d-4b51-948f-7a511e8aee68\" class=\"jrnlTblBody\">28 per 1,000<\/p>\n<\/td>\n<td id=\"fa958b19-76bd-439f-abc9-fc02506f5e15\" class=\"\">\n<p id=\"ae6067ca-d12c-4da6-98e5-6c752db9e6bb\" class=\"jrnlTblBody\"><b id=\"2276c16c-4181-47b2-8b2c-c03fec91bbd6\">29 per 1,000<\/b>\u00a0(23\u221236)<\/p>\n<\/td>\n<td id=\"8c3b91e7-49a2-4d3f-89ca-b39000825ade\" class=\"\">\n<p id=\"5810763e-bfd3-4f44-948f-bc40469cf5a0\" class=\"jrnlTblBody\"><b id=\"b944e73b-49f1-420e-9a6b-99a61fb82dfa\">OR 1.04<\/b>\u00a0(0.83\u22121.30)<\/p>\n<\/td>\n<td id=\"be0d43af-fb5f-4234-bb91-f38ac64c8bbf\" class=\"\">\n<p id=\"360ff512-7569-4687-8301-8a1fd519a59a\" class=\"jrnlTblBody\">11,108 (four RCTs)<\/p>\n<\/td>\n<td id=\"fcf05441-7446-4a38-aca4-04f74b58799e\" class=\"\">\n<p id=\"dafeb47b-6bc0-41fc-86e8-fa447da81546\" class=\"jrnlTblBody\"><span id=\"35ed9699-210c-4edb-93bc-a3e7b9b01ad6\">\u2a01\u2a01\u2a01\u2a01<\/span>\u00a0High<\/p>\n<\/td>\n<\/tr>\n<tr id=\"e38ab333-ff89-458e-ad38-a913a9c8a1d5\">\n<td id=\"429dcc6e-e0a6-4c71-bae4-5cab85dfc8a1\" class=\"\">\n<p id=\"815e93b7-4f37-4f8e-8532-7f33b62d1751\" class=\"jrnlTblBody\"><b id=\"e3bd93d5-9305-47b8-a13f-c2d6bedb1a12\">All-cause death<\/b><\/p>\n<\/td>\n<td id=\"a3ee26c2-9db4-41d5-a171-c0fef9a898ed\">\n<p id=\"a2fe0b07-f420-4b7c-a799-a4a6d0e7e9b1\" class=\"jrnlTblBody\">38 per 1,000<\/p>\n<\/td>\n<td id=\"a216c44b-dbfe-4f21-9378-00ca62c75865\" class=\"\">\n<p id=\"1b5a65b1-64ec-494e-8652-f370004aa72d\" class=\"jrnlTblBody\"><b id=\"7cb73499-0ccd-4766-b7e6-8209275661dc\">38 per 1,000<\/b>\u00a0(32\u221246)<\/p>\n<\/td>\n<td id=\"159c89eb-b7f7-4126-a70f-dcebbb51ca45\" class=\"\">\n<p id=\"83e43da7-9bea-47b6-9d51-8cb449ea7e0c\" class=\"jrnlTblBody\"><b id=\"57abe5ee-24d1-46d9-86c8-828f44ee835c\">OR 1.00<\/b>\u00a0(0.82\u22121.21)<\/p>\n<\/td>\n<td id=\"514e2d91-6549-47da-8fa2-a8490d46f7bf\" class=\"\">\n<p id=\"9ab8df0c-c6e1-40ab-87be-0c7b1632d170\" class=\"jrnlTblBody\">11,108 (four RCTs)<\/p>\n<\/td>\n<td id=\"d7694a67-1699-4da3-8b60-1ed9d7920d27\" class=\"\">\n<p id=\"c3dae537-b7f4-4350-9b01-a4af6ebec865\" class=\"jrnlTblBody\"><span id=\"03784d3f-0146-4214-abb6-6d8da1081aae\">\u2a01\u2a01\u2a01\u2a01<\/span>\u00a0High<\/p>\n<\/td>\n<\/tr>\n<tr id=\"735ec96e-b1d4-4983-877c-67b3354c98ff\">\n<td id=\"4855ac69-475f-47cf-90d5-18e8a4c1e54b\" class=\"\">\n<p id=\"8f0f79bd-6eed-4db4-9f97-2bc8299ff61c\" class=\"jrnlTblBody\"><b id=\"5567902d-659a-4803-a40a-a72248ad1ce4\">Hospitalization for heart failure<\/b><\/p>\n<\/td>\n<td id=\"088d6eea-62f2-48a5-a659-72b502352d39\">\n<p id=\"f117d964-1811-4ca1-a445-1683e1ba8aab\" class=\"jrnlTblBody\">49 per 1,000<\/p>\n<\/td>\n<td id=\"a6095a70-327b-4797-b19a-ba8fa675c82b\" class=\"\">\n<p id=\"24689e94-e09b-434b-b92e-b58c37598ff1\" class=\"jrnlTblBody\"><b id=\"67ffc85f-bd52-4f8f-af86-60daa8ac0f2d\">37 per 1,000<\/b>\u00a0(31\u221244)<\/p>\n<\/td>\n<td id=\"d0cf8b27-8413-4da3-ad29-780cf14cfb2e\" class=\"\">\n<p id=\"406333d9-8382-4b65-b9b3-92e048c71150\" class=\"jrnlTblBody\"><b id=\"41b16aeb-7105-4d45-8165-52b2ce8cfab6\">OR 0.75<\/b>\u00a0(0.62\u22120.90)<\/p>\n<\/td>\n<td id=\"27b651d5-648f-4af4-b8f7-283e763a68d3\" class=\"\">\n<p id=\"47cbace5-deab-4cd2-ab83-13448db244d9\" class=\"jrnlTblBody\">11,108 (four RCTs)<\/p>\n<\/td>\n<td id=\"7b385704-7810-4e1e-b52f-5c9062d0a7da\" class=\"\">\n<p id=\"460ec6dd-c4a4-4401-964f-ed711f5b85c6\" class=\"jrnlTblBody\"><span id=\"d6c1b59c-6481-4b2f-9c3c-48b40a8c39d4\">\u2a01\u2a01\u2a01\u2a01<\/span>\u00a0High<\/p>\n<\/td>\n<\/tr>\n<tr id=\"9c6c14b6-e57b-4918-a3ec-b85f1dd87aad\">\n<td id=\"f345fa8d-fd57-4a4f-b4f3-a2dba5b53f07\" class=\"\">\n<p id=\"3e26aed9-4514-445a-b84e-b42ce32ee958\" class=\"jrnlTblBody\"><b id=\"dff558bc-16fa-4386-8f36-bf7ecacef59e\">All-cause hospitalization<\/b><\/p>\n<\/td>\n<td id=\"c251bc04-0912-4cb4-b2b0-07ca861d0ccf\">\n<p id=\"b1c4e610-9934-4e07-a0b7-84c7e7de6e99\" class=\"jrnlTblBody\">184 per 1,000<\/p>\n<\/td>\n<td id=\"96e12bd4-1ab3-4210-83bc-439363bf2e13\" class=\"\">\n<p id=\"1d558004-8b8c-47f8-8255-191f4808bc46\" class=\"jrnlTblBody\"><b id=\"789e80d3-907a-4f73-835f-faa15d7cbdf2\">203 per 1,000<\/b>\u00a0(179\u2212229)<\/p>\n<\/td>\n<td id=\"9b59975a-c787-48e6-b069-5de376d71eaf\" class=\"\">\n<p id=\"6f13f7eb-8437-4ffb-853e-850adc1ffeef\" class=\"jrnlTblBody\"><b id=\"49904d65-2c0a-4f9f-8fa5-838030db8d6e\">OR 1.13<\/b>\u00a0(0.97\u22121.32)<\/p>\n<\/td>\n<td id=\"823fec56-5423-40ff-af95-c0ccffa78047\" class=\"\">\n<p id=\"2d7e26da-dae4-4ae1-bccb-0568d86c3f09\" class=\"jrnlTblBody\">4,110 (two RCTs)<\/p>\n<\/td>\n<td id=\"988f4668-f717-494a-b6f3-8402df8a34bc\" class=\"\">\n<p id=\"2ac91e88-8e96-4d6e-bf78-fa9dd71ab958\" class=\"jrnlTblBody\"><span id=\"f8f2f59d-b145-4d62-9a57-791088c87cd1\">\u2a01\u2a01\u2a01\u2a01<\/span>\u00a0High<\/p>\n<\/td>\n<\/tr>\n<tr id=\"a3fb7d45-2a12-4b1d-86cb-b102ba434dd2\">\n<td id=\"6a470592-8c10-4b51-99db-5daea16c7dc9\" class=\"\">\n<p id=\"d26cdc9b-cccf-40f9-96c2-d7aa7ac77009\" class=\"jrnlTblBody\"><b id=\"463e09e4-9fe3-4b6f-baac-eae264bef390\">Acute renal failure<\/b><\/p>\n<\/td>\n<td id=\"a3b2e447-cf9d-44ac-a2b4-507357c9152a\">\n<p id=\"e035b685-62f0-49e5-95b1-30e4854f69cb\" class=\"jrnlTblBody\">17 per 1,000<\/p>\n<\/td>\n<td id=\"4581f7c4-6229-4a89-90ad-14d5e5d7c869\" class=\"\">\n<p id=\"c432ae5c-532f-46f9-932a-d882a9725da9\" class=\"jrnlTblBody\"><b id=\"eb16328d-0c34-4a7f-9883-4ace98428165\">12 per 1,000<\/b>\u00a0(8\u221218)<\/p>\n<\/td>\n<td id=\"0a245d4f-c6df-439c-ade2-57da53217043\" class=\"\">\n<p id=\"5469cc72-49dc-4ea5-ac88-31f69fbeb178\" class=\"jrnlTblBody\"><b id=\"67f536ec-64eb-4e5d-8200-5d1e7ec472ef\">OR 0.72<\/b>\u00a0(0.49\u22121.08)<\/p>\n<\/td>\n<td id=\"01bb0128-d7f3-4caf-9a43-6a11bbc5dad5\" class=\"\">\n<p id=\"e70a0ad4-f01c-441c-b07b-e58e9f2bb444\" class=\"jrnlTblBody\">6,939 (two RCTs)<\/p>\n<\/td>\n<td id=\"f41536aa-af88-40dd-b0e6-6e8a629ac0e5\" class=\"\">\n<p id=\"0b28f245-8ecc-44cd-8acb-c55ecc1ff70c\" class=\"jrnlTblBody\"><span id=\"453c4c53-43dc-4164-8ce4-cfcd2f7bc618\">\u2a01\u2a01\u2a01\u2a01<\/span>\u00a0High<\/p>\n<\/td>\n<\/tr>\n<tr id=\"12cbad8f-c8f1-4d67-85db-7c76a2bf50fa\">\n<td id=\"2f167be9-d031-4030-a8d4-19bcee8c7563\" class=\"\">\n<p id=\"6ea0d372-3052-4d9a-a99d-a6c7fb132e7e\" class=\"jrnlTblBody\"><b id=\"f80b3532-917a-47c8-9907-541b37e0ef8f\">Hepatic injury<\/b><\/p>\n<\/td>\n<td id=\"b092101d-e100-42f7-93c9-c200cb8a5ee9\" class=\"\">\n<p id=\"1d4d80e3-d59c-4be9-ac40-b9e6356bfd3d\" class=\"jrnlTblBody\">1 per 1,000<\/p>\n<\/td>\n<td id=\"e88b6a4d-7bdc-4c73-9b82-4ad049b1ee59\" class=\"\">\n<p id=\"d48790ff-10ca-4af9-9183-6eafc2873e1c\" class=\"jrnlTblBody\"><b id=\"287f49ad-1d5b-4f01-a9f4-ea10a2c78d08\">2 per 1,000<\/b>\u00a0(1\u221210)<\/p>\n<\/td>\n<td id=\"c9d53451-8d0a-45b8-8605-5a4f356374bb\" class=\"\">\n<p id=\"37e445df-2e99-4d09-9ae4-bae7fa099dea\" class=\"jrnlTblBody\"><b id=\"64151ed5-7b02-404b-8a57-8655df1f765f\">OR 2.88<\/b>\u00a0(0.74\u221211.17)<\/p>\n<\/td>\n<td id=\"ae1b5c16-b402-483d-92f3-1e9df5b95fc8\" class=\"\">\n<p id=\"e120c6fb-015e-47bb-ad71-e3c1ec2ec63d\" class=\"jrnlTblBody\">6,939 (two RCTs)<\/p>\n<\/td>\n<td id=\"fca82223-0eee-48b5-b1fd-e7987621bcf4\" class=\"\">\n<p id=\"e77efa92-8876-4faa-aec9-942864a607e7\" class=\"jrnlTblBody\"><span id=\"a5a2789d-b36c-47b7-959c-bec97ec226cc\">\u2a01\u2a01\u2a01\u2a01<\/span>\u00a0High<\/p>\n<\/td>\n<\/tr>\n<tr id=\"9045367e-cc99-411d-a919-4e8190560093\">\n<td id=\"7ea8bf12-1533-4dd8-8748-ea13d46a6e1f\" class=\"\">\n<p id=\"bd494e9b-835c-4d48-bf15-981ea9494ebc\" class=\"jrnlTblBody\"><b id=\"2e69f0e3-9685-41ae-a865-4b397d999324\">Ketoacidosis<\/b><\/p>\n<\/td>\n<td id=\"772653be-45eb-4d2c-a36f-80de91084c8d\" class=\"\">\n<p id=\"8109cf56-03d0-4958-acd1-30a28c62b7bb\" class=\"jrnlTblBody\">0 per 1,000<\/p>\n<\/td>\n<td id=\"399fb098-1d8e-44d4-93d3-c4c34f5793a1\" class=\"\">\n<p id=\"f8cad6dd-749d-468e-ad5d-1d8a1adfd4a4\" class=\"jrnlTblBody\"><b id=\"9233f098-f72d-4173-aef5-b78aaa72f79e\">1 per 1,000<\/b>\u00a0(0\u22126)<\/p>\n<\/td>\n<td id=\"ac59c2e0-8663-46e6-8ff2-d6a838a63dec\" class=\"\">\n<p id=\"d0e9fc18-fcb9-46b0-be54-e7c3d6209e2c\" class=\"jrnlTblBody\"><b id=\"e0b09a20-24a7-42cb-bb40-0310b48a497c\">OR 2.00<\/b>\u00a0(0.18\u221222.04)<\/p>\n<\/td>\n<td id=\"0c61f811-c3ea-434b-8736-5d88348090aa\" class=\"\">\n<p id=\"8b98e3d8-de22-4568-ab7e-82120c27eaa4\" class=\"jrnlTblBody\">6,939 (two RCTs)<\/p>\n<\/td>\n<td id=\"2d616fec-1d13-4eca-a34b-47c59d1058b5\" class=\"\">\n<p id=\"646f41e8-9831-4706-a713-1270037a0278\" class=\"jrnlTblBody\"><span id=\"4a82ee4b-73a7-439e-8e25-9274121475b9\">\u2a01\u2a01\u2a01\u2a01<\/span>\u00a0High<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div id=\"28d82804-aed9-4d8f-b7b1-3d855757ca92\" class=\"jrnlTblFootGroup\">\n<div id=\"T2_FN1\" class=\"jrnlTblFoot\">\n<p class=\"jrnlTblFootText\"><em>*<span id=\"ccce0d93-bfe5-4932-99d3-594bb3f7aa61\" class=\"styrm cts-4\">The risk in the intervention group<\/span>\u00a0(and its 95% CI) is based on the assumed risk in the comparison group and the\u00a0<span id=\"963bd779-9492-4a4b-bd28-b5802ec6efb7\" class=\"styrm cts-4\">relative effect<\/span>\u00a0of the intervention (and its 95% CI).<b id=\"15208a21-933d-424f-9506-10311710ba92\"><\/b><b id=\"e059cb75-1ec2-4fda-a7a5-31dfb20d5bcd\"><\/b><\/em><\/p>\n<\/div>\n<div id=\"T2_FN2\" class=\"jrnlTblFoot\">\n<p class=\"jrnlTblFootText\"><em>GRADE Working Group grades of evidence \u2013 high certainty: we are very confident that the true effect lies close to that of the estimate of the effect.\u00a0<span id=\"ea83532f-29fd-40c6-85af-60cc790d5956\" class=\"styrm cts-4\">Moderate certainty:<\/span>\u00a0we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.\u00a0<span id=\"fe8d7378-1fce-4837-9b3f-8a1324a35422\" class=\"styrm cts-4\">Low certainty:<\/span>\u00a0our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.\u00a0<span id=\"b1953f2e-36a6-4143-a02c-205e7757a679\" class=\"styrm cts-4\">Very low certainty:<\/span>\u00a0we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of the effect.<\/em><\/p>\n<\/div>\n<div id=\"ea653ce8-d229-45f5-8f9e-223b8d152ce4\" class=\"jrnlTblFoot\">\n<p class=\"jrnlTblFootText\"><em><span id=\"f7e9c65e-3491-471b-a653-551c3dc62660\" class=\"jrnlTblDefItem\"><span id=\"bb34434d-6e5c-406e-aafe-73269c5fe1ac\" class=\"jrnlAbbrevTerm\">CI<\/span>\u00a0=\u00a0<span id=\"04f1fd7b-74a0-49cd-8e25-a66e80187ad1\" class=\"jrnlFootDefinition\">confidence interval<\/span>; <\/span><span id=\"3dcf7bfd-9dc7-41cb-854d-5f5fb2d3834c\" class=\"jrnlTblDefItem\"><span id=\"53788d63-dcba-4abd-9983-e194638b5195\" class=\"jrnlAbbrevTerm\">CV<\/span>\u00a0=\u00a0<span id=\"3ece9b19-498c-425a-b530-0819f9bae76f\" class=\"jrnlFootDefinition\">cardiovascular<\/span>; <\/span><span id=\"4289ee96-23c3-4108-a8cc-234ec843bbe6\" class=\"jrnlTblDefItem\"><span id=\"1bd3c70a-783f-4a45-a53f-35eb720ef996\" class=\"jrnlAbbrevTerm\">GRADE<\/span>\u00a0=\u00a0<span id=\"347c6a43-a5f0-4a40-92b3-197c31e39986\" class=\"jrnlFootDefinition\">Grading of Recommendations Assessment, Development and Evaluation<\/span>; <\/span><span id=\"7df6a48c-05bb-4aa1-b0c1-9e0c8b137941\" class=\"jrnlTblDefItem\"><span id=\"9ba108f5-78c8-4f85-ae79-be8ea1dec711\" class=\"jrnlAbbrevTerm\">MI<\/span>\u00a0=\u00a0<span id=\"583ba922-9703-4d7b-aa3d-b8320865b066\" class=\"jrnlFootDefinition\">myocardial infarction<\/span>; <\/span><span id=\"39ed87b9-7240-4dfc-afe4-8c6b1904bcd4\" class=\"jrnlTblDefItem\"><span id=\"779fee37-0b99-4300-aedf-7a41df36bbfc\" class=\"jrnlAbbrevTerm\">OR<\/span>\u00a0=\u00a0<span id=\"ddb9d2f4-10e2-4625-b430-22df20af1224\" class=\"jrnlFootDefinition\">odds ratio<\/span>; <\/span><span id=\"fc4fb6d1-a927-4a62-a3bf-2533cc2ebefe\" class=\"jrnlTblDefItem\"><span id=\"94702db9-bad9-46a4-8030-fb360a1c700f\" class=\"jrnlAbbrevTerm\">RCT<\/span>\u00a0=\u00a0<span id=\"82428032-0c0a-489a-9636-864a9a28bb76\" class=\"jrnlFootDefinition\">randomized controlled trial<\/span>; <\/span><span id=\"ad756210-3f1f-4458-9aa7-101165794a90\" class=\"jrnlTblDefItem\"><span id=\"9ad5ce0c-b721-4ec9-8414-e93422a2d587\" class=\"jrnlAbbrevTerm\">SGLT2i<\/span>\u00a0=\u00a0<span id=\"2745a050-72b5-4160-bdf8-467c91ed797c\" class=\"jrnlFootDefinition\">sodium\u2013glucose co-transporter-2 inhibitors<\/span>.<\/span><\/em><\/p>\n<\/div>\n<\/div>\n<\/div>\n<h1 id=\"252fea1e-d6d2-4e6b-941a-ef00ebaf7881\" class=\"jrnlHead1\">Discussion<\/h1>\n<p id=\"c54073e7-944d-4f4f-916b-6b1e23454ce2\" class=\"jrnlSecPara\">In the different cardiovascular outcome trials (CVOTs) in patients with T2D, only empagliflozin and canagliflozin have demonstrated superiority in reducing 3-point major adverse CV events (3P MACE; CV mortality, nonfatal MI and nonfatal stroke) compared with placebo.<span id=\"be7a35a9-9fba-4d44-ae22-374f3d1e0768\" class=\"jrnlBibRef\" data-citation-string=\" R28 R29 \"><sup id=\"4a9559f2-02d5-412d-89d7-94c414351f39\">28,29<\/sup><\/span>\u00a0The same has not been seen in CVOTs with dapagliflozin, ertugliflozin and sotagliflozin, highlighting the heterogeneity in outcomes across different SGLT2i.<span id=\"c358e9d3-f0d0-42a1-9975-845b473aa890\" class=\"jrnlBibRef\" data-citation-string=\" R30 R31 R32 \"><sup id=\"7da42487-89f7-42dd-98c9-e34812409b0f\">30\u201332<\/sup><\/span>\u00a0The heterogeneity seen with SGLT2is in terms of CVOT outcomes may be related to trial populations and study designs rather than the individual molecules. In a meta-analysis of CVOTs of different SGLT2i in T2D, a significant reduction in CV death and all-cause mortality has been documented.<span id=\"cb0f3747-32e6-4958-b17d-fb41616f4718\" class=\"jrnlBibRef\" data-citation-string=\" R33 \"><sup id=\"21033c5a-47b8-4ddc-97c0-44a060ae29f6\">33<\/sup><\/span>\u00a0Data with regard to the reduction of HHF and heart failure-related deaths with the use of SGLT2i in patients with or without diabetes are more homogeneous and robust across the different SGLT2i.<span id=\"0d6ad558-7123-4371-b631-5b29c8d58823\" class=\"jrnlBibRef\" data-citation-string=\" R4 \"><sup id=\"7109e35c-1498-4a09-824b-d2cbc02338fb\">4<\/sup><\/span><\/p>\n<p id=\"b55865c0-5a58-4cec-a6fb-32ab1a306f8c\" class=\"jrnlSecPara\">SGLT2 inhibitors may have some protective benefit in reducing contrast-induced acute kidney injury events in patients with ACS undergoing PCI.<span id=\"bce1db9c-1ce8-47eb-8b7d-163d4a807f9b\" class=\"jrnlBibRef\" data-citation-string=\" R34 \"><sup id=\"c99be959-6207-4b5e-896f-c410a1b4604e\">34<\/sup><\/span>\u00a0Patients with AMI tend to be in a more critical condition and have a different metabolic milieu compared with stable patients living with T2D seen in the outpatient departments. Whether SGLT2i can replicate the same CV benefits in patients with MI as has been seen in patients living with T2D is not known.<span id=\"e885e265-1f65-44fc-9250-3c88524f856c\" class=\"jrnlBibRef\" data-citation-string=\" R34 \"><sup id=\"7aa5455f-5605-4f6b-99be-22ab8f3ba24f\">34<\/sup><\/span><\/p>\n<p id=\"e23adb09-0c4f-4b0e-85a1-8104027d8264\" class=\"jrnlSecPara\">This is the first SRM to highlight the efficacy and safety of early initiation of SGLT2i following AMI. The initiation of SGLT2i within 2 weeks of AMI was associated with significantly reduced future risk of HHF, without any additional beneficial impact on CV mortality, all-cause mortality, stroke and all-cause hospitalization. No significant improvement in circulating levels of NT-pro-BNP was noted. In addition, no improvement in systematic inflammation (hs-CRP) was noted. The use of SGLT2i following MI was well tolerated, without any increased occurrence of ketoacidosis, acute renal failure and hepatic injury. A mild but statistically significant reduction in body weight was noted.<\/p>\n<p id=\"c9be3e1a-85c5-47bc-9a1c-53ec83392225\" class=\"jrnlSecPara\">This SRM highlights that the benefits of using SGLT2i in patients with MI are restricted to improving heart failure outcomes, without any impact on ASCVD and mortality. Therefore, the results are much more tempered compared with those seen in patients with T2D with ASCVD. Mukhopadhyay\u00a0<span id=\"1d20bdb2-bbbe-484b-8a05-13c8e8a9328c\" class=\"styrm cts-3\">et al<\/span><em id=\"7b655096-6a93-4024-8d3b-aaf6abc94e8e\" class=\"sty cts-2\">.,<\/em>\u00a0in their meta-analysis of CVOTs of SGLT2i in T2D, highlighted that SGLT2i reduces MACE without significantly reducing the incidence of MI or stroke (fatal and nonfatal), probably implicating mechanisms unrelated to anti-atherogenic effects.<span id=\"dbd2fc20-a414-47ce-8a6c-dc2d9caa31f9\" class=\"jrnlBibRef\" data-citation-string=\" R35 \"><sup id=\"3d92cbde-4c49-4351-be81-c98702eb8b0f\">35 <\/sup><\/span>It is now increasingly being considered that the reduction in CV death and all-cause mortality with the use of SGLT2i in T2D, without any significant reduction in MI and stroke, may be due to non-atherosclerotic mechanisms such as reduction in heart failure-related events, sudden cardiac death and arrhythmias.<span id=\"47dcb72c-db1b-4f0b-be89-52a8a89ad896\" class=\"jrnlBibRef\" data-citation-string=\" R35 \"><sup id=\"62f4fd25-8a1d-478d-a483-cc59246663f4\">35<\/sup><\/span>\u00a0The outcomes of this SRM in patients with MI sync with the evolving understanding of the predominantly vascular non-atherosclerotic mechanism of action of SGLT2i in improving cardiac outcomes. In patients with MI, early use of SGLT2i results in predominantly vascular benefits of reduction in hospital admissions for heart failure, without any beneficial impact on stroke, CV mortality and all-cause mortality. Another reason for the tempered results with SGLT2i use in AMI, as seen in this SRM, may be because the heart failure seen in the setting of AMI is often transient. It results from myocardial stunning, neurohumoral activation and systemic inflammation, which are reversed to a great extent following prompt re-vascularization.<span id=\"88f86231-8822-482d-89e9-ee26c7aa8eb5\" class=\"jrnlBibRef\" data-citation-string=\" R36 \"><sup id=\"69a1ef21-5f66-4370-8f78-731d0316c965\">36<\/sup><\/span><\/p>\n<p id=\"f9343f78-bf48-4042-a23e-a04b572e399e\" class=\"jrnlSecPara\">Another class of medication, which has played a major role in improving CV outcomes in patients with diabetes and stable established ASCVD, is glucagon-like peptide-1 receptor agonists (GLP1RAs).<span id=\"589ffdb5-0f79-48f4-acc9-369365ff3647\" class=\"jrnlBibRef\" data-citation-string=\" R37 \"><sup id=\"a7484b4c-e40b-4097-821b-9c2c6f9eec26\">37 <\/sup><\/span>In a meta-analysis of data from six RCTs involving patients with AMI undergoing PCI, GLP1RA treatment was associated with improvement in the LVEF along with a reduction in the infarct size, without any significant reduction in CV events.<span id=\"7823f0ae-4de2-4f50-a6d0-98da2b04bb34\" class=\"jrnlBibRef\" data-citation-string=\" R38 \"><sup id=\"1740a12b-20cd-4775-a670-e71c2e52a76a\">38<\/sup><\/span>\u00a0Therefore, the outcomes of the use of GLP1RAs in the setting of AMI may be considered to be more tempered compared with the use in stable patients with ASCVD. As suggested by Karakasis\u00a0<span id=\"16fdd783-61b0-48e6-8a47-812bd1bd30c4\" class=\"styrm cts-3\">et al<\/span><em id=\"965f3e53-b193-452d-857a-3c0f9e6232ba\" class=\"sty cts-2\">.<\/em>, one reason may be the lack of dedicated CVOTs with GLP1RA in the setting of ACS; therefore, no solid evidence regarding their true CV efficacy on surrogate endpoints can be generated.<span id=\"5beed6e7-99eb-45b0-8a9e-e36da7cc5c23\" class=\"jrnlBibRef\" data-citation-string=\" R37 \"><sup id=\"531d5be5-7b7c-4dfc-9859-040ec160bf6b\">37<\/sup><\/span>\u00a0Thus, there remains an urgent need for dedicated studies evaluating the combination therapy of SGLT2i and GLP1RAs in patients with ACS, unstable angina and MI with non-obstructive coronaries. This combination therapy offers a dual beneficial impact on inflammation as well as on endothelial dysfunction.<span id=\"89db7689-6b7e-4457-9e40-49289ba98430\" class=\"jrnlBibRef\" data-citation-string=\" R37 \"><sup id=\"aa90090d-8217-44be-ba49-8326822fd405\">37<\/sup><\/span><\/p>\n<p id=\"68fa00d6-6f57-42c1-8cac-8f4607a32df0\" class=\"jrnlSecPara\">From this SRM, it is interesting to consider that the reduction in HHF with the use of SGLT2i in MI was not associated with a significant reduction in circulating levels of NT-proBNP, a commonly accepted serologic measure of heart failure. This may primarily be due to the small number of patients evaluated with data being available from three different RCTs only. A limitation of the current SRM is that the analysis was done on extracted summary data of the published RCTs, rather than individual patient data. Only dapagliflozin and empagliflozin have been evaluated in AMI. Data from other SGLT2i are not available. The actual number of different types of CV events in the different RCTs was relatively small. The follow-up duration was short in three of the six RCTs analysed (<em><span class=\"jrnlTblRef\" data-citation-string=\" T1 \">Table 1<\/span><\/em>). Additionally, outcome data of all the variables analysed were not available from all the RCTs analysed.<\/p>\n<p id=\"e14ed0dd-1808-4978-b20f-f68ab1182e0e\" class=\"jrnlSecPara\">Our SRM provides reassuring data on the safety of SGLT2i use in AMI. SGLT2i should be especially used in the setting of AMI when there is a history of chronic heart failure, T2D or chronic kidney disease. This SRM supports the early initiation of SGLT2i in patients with AMI during their stay in the hospital or discharge from the hospital. Delayed initiation of SGLT2i post-AMI has the risk of patients being lost to follow up and thus missing out on the benefits of this class of medication. In conclusion, it may be said that the early use of SGLT2i in AMI is safe, well tolerated and associated with a reduction in HHF.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Article Highlights Early use of sodium\u2013glucose co-transporter-2 inhibitors following myocardial infarction was associated with the following factors: Lower hospitalization for heart failure (odds ratio [OR]: 0.75; 95% confidence interval [CI]: 0.62\u20130.90; p=0.002). Similar cardiovascular deaths (OR: 1.04; 95% CI: 0.83\u20131.30; p=0.76). Similar all-cause mortality (OR: 1.00; 95% CI: 0.82\u20131.21; p=0.98). Similar risks of ketoacidosis, acute [&hellip;]<\/p>\n","protected":false},"author":100365,"featured_media":104812,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","rank_math_lock_modified_date":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-104762","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","vocabulary_1-diabetes","journal-touchreviews-in-endocrinology"],"acf":{"wpcf-article_introduction":"","wpcf-article_abstract":"<p id=\"ba2ad697-6f59-4023-b948-55566711e8db\" class=\"jrnlAbsPara\"><b id=\"f3085447-5d51-4b82-b9ec-40f253628cdc\" class=\"sty cts-4\">Background<\/b>. Sodium<span id=\"be3f775a-259f-4f6c-9d91-4c59798b81e5\">\u2013<\/span>glucose co-transporter-2 inhibitors (SGLT2i) are the preferred agents for managing type 2 diabetes in patients with established atherosclerotic cardiovascular disease and for reducing hospitalization for heart failure (HHF) in patients with heart failure with reduced and preserved ejection fraction. We undertook this meta-analysis, as, to date, no meta-analysis has holistically analysed the potential benefits and safety of SGLT2i in patients with acute myocardial infarction (MI).<\/p>\r\n<p id=\"9276c210-4adb-460a-8942-ea3708a8976a\" class=\"jrnlAbsPara\"><b id=\"447dbe25-ebce-4076-9cec-a5c7e45b3919\" class=\"sty cts-4\">Methods<\/b>. Electronic databases were searched for randomized controlled trials (RCTs) involving patients with MI who received SGLT2i in the intervention arm (initiated within 2 weeks of the index event) and placebo\/active comparator in the control arm. The primary outcome was to evaluate the impact on cardiovascular death, all-cause death and HHF. The secondary outcomes were to evaluate the impact on echocardiographic parameters,\r\nN-terminal pro-b-type natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein, MI, stroke, all-cause hospitalization and safety issues.<\/p>\r\n<p id=\"2c49933b-5523-422d-82dc-a54886cd4730\" class=\"jrnlAbsPara\"><b id=\"a12d50a4-6814-4b10-afe2-aa752a014189\" class=\"sty cts-4\">Results<\/b>. From initially screened 8,922 articles, data from 6 RCTs were analysed (7,409 patients). Early initiation of SGLT2i following MI was associated with significantly lower future HHF (odds ratio [OR]: 0.75; 95% confidence interval [CI]: 0.62\u20130.90;<em id=\"5fd6ac04-8ea1-4c98-a350-3986e643b241\"><\/em>\u00a0p=0.002;\u00a0<em id=\"24ee7bcd-afe9-425c-b092-9d5d50578fa5\" class=\"sty cts-3\">I<\/em><sup id=\"4d84a102-54c1-4a0d-91f9-fff8cf321957\">2<\/sup>=0%) and significantly higher left-ventricular ejection fraction (mean difference [MD]: 1.65%; 95% CI: 0.34\u20132.96;<em id=\"dfd53662-b7fe-4c56-b3d1-a23270e96b44\"><\/em>\u00a0p=0.01;\u00a0<em id=\"ec960048-fbe3-4165-b17f-6ff5d6886f00\" class=\"sty cts-3\">I<\/em><sup id=\"4800ff89-f723-4925-9acb-7b65055dedcb\">2<\/sup>=0%) compared with placebo. Compared with placebo, SGLT2i following MI had no beneficial impact on cardiovascular deaths (OR: 1.04; 95% CI: 0.83\u20131.30;<em id=\"f2b3d528-2503-4558-a86b-2d4219eeb55f\"><\/em>\u00a0p=0.76;\u00a0<em id=\"2bc55207-ce56-4f5c-b82a-b8bd4afbb82d\" class=\"sty cts-3\">I<\/em><sup id=\"7253e938-1ad7-4ee3-986f-bdd833321288\">2<\/sup>=0%), all-cause mortality (OR: 1.00; 95% CI: 0.82\u20131.21;<em id=\"7c8ba732-fc71-4b99-ad45-f57f698527ea\"><\/em>\u00a0p=0.98;\u00a0<em id=\"1ad0c607-2d0c-4033-9abe-dd12b2e0711f\" class=\"sty cts-3\">I<\/em><sup id=\"c7263e61-0e20-485b-acdd-cc9532bcb99d\">2<\/sup>=0%), stroke (OR: 0.58; 95% CI: 0.26\u20131.27;<em id=\"bcbc1d5d-15f8-43c7-a187-52a930a46b99\"><\/em>\u00a0p=0.17), all-cause hospitalization (OR: 1.13; 95% CI: 0.97\u20131.32;<em id=\"4fdb94c9-bfb0-483b-8ad6-c37f434d2f0a\"><\/em>\u00a0p=0.11;\u00a0<em id=\"e216b490-9603-42fd-adee-54a7c2947605\" class=\"sty cts-3\">I<\/em><sup id=\"a536edf8-ff7e-42db-9021-b119f44434b0\">2<\/sup>=0%) and percentage change in NT-proBNP (MD: 1.18%; 95% CI: -9.78 to 12.14;<em id=\"78ed734b-e117-484b-b0ad-546986659bcf\"><\/em>\u00a0p=0.83;\u00a0<em id=\"a35028e0-614d-421f-9db9-e06106ec54d6\" class=\"sty cts-3\">I<\/em><sup id=\"963ef1aa-9a82-4509-baed-8dc5de6e9c89\">2<\/sup>=52%). SGLT2i were well tolerated without increased ketoacidosis, acute renal failure or hepatic injury.<\/p>\r\n<p id=\"7b283f4a-9d26-4468-85d6-a686440b175d\" class=\"jrnlAbsPara\"><b id=\"326ef953-3b16-4631-b7bb-fd322970eb86\" class=\"sty cts-4\">Conclusion<\/b>. Early initiation of SGLT2i in acute MI is safe, well tolerated and associated with a reduction in HHF.<\/p>","wpcf-article_keywords":"<span id=\"153d7e16-b6fd-4cbd-ac32-cc4ed92678c2\" class=\"jrnlKeyword\">Dapagliflozin<\/span>,\u00a0<span id=\"bd510dda-1ffd-4f82-ae6c-1477cf57f51e\" class=\"jrnlKeyword\">empagliflozin<\/span>,\u00a0<span id=\"ff184e47-9f0a-4298-98c0-fa212a243457\" class=\"jrnlKeyword\">meta-analysis<\/span>,\u00a0<span id=\"834624ab-f8be-4391-8c5e-c5ac51464fd3\" class=\"jrnlKeyword\">myocardial infarction<\/span>,\u00a0<span id=\"e50db87a-1a71-4296-b6e9-78eea40ed9f4\" class=\"jrnlKeyword\">safety<\/span>,\u00a0<span id=\"ce8ece9a-b1ef-4f9d-b3d2-fd13ee9808d9\" class=\"jrnlKeyword\">sodium\u2013glucose co-transporter-2 inhibitor<\/span>","wpcf-article_citation_override":"<I>touchREVIEWS in Endocrinology.<\/I> 2025;21(1):Online ahead of journal publication","wpcf-compliance-with-ethics":"<div class=\"\">\r\n<div id=\"56f5af7c-329a-463f-b8cc-f2e066d2b9c5\" class=\"jrnlFN\">\r\n<div class=\"jrnlFNText\">\r\n<p id=\"128e0e11-2b99-46a1-b739-e367c338ef72\" class=\"jrnlFNPara\">This article involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors. Data have been sourced from publicly available databases.<\/p>\r\n\r\n<\/div>\r\n<\/div>\r\n<\/div>","wpcf-article_disclosure":"<div class=\"\">\r\n<div id=\"a0523f1f-60e7-4e11-9c24-fc9f0e41e01a\" class=\"jrnlFN\">\r\n<div class=\"jrnlFNText\">\r\n<p id=\"75cb3bd2-9c26-4523-b5ac-46f3cc2ac8fa\" class=\"jrnlFNPara\">Deep Dutta, Lakshmi Nagendra, ABM Kamrul Hasan and Kunal Mahajan have no financial or non-financial relationships or activities to declare in relation to this article.<\/p>\r\n\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<div class=\"\"><\/div>","wpcf-review_process":"<div id=\"6181a3d5-ffe5-4512-8824-1f40182201d0\" class=\"author-notes\">\r\n<div id=\"1b469c16-16c7-473b-a982-673d8bca0040\" class=\"jrnlFN\">\r\n<div class=\"jrnlFNText\">\r\n<p id=\"9e7bd039-6482-4e17-aebb-9f79a5a6d727\" class=\"jrnlFNPara\">Double-blind peer review.<\/p>\r\n\r\n<\/div>\r\n<\/div>\r\n<\/div>","wpcf-authorship":"<div class=\"\">\r\n<div id=\"da6d650f-d92a-40b5-a747-51122b2a9874\" class=\"jrnlFN\">\r\n<div class=\"jrnlFNText\">\r\n<p id=\"d865d77f-8107-4597-9604-fc0328df0f9c\" class=\"jrnlFNPara\">All named authors meet the criteria of the International Committee of Medical Journal Editors for authorship for this manuscript, take responsibility for the integrity of the work as a whole and have given final approval for the version to be published.<\/p>\r\n\r\n<\/div>\r\n<\/div>\r\n<\/div>","wpcf-article_correspondence":"<p id=\"af441d2e-9a49-4e72-b0ac-0a5bc2f719d1\" class=\"jrnlCorrAff\"><span id=\"492e00b3-f8ce-4927-baba-c933e3ae8175\" class=\"jrnlAuthor\"><span class=\"jrnlGivenName\">Deep<\/span>\u00a0<span class=\"jrnlSurName\">Dutta<\/span><\/span>,\u00a0<span id=\"a1a9ef01-d95d-4d8f-ab6a-d560f36c1815\" class=\"jrnlCorAddress\"><span id=\"c2b7666d-06ca-4aef-9ca1-c507abdd2130\" class=\"jrnlInstitution\">Centre for Endocrinology, Diabetes, Arthritis and Rheumatism (CEDAR) Super-speciality Clinics<\/span>,\u00a0<span id=\"ea64e41d-c2db-4345-9863-b090a306cfb6\" class=\"jrnlCity\">Plot 107 &amp; 108, Sector 12A<\/span>,\u00a0<span id=\"91cd42c0-6aad-43b5-9b78-8db5085ccbb7\" class=\"jrnlState\">Dwarka, New Delhi 110075<\/span>,\u00a0<span id=\"9718caad-3835-4d13-b69f-5e211afc2e31\" class=\"jrnlCountry\">India<\/span><\/span>;\u00a0<span id=\"b1cfb24f-4065-4bcb-afe4-27a513407660\" class=\"jrnlEmail\">deepdutta2000@yahoo.com<\/span><\/p>\r\n\r\n<div id=\"6181a3d5-ffe5-4512-8824-1f40182201d0\" class=\"author-notes\">\r\n<div class=\"\"><\/div>\r\n<\/div>","wpcf-article_support":"<div id=\"08c9c43f-37e1-4ed8-914c-71bee5267c2b\" class=\"jrnlFundingGroup\">\r\n<div id=\"a6796ec0-0131-4bf5-b1cb-0117949a1340\" class=\"jrnlFN\">\r\n<div class=\"jrnlFNText\">\r\n<p id=\"a6796ec0-0131-4bf5-b1cb-0117949a1340\" class=\"jrnlFNPara\">No funding was received in the publication of this article.<\/p>\r\n\r\n<\/div>\r\n<\/div>\r\n<\/div>","wpcf-open_access":"<div class=\"\">\r\n<div id=\"29481fe2-6ee2-4162-84fc-d9631e1ee784\" class=\"jrnlFN\">\r\n<div class=\"jrnlFNText\">\r\n<p id=\"a8fd612e-48b3-4ae2-b103-2d45680c12aa\" class=\"jrnlFNPara\">This article is freely accessible at touchENDOCRINOLOGY.com. \u00a9 Touch Medical Media 2025<span id=\"f1482033-39fb-4437-9719-bad3937dbfc8\">.<\/span><\/p>\r\n\r\n<\/div>\r\n<\/div>\r\n<\/div>","wpcf-article_pdf":"https:\/\/touchendocrinology.com\/wp-content\/uploads\/sites\/5\/2025\/02\/touchENDOCRINOLOGY-D-24-00033.pdf","wpcf-article_pdf-gated":false,"wpcf-article_doi":"","wpcf-old_nid":"","wpcf-article_image":"","wpcf-editor_choice":false,"wpcf-old_author_ids":"","wpcf-article_references":"<p id=\"R1\" class=\"jrnlRefText\"><span class=\"RefSlNo\">1.<\/span>\u00a0<span id=\"e27fe66f-8182-45cc-9929-e4e94f2b9da4\" class=\"RefAuthor\"><span id=\"0b45b68e-3fc9-4321-bd57-09854c4c46c1\" class=\"RefSurName\">Szummer<\/span>\u00a0<span id=\"58d6e42b-e024-4ec3-a92b-7dbdf9896cb0\" class=\"RefGivenName\">K<\/span><\/span>,\u00a0<span id=\"4789ed99-ea1d-4d7d-9c3b-87c19c0fa8bb\" class=\"RefAuthor\"><span id=\"aab56296-6c88-4fda-b65e-cf1735e9fcb5\" class=\"RefSurName\">Wallentin<\/span>\u00a0<span id=\"91143910-cd01-407c-a1a2-44b82c086daf\" class=\"RefGivenName\">L<\/span><\/span>,\u00a0<span id=\"78a6ecee-0f70-42a2-8242-829f0892a598\" class=\"RefAuthor\"><span id=\"089f5741-16ca-45e8-b650-203f7aa4bd0a\" class=\"RefSurName\">Lindhagen<\/span>\u00a0<span id=\"5c07f4b0-4f19-4ac7-aaa2-751d8b408e9a\" class=\"RefGivenName\">L<\/span><\/span>,\u00a0<span id=\"c906cc2c-2fc2-4e23-96ee-e285e05a5cb4\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"a3ca6cb2-8a7d-4fa8-ab14-7afa8a2bd00b\" class=\"RefArticleTitle\">Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years:\u00a0<span id=\"d453a775-b300-4c13-a856-526cbd033824\" class=\"changeCase sty cts-2\">E<\/span>xperiences from SWEDEHEART registry 1995 to 2014<\/span>.\u00a0<span id=\"8db7a756-0486-4eaa-b26e-73dc90bad69b\" class=\"RefJournalTitle\"><em id=\"21036995-d9ee-4d30-b7e0-b52d99b7887a\">Eur Heart J<\/em><\/span>.\u00a0<span id=\"13d7a42a-2318-4cbb-9bab-5d8cd83d0400\" class=\"RefYear\">2018<\/span>;<span id=\"a3d8bbfb-d3b8-4ebe-9924-fb5c7d3feb4e\" class=\"RefVolume\">39<\/span>:<span id=\"bbcbb055-c67c-4279-a7e1-53db47f5907a\" class=\"RefFPage\">3766<\/span>\u2013<span id=\"e35232d0-1315-4ed2-ab03-af27cda8fc65\" class=\"RefLPage\">76<\/span>.\u00a0<span class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"4daa345b-a514-45f1-9e56-b31939e07f7b\" class=\"RefDOI\">10.1093\/eurheartj\/ehy554<\/span>.<\/p>\r\n<p id=\"R2\" class=\"jrnlRefText\"><span class=\"RefSlNo\">2.<\/span>\u00a0<span id=\"8969d254-a1fd-42e7-acf0-da1201e9bbbe\" class=\"RefAuthor\"><span id=\"58001171-df5c-4284-9099-2510f7eb8969\" class=\"RefSurName\">McGuire<\/span>\u00a0<span id=\"3fa81f8e-98a3-4755-9a34-363b61fb3f68\" class=\"RefGivenName\">DK<\/span><\/span>,\u00a0<span id=\"2bfb09f6-29a3-4db0-beb8-8c3c7e892d5c\" class=\"RefAuthor\"><span id=\"dad6f049-608e-41fe-bfbd-ddc5e54f564a\" class=\"RefSurName\">Shih<\/span>\u00a0<span id=\"f3a5b69a-d6e7-4142-ae08-8519614057d5\" class=\"RefGivenName\">WJ<\/span><\/span>,\u00a0<span id=\"b39b8841-42e1-49b7-bc58-d1bafd2648c9\" class=\"RefAuthor\"><span id=\"c383c4f6-254d-40c9-80fb-b2ce812a839b\" class=\"RefSurName\">Cosentino<\/span>\u00a0<span id=\"bce78147-5ebd-4e0f-b06c-03096aa0f19f\" class=\"RefGivenName\">F<\/span><\/span>,\u00a0<span id=\"8348af23-47d1-408b-9af6-4ab9b409b9e4\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"f655c4bd-5c96-4a92-865a-f4c4ffdf6bf5\" class=\"RefArticleTitle\">Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes:\u00a0<span id=\"a0da1695-d60f-4ce2-8e14-1ef67f558e23\" class=\"changeCase sty cts-2\">A<\/span>\u00a0meta-analysis<\/span>.\u00a0<span id=\"5ccfe4f5-b8f6-44b8-b3b0-20d94470eac5\" class=\"RefJournalTitle\"><em id=\"60b43d23-fcc4-42a8-a75c-1bbe0dbb9671\">JAMA Cardiol<\/em><\/span>.\u00a0<span id=\"0dc17205-886a-4812-9a97-419a97c11161\" class=\"RefYear\">2021<\/span>;<span id=\"88c3a0d7-aef9-4994-87d5-544df8aa4cbf\" class=\"RefVolume\">6<\/span>:<span id=\"8a13077d-b960-4ae6-9c8d-d0f64db5ea03\" class=\"RefFPage\">148<\/span>\u2013<span id=\"d008c807-6c29-4216-8e8c-def1658923c1\" class=\"RefLPage\">58<\/span>.\u00a0<span class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"b56378e3-b028-4a39-84a7-cb0ebbc6daab\" class=\"RefDOI\">10.1001\/jamacardio.2020.4511<\/span>.<\/p>\r\n<p id=\"R3\" class=\"jrnlRefText\"><span id=\"0421fba0-bb23-4b3f-b35f-68adc54a5d6e\" class=\"RefSlNo\">3.<\/span>\u00a0<span id=\"434322d2-d841-450f-92c6-03a8ff892921\" class=\"RefAuthor\"><span id=\"03adfb38-38a6-477e-9db8-fddd06c3c980\" class=\"RefSurName\">Solomon<\/span>\u00a0<span id=\"887261fc-39df-4daa-b6b3-50ad1397e30d\" class=\"RefGivenName\">SD<\/span><\/span>,\u00a0<span id=\"4c3495f1-cb29-432e-bd79-ea04f5939671\" class=\"RefAuthor\"><span id=\"f0908cc9-619b-4455-952c-5de79b17111a\" class=\"RefSurName\">McMurray<\/span>\u00a0<span id=\"5a88c8c3-272b-4edd-b295-2d3a0a88c221\" class=\"RefGivenName\">JJV<\/span><\/span>,\u00a0<span id=\"f35841b6-dafd-46ad-8dd1-020f0638fae8\" class=\"RefAuthor\"><span id=\"6b5cb813-7d78-42ab-a7cd-948ce8614597\" class=\"RefSurName\">Claggett<\/span>\u00a0<span id=\"ec3715ab-1adb-4977-82b1-43ae4f1a93b1\" class=\"RefGivenName\">B<\/span><\/span>,\u00a0<span id=\"aa399204-0b46-4c39-a637-7aad8b93a970\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"78b56a08-91e8-4fb8-ad92-fa5128ce09a6\" class=\"RefArticleTitle\">Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction<\/span>.\u00a0<span id=\"a0150ce8-a974-47e3-8351-25b922a283bb\" class=\"RefJournalTitle\"><em id=\"3fb7e70c-b336-4b2f-8bb9-662746e076e3\">N Engl J Med<\/em><\/span>.\u00a0<span id=\"9cbcd18e-3043-4bef-84fd-1f1745d5e257\" class=\"RefYear\">2022<\/span>;<span id=\"891d1a1b-5c4d-4b8f-8beb-dd2826b39708\" class=\"RefVolume\">387<\/span>:<span id=\"3317099d-c9f4-41bb-a3a9-c6b4007a3f22\" class=\"RefFPage\">1089<\/span>\u2013<span id=\"b8b88ce2-d8e0-4ba3-8eb8-b5e8ba69eea2\" class=\"RefLPage\">98<\/span>.\u00a0<span id=\"aea6e9f8-b9fe-4c58-9d0c-d0bea31fedf6\" class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"bb53900b-b7ae-484a-8cb9-5382bb967756\" class=\"RefDOI\">10.1056\/NEJMoa2206286<\/span>.<\/p>\r\n<p id=\"R4\" class=\"jrnlRefText\"><span class=\"RefSlNo\">4.<\/span>\u00a0<span id=\"7f34c0f3-997d-4406-9237-d35647857cbb\" class=\"RefAuthor\"><span id=\"87de0cba-0cb8-4f8a-b073-70e57b68bd4b\" class=\"RefSurName\">Vaduganathan<\/span>\u00a0<span id=\"b3cb0dc8-d2f4-4d4a-b11e-6bf2f5ad3e90\" class=\"RefGivenName\">M<\/span><\/span>,\u00a0<span id=\"c2753450-a32e-4f7e-a2af-9a30a2987357\" class=\"RefAuthor\"><span id=\"8f1b34ed-68bb-4598-99a1-21eba32b36f4\" class=\"RefSurName\">Docherty<\/span>\u00a0<span id=\"714c3f85-0b58-4b3c-bda3-c6e20cd07dcf\" class=\"RefGivenName\">KF<\/span><\/span>,\u00a0<span id=\"ec10cd54-5940-4aac-9d9c-2dd6cdd4fd47\" class=\"RefAuthor\"><span id=\"efbe59fa-737c-4811-b0f0-ae64ae5770ed\" class=\"RefSurName\">Claggett<\/span>\u00a0<span id=\"bb8ae044-a449-4e9e-8d10-377fe615fb2e\" class=\"RefGivenName\">BL<\/span><\/span>,\u00a0<span id=\"2b57fc6f-f8c1-4456-b70b-335338166ead\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"d1a63523-9d1f-47e4-9f62-a40109674740\" class=\"RefArticleTitle\">SGLT-2 inhibitors in patients with heart failure:\u00a0<span id=\"5e378b1f-68cc-4443-b972-da2812d104c1\" class=\"changeCase sty cts-2\">A<\/span>\u00a0comprehensive meta-analysis of five randomised controlled trials<\/span>.\u00a0<span id=\"05b2ef24-6c7a-48e7-b8c3-c3f01ebc3abd\" class=\"RefJournalTitle\"><em id=\"733a1aec-c25f-4c8c-aab8-4dbd74611db1\">Lancet<\/em><\/span>.\u00a0<span id=\"96f88182-2881-4720-89cc-a91bb4202f44\" class=\"RefYear\">2022<\/span>;<span id=\"d0e76f37-d53a-41b6-8354-19e8dbbb58fd\" class=\"RefVolume\">400<\/span>:<span id=\"c250e473-0b60-49f0-8d5b-5ce0bf08f77c\" class=\"RefFPage\">757<\/span>\u2013<span id=\"3b7a0f57-1a7c-4388-86f7-008ffc094f89\" class=\"RefLPage\">67<\/span>.\u00a0<span class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"66e03db2-9588-46a4-a434-2fbf322c61e6\" class=\"RefDOI\">10.1016\/S0140-6736(22)01429-5<\/span>.<\/p>\r\n<p id=\"R5\" class=\"jrnlRefText\"><span id=\"c57051d0-4240-4f5e-99b7-e422660532f4\" class=\"RefSlNo\">5.<\/span>\u00a0<span id=\"d5cba432-49ee-4091-85e2-4d6451c87824\" class=\"RefAuthor\"><span id=\"3014c5f3-ce10-4209-b3f8-54dc63e3803c\" class=\"RefSurName\">Anker<\/span>\u00a0<span id=\"e239d2c0-83d0-4ca4-8b5f-5566ee292e0e\" class=\"RefGivenName\">SD<\/span><\/span>,\u00a0<span id=\"e6335a92-6e11-474b-8c41-b93511a07634\" class=\"RefAuthor\"><span id=\"526b2c57-13a1-4523-9706-e8b7289fc385\" class=\"RefSurName\">Butler<\/span>\u00a0<span id=\"0f088750-c6b8-4182-8a5c-99172a795c3f\" class=\"RefGivenName\">J<\/span><\/span>,\u00a0<span id=\"d31c2117-628b-4339-9f38-17de0b0e3870\" class=\"RefAuthor\"><span id=\"1342c668-4b30-4de0-a9f9-dbc8526e0cbe\" class=\"RefSurName\">Filippatos<\/span>\u00a0<span id=\"1f45f9c7-de98-406b-83a8-1988a290784f\" class=\"RefGivenName\">G<\/span><\/span>,\u00a0<span id=\"ebd7c517-44b7-4e38-ba52-a31fa261630f\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"29f431b9-de65-448b-8dba-59847dd05579\" class=\"RefArticleTitle\">Empagliflozin in heart failure with a preserved ejection fraction<\/span>.\u00a0<span id=\"1e44e43a-0206-43de-abd5-fa6b77d1f51d\" class=\"RefJournalTitle\"><em id=\"5d98b07e-5f84-478b-b9af-71792d71d938\">N Engl J Med<\/em><\/span>.\u00a0<span id=\"d151f2b9-525e-466c-99d7-2c57292468c0\" class=\"RefYear\">2021<\/span>;<span id=\"917b7946-324c-4863-922c-5f48232c6c5f\" class=\"RefVolume\">385<\/span>:<span id=\"f0226170-6e51-48d4-8ca8-311878763cc9\" class=\"RefFPage\">1451<\/span>\u2013<span id=\"3b7b9e55-af5f-40a3-9b68-4ac298c67a0d\" class=\"RefLPage\">61. <\/span><span id=\"e7cbabea-d74e-4fcb-b67f-fffca45967aa\" class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"e2c5e084-352c-48c0-b7a2-72c0e793d09a\" class=\"RefDOI\">10.1056\/NEJMoa2107038<\/span>.<\/p>\r\n<p id=\"R6\" class=\"jrnlRefText\"><span id=\"a410fdd2-3dde-4943-a9d7-b5542da84a5a\" class=\"RefSlNo\">6.<\/span>\u00a0<span id=\"b83c57c5-49c9-481a-b801-39a622f9ea4c\" class=\"RefAuthor\"><span id=\"22ac002e-547c-4986-89c5-0fef53004bdc\" class=\"RefSurName\">James<\/span>\u00a0<span id=\"e2049cdc-5d81-4dfc-a8fb-2318159d8776\" class=\"RefGivenName\">S<\/span><\/span>,\u00a0<span id=\"939a278b-41c5-4745-954e-d2b55b184d7c\" class=\"RefAuthor\"><span id=\"48024b3c-34d9-457d-b66a-d7b22139c636\" class=\"RefSurName\">Erlinge<\/span>\u00a0<span id=\"0e3212c2-a503-4f4a-afd8-577997edb1cc\" class=\"RefGivenName\">D<\/span><\/span>,\u00a0<span id=\"09a43952-bab7-4d70-bf08-48d7653d290b\" class=\"RefAuthor\"><span id=\"7f691e35-4394-4003-b329-a9508f770c9a\" class=\"RefSurName\">Storey<\/span>\u00a0<span id=\"e9a9f379-34b6-4823-9099-5e5d53ac1ac1\" class=\"RefGivenName\">RF<\/span><\/span>,\u00a0<span id=\"d2910f1b-9258-4072-b9b9-dcf6075d7ea2\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"229710a1-2061-49a2-92d8-e972ed92abfb\" class=\"RefArticleTitle\">Dapagliflozin in myocardial infarction without diabetes or heart failure<\/span>.\u00a0<span id=\"f81b8494-9ac3-48fa-9c55-fa5ddb343422\" class=\"RefJournalTitle\"><em id=\"c812f3a5-0c48-4969-9a12-30d676960cd9\">NEJM Evid. <\/em><\/span><span id=\"c0ebad24-5f46-4c1a-bed2-3064a69f46f2\" class=\"RefYear\">2024<\/span>;<span id=\"efd5187b-3d6b-400b-a593-8d3f51f2aed2\" class=\"RefVolume\">3<\/span>:<span id=\"25ceac06-794a-4135-9875-e7cdc4225c36\" class=\"RefELocation\">EVIDoa2300286. <\/span><span id=\"f797ec9f-99f4-4728-8052-18032d075382\" class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"97ef3d68-3d1f-458d-b01b-67ea04c1ba00\" class=\"RefDOI\">10.1056\/EVIDoa2300286<\/span>.<\/p>\r\n<p id=\"R7\" class=\"jrnlRefText\"><span class=\"RefSlNo\">7.<\/span>\u00a0<span id=\"ea40f557-817c-4db1-8a5f-6a83e89b8254\" class=\"RefAuthor\"><span id=\"c92675a1-1f3c-409e-9ac4-48c7449ec206\" class=\"RefSurName\">Butler<\/span>\u00a0<span id=\"e9d9a98c-6ac6-407d-ac9f-89a09e0d5844\" class=\"RefGivenName\">J<\/span><\/span>,\u00a0<span id=\"b6bae999-5afb-48a1-b0dc-8d37331b6cc0\" class=\"RefAuthor\"><span id=\"b751c2bf-58ef-4671-bbf4-868abd48ec2b\" class=\"RefSurName\">Jones<\/span>\u00a0<span id=\"2909f13f-8c29-446a-8779-7373e218efd6\" class=\"RefGivenName\">WS<\/span><\/span>,\u00a0<span id=\"d07b6e8b-e4bf-489b-ba32-3c55f43ad1ce\" class=\"RefAuthor\"><span id=\"9d88f3b9-f6b1-472d-ba83-75e4535afa06\" class=\"RefSurName\">Udell<\/span>\u00a0<span id=\"4df93da1-308b-4f4a-a531-4b09da81537c\" class=\"RefGivenName\">JA<\/span><\/span>,\u00a0<span id=\"120f48dd-6cde-4195-8e3b-15112e3869ec\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"24654f21-c244-4cca-b55e-d6401c2f46f1\" class=\"RefArticleTitle\">Empagliflozin after acute myocardial infarction<\/span>.\u00a0<span id=\"b5262ef0-45d9-4928-9f3d-1f52db29e9f2\" class=\"RefJournalTitle\"><em id=\"cbf2c4b3-e559-4d4c-addf-b9c6c366518e\">N Engl J Med<\/em><\/span>.\u00a0<span id=\"bb5bba30-0eda-4b64-85db-5e97d5194c09\" class=\"RefYear\">2024<\/span>;<span id=\"1d88a909-51d8-4cf2-a615-416853d0ac94\" class=\"RefVolume\">390<\/span>:<span id=\"034e687a-5f07-431e-905c-1b9fab96dff0\" class=\"RefFPage\">1455<\/span>\u2013<span id=\"e86f8478-5dc8-493f-bc24-b5fca16133d8\" class=\"RefLPage\">66. <\/span><span class=\"RefComments\">DOI<\/span>: 1<span id=\"5672f918-26a2-42b3-8e84-7d15a3ff985f\" class=\"RefDOI\">0.1056\/NEJMoa2314051<\/span>.<\/p>\r\n<p id=\"R8\" class=\"jrnlRefText\"><span class=\"RefSlNo\">8.<\/span>\u00a0<span id=\"6f17213f-f7b4-47ed-9544-ca369cc3d434\" class=\"RefAuthor\"><span id=\"3eeefa6d-86a7-4fff-84cf-ab016c2cb773\" class=\"RefSurName\">Dayem<\/span>\u00a0<span id=\"e65cdb0d-8219-4bc0-a3a7-4d406793065b\" class=\"RefGivenName\">KA<\/span><\/span>,\u00a0<span id=\"e7300afa-bc71-40a4-acb2-cfd1624c8a53\" class=\"RefAuthor\"><span id=\"ed0ac2b4-c364-4b71-a7a8-4b3e9d9113d6\" class=\"RefSurName\">Younis<\/span>\u00a0<span id=\"a1d06a89-0154-44c5-8e81-f132f244474c\" class=\"RefGivenName\">O<\/span><\/span>,\u00a0<span id=\"4b0b5a86-16cf-42fd-9a2f-63205794083f\" class=\"RefAuthor\"><span id=\"57c588bb-1e71-4bee-b09c-4cb030b03cd9\" class=\"RefSurName\">Zarif<\/span>\u00a0<span id=\"bcb778cb-c410-47da-a9be-9527cc27f96e\" class=\"RefGivenName\">B<\/span><\/span>,\u00a0<span id=\"c2c75462-205c-4052-87f9-be7e744d6bc5\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"20bbb490-0e84-4677-a9bf-d2da1c74f8a7\" class=\"RefArticleTitle\">Impact of dapagliflozin on cardiac function following anterior myocardial infarction in non-diabetic patients \u2013 DACAMI (a randomized controlled clinical trial)<\/span>.\u00a0<span id=\"67e252f3-8b74-4227-8662-104532f35e8d\" class=\"RefJournalTitle\"><em id=\"3f9434ca-7300-419e-9e77-cb0b0db802b5\">Int J Cardiol<\/em><\/span>.\u00a0<span id=\"e45b8fad-e53a-4c0d-b750-7081e94ed9e3\" class=\"RefYear\">2023<\/span>;<span id=\"f99dda54-0a9e-4b11-89be-aa63cf3bbdf9\" class=\"RefVolume\">379<\/span>:<span id=\"e8f9df74-8348-455c-a589-e52a27eed263\" class=\"RefFPage\">9<\/span>\u2013<span id=\"60ad373a-2ef9-4741-87a0-b6a517e190ee\" class=\"RefLPage\">14<\/span>.\u00a0<span class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"8a972da3-46c8-46b1-8610-97f0355bde77\" class=\"RefDOI\">10.1016\/j.ijcard.2023.03.002<\/span>.<\/p>\r\n<p id=\"R9\" class=\"jrnlRefText\"><span class=\"RefSlNo\">9.<\/span>\u00a0<span id=\"d0f6307f-3026-49c9-a3ab-e2b128320294\" class=\"RefAuthor\"><span id=\"2332bf36-a3bf-432c-938f-44ab4068e62c\" class=\"RefSurName\">von Lewinski<\/span>\u00a0<span id=\"8d09eb75-6d7e-4594-bba7-2e5fbcfe206c\" class=\"RefGivenName\">D<\/span><\/span>,\u00a0<span id=\"33a0b6a7-a33d-46cf-a8d6-c7c00d35129d\" class=\"RefAuthor\"><span id=\"06936ff7-f825-4be4-b401-a55e8febd462\" class=\"RefSurName\">Kolesnik<\/span>\u00a0<span id=\"ba012589-2b0f-4251-be62-cc91a1f645de\" class=\"RefGivenName\">E<\/span><\/span>,\u00a0<span id=\"0b878944-dabe-4ad9-91f8-646bf615ef61\" class=\"RefAuthor\"><span id=\"b448dc00-c50f-4d52-bf07-a33a1be723e4\" class=\"RefSurName\">Tripolt<\/span>\u00a0<span id=\"7b2a4adf-7244-437d-be2a-c2aba921881a\" class=\"RefGivenName\">NJ<\/span><\/span>,\u00a0<span id=\"e7d349ab-e95d-471b-9296-24136e5f98d2\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"9767b4bd-9b8e-4fee-84bb-0ff9cced1a65\" class=\"RefArticleTitle\">Empagliflozin in acute myocardial infarction:\u00a0<span id=\"5cdb9b07-4bb0-4c7f-89c5-56d09f9cefe2\" class=\"changeCase sty cts-2\">T<\/span>he EMMY trial<\/span>.\u00a0<span id=\"a92819ae-10f0-4795-aa87-6e707d75eb8c\" class=\"RefJournalTitle\"><em id=\"83e5cb17-260f-42ba-86bf-07d2b5e8a489\">Eur Heart J<\/em><\/span>.\u00a0<span id=\"34b74515-1960-4c33-930a-057cf05310e0\" class=\"RefYear\">2022<\/span>;<span id=\"4d678a2c-ca3f-4c78-ac58-35c56b5c6679\" class=\"RefVolume\">43<\/span>:<span id=\"28592f54-6a11-4c40-90df-052d95a17fdb\" class=\"RefFPage\">4421<\/span>\u2013<span id=\"a925b2ee-e2af-4b1f-8e02-12d417dc3d7d\" class=\"RefLPage\">32. <\/span><span class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"b6962b9e-f0ec-4d8f-96a0-940be51c6eb0\" class=\"RefDOI\">10.1093\/eurheartj\/ehac494<\/span>.<\/p>\r\n<p id=\"R10\" class=\"jrnlRefText\"><span class=\"RefSlNo\">10.<\/span>\u00a0<span id=\"989e1fbc-bc4a-4d5d-8c43-0bd5c21bc0c8\" class=\"RefAuthor\"><span id=\"274d44a2-481e-4757-bfd5-d73b37823232\" class=\"RefSurName\">Pf\u00fctzner<\/span>\u00a0<span id=\"5aa49393-cb68-4c35-bed6-47031684e1ba\" class=\"RefGivenName\">A<\/span><\/span>,\u00a0<span id=\"1381b319-dc81-4733-a72e-f8bcd391e753\" class=\"RefAuthor\"><span id=\"3fa69836-2a85-493e-9ce8-efbba2669db0\" class=\"RefSurName\">Klonoff<\/span>\u00a0<span id=\"6ba49620-1080-4c3b-9db7-47a2d9110db6\" class=\"RefGivenName\">D<\/span><\/span>,\u00a0<span id=\"ebe8a863-f4dc-4a15-bb5a-b88899cbd549\" class=\"RefAuthor\"><span id=\"1f3b3e2b-aef3-4ed2-a07c-bd08c04c0a18\" class=\"RefSurName\">Heinemann<\/span>\u00a0<span id=\"6d56436d-594a-47a4-9434-e5d73e34d525\" class=\"RefGivenName\">L<\/span><\/span>,\u00a0<span id=\"3bf7b3e5-f047-4776-ba8c-6fcf9918d3dd\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"342c9661-d90a-4a2a-8835-14ca2c263b16\" class=\"RefArticleTitle\">Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy \u2013 An emerging problem and solutions offered by diabetes technology<\/span>.\u00a0<span id=\"09320b60-01d6-45c7-b7da-7ec190894a66\" class=\"RefJournalTitle\"><em id=\"0f12a0c2-9bb1-4a9e-b000-ac1e3f57efbc\">Endocrine<\/em><\/span>.\u00a0<span id=\"469f4898-e7f8-4c67-9570-2b3b67e2f97a\" class=\"RefYear\">2017<\/span>;<span id=\"cc852b31-a78e-4447-a99f-302d62e4fc6f\" class=\"RefVolume\">56<\/span>:<span id=\"c4c696e3-91ff-4357-a19a-4d2270070eeb\" class=\"RefFPage\">212<\/span>\u2013<span id=\"028f57d0-999d-463b-93bf-e3d058c8da2a\" class=\"RefLPage\">6<\/span>.\u00a0<span class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"c02d480e-caf8-4484-8f85-7908e59d2ed7\" class=\"RefDOI\">10.1007\/s12020-017-1264-y<\/span>.<\/p>\r\n<p id=\"R11\" class=\"jrnlRefText\"><span id=\"18e507c0-fad8-4787-b967-8e6cebb85184\" class=\"RefSlNo\">11.<\/span>\u00a0<span id=\"d84c5f18-d230-4d35-96da-ed455d42632e\" class=\"RefAuthor\"><span id=\"e5435be4-4e3b-4d51-a51b-e27c35f75aec\" class=\"RefSurName\">Solomon<\/span>\u00a0<span id=\"adba2e51-b46a-4aa9-9b46-5e4b828e6152\" class=\"RefGivenName\">SD<\/span><\/span>,\u00a0<span id=\"dff852da-0160-4792-86c5-b48fe6524cbe\" class=\"RefAuthor\"><span id=\"2469bf7b-ab32-45cd-852c-bbe59f037850\" class=\"RefSurName\">Vaduganathan<\/span>\u00a0<span id=\"c8cfd368-8371-4d1b-9c20-f1ea243e98e3\" class=\"RefGivenName\">M<\/span><\/span>,\u00a0<span id=\"49415bf9-38c3-4746-b051-7d6d22e91147\" class=\"RefAuthor\"><span id=\"b3bf5126-9b78-4ab4-a790-af26f2e77a5b\" class=\"RefSurName\">L. Claggett<\/span>\u00a0<span id=\"90a824ad-4af7-4d00-8dbe-0d3a356879c6\" class=\"RefGivenName\">B<\/span><\/span>,\u00a0<span id=\"dd668bc0-3353-4f54-9e26-b4599ee29dc8\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"8b7f50fb-2d4e-43f4-a5fa-e01bd2155b81\" class=\"RefArticleTitle\">Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure. <\/span><span id=\"79a5c6b4-2508-4873-b995-608729204a6e\" class=\"RefJournalTitle\"><em id=\"4119d636-3d2a-4a67-8055-dae320954c40\">Circulation. <\/em><\/span><span id=\"5d51d5a2-b57a-4971-965e-003d68b714e5\" class=\"RefYear\">2020<\/span>;<span id=\"11159f10-3822-4cc1-9db0-7ab2a49ae982\" class=\"RefVolume\">141<\/span>:<span id=\"1ead6c89-af2b-4142-b973-0aa1dfb4537e\" class=\"RefFPage\">352<\/span>\u2013<span id=\"ad027fd3-3828-4a3e-837f-bb851b8bee17\" class=\"RefLPage\">61. <\/span><span id=\"2e4f43bf-a80b-4bce-9844-a9c64ee3e2f6\" class=\"RefComments\">DOI<\/span>: 1<span id=\"19c8fd6d-9a47-4533-84ce-ae9d95de618e\" class=\"RefDOI\">0.1161\/CIRCULATIONAHA.119.044586<\/span>.<\/p>\r\n<p id=\"R12\" class=\"jrnlRefText\"><span id=\"244501fd-081c-4240-b5bf-dacccceffc8d\" class=\"RefSlNo\">12.<\/span>\u00a0<span id=\"411a6a7f-0436-42fe-a3e4-d5a57ee93db5\" class=\"RefAuthor\"><span id=\"d2cdd54f-fbd7-4f17-acc8-1c5fccfd27fd\" class=\"RefSurName\">Pfeffer<\/span>\u00a0<span id=\"79d56d8b-55d8-4112-baa2-b1d89160ce50\" class=\"RefGivenName\">MA<\/span><\/span>,\u00a0<span id=\"e9facdd6-054e-48a0-976b-9adede4de1d5\" class=\"RefAuthor\"><span id=\"ab7ae561-d4d6-4da5-91d7-8a8f647564b1\" class=\"RefSurName\">Claggett<\/span>\u00a0<span id=\"55fd46a7-b366-494f-abeb-ae6b4f48b21c\" class=\"RefGivenName\">B<\/span><\/span>,\u00a0<span id=\"6629f71f-7641-4560-9258-d59f7c889a2e\" class=\"RefAuthor\"><span id=\"dd3c71b5-5553-4cab-9639-abd07cf60f0d\" class=\"RefSurName\">Lewis<\/span>\u00a0<span id=\"053073fd-8945-49fd-a3d5-4f5de0aedbcc\" class=\"RefGivenName\">EF<\/span><\/span>,\u00a0<span id=\"4ee419b3-2e93-4f2e-b073-5b30bdc5e486\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"07d9bcb0-5ae8-43c8-90ae-1bbb1bbb05c9\" class=\"RefArticleTitle\">Angiotensin receptor-neprilysin inhibition in acute myocardial infarction<\/span>.\u00a0<span id=\"dd19f65f-c3e7-4f01-b4bb-9884d8f5e194\" class=\"RefJournalTitle\"><em id=\"f13f2224-5697-4db6-9ab7-5fc6d8c58241\">N Engl J Med. <\/em><\/span><span id=\"798c837a-7846-467d-9438-db479c5b60be\" class=\"RefYear\">2021<\/span>;<span id=\"c71d9354-e546-469c-8689-6a619532f931\" class=\"RefVolume\">385<\/span>:<span id=\"15dba402-7ddc-4df9-9a09-ca131402e023\" class=\"RefFPage\">1845<\/span>\u2013<span id=\"68237fc8-a13d-4c42-b8a3-6696f889a007\" class=\"RefLPage\">55. <\/span><span id=\"12c7456d-27e9-4861-b928-0ec8425586f2\" class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"4d61f65b-8aec-409f-bb28-a358b15dc91c\" class=\"RefDOI\">10.1056\/NEJMoa2104508<\/span>.<\/p>\r\n<p id=\"R13\" class=\"jrnlRefText\"><span class=\"RefSlNo\">13.<\/span>\u00a0<span id=\"ba3f08d2-7169-4d0d-8c6c-24d7526563d1\" class=\"RefAuthor\"><span id=\"c3fcae57-2c1d-49d5-9719-4469f321cb6c\" class=\"RefSurName\">Higgins<\/span>\u00a0<span id=\"fcb29c2e-c4e2-482b-97ef-040a1f9d4488\" class=\"RefGivenName\">JPT<\/span><\/span>,\u00a0<span id=\"2b59cafd-9468-49ae-b348-a2e27f1957d9\" class=\"RefAuthor\"><span id=\"b5a0da61-0fbe-47fc-adf0-5e5e68994c76\" class=\"RefSurName\">Altman<\/span>\u00a0<span id=\"b256cecf-0609-43f6-a580-7f91783ebd1c\" class=\"RefGivenName\">DG<\/span><\/span>,\u00a0<span id=\"4a9e1200-858a-4ac1-b7cb-036e56887ff3\" class=\"RefAuthor\"><span id=\"9ba78a44-5c38-4e2f-a47e-c29c00df58f6\" class=\"RefSurName\">G\u00f8tzsche<\/span>\u00a0<span id=\"4029153e-a15e-4582-a6b9-a9d210efe488\" class=\"RefGivenName\">PC<\/span><\/span>,\u00a0<span id=\"20ea8d6b-e8a3-4667-8d05-f9267d57f0fe\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"f7e4326e-f7df-4d84-919b-a8ea59bde388\" class=\"RefArticleTitle\">The\u00a0<span id=\"52bbd4a3-4365-46e7-aadd-57cae0e3b0db\" class=\"changeCase sty cts-4\">C<\/span>ochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. <\/span><span id=\"113aa9ec-4e60-44a9-b095-92ad5e6c17ff\" class=\"RefJournalTitle\"><em id=\"587b59c5-76c8-49c1-aeac-c56e07f303db\">BMJ. <\/em><\/span><span id=\"67f90771-d9fa-4fbf-a0be-074bebce8466\" class=\"RefYear\">2011<\/span>;<span id=\"123aa3b6-9a4d-461d-86db-0eb2cfa1e0ce\" class=\"RefVolume\">343<\/span>:<span id=\"9bbb2da7-8079-4417-94a4-4730b9a71551\" class=\"RefELocation\">d5928. <\/span><span class=\"RefComments\">DOI<\/span>: 1<span id=\"a5e3c5c9-52da-462f-a872-6cab5deba2d0\" class=\"RefDOI\">0.1136\/bmj.d5928<\/span>.<\/p>\r\n<p id=\"R14\" class=\"jrnlRefText\"><span class=\"RefSlNo\">14.<\/span>\u00a0<span id=\"65d6b8f7-f947-4549-9b62-5b839646f111\" class=\"RefAuthor\"><span id=\"7c72f052-bc6c-4536-9b23-8a810ef17c1e\" class=\"RefSurName\">Liberati<\/span>\u00a0<span id=\"12a2d6d0-3cd0-4d1b-b72d-7066c122ea77\" class=\"RefGivenName\">A<\/span><\/span>,\u00a0<span id=\"f5c62cbc-8ba4-4c74-a891-4a5f87cbf114\" class=\"RefAuthor\"><span id=\"1c64f214-dbfa-4727-a079-4fab3758f980\" class=\"RefSurName\">Altman<\/span>\u00a0<span id=\"f44f6a7c-dd64-498a-9aca-5ce45df408a2\" class=\"RefGivenName\">DG<\/span><\/span>,\u00a0<span id=\"fa4a3253-78fc-4975-9816-ca17c7cd07f6\" class=\"RefAuthor\"><span id=\"5fbec85c-526e-49f1-a53b-c57d2818e695\" class=\"RefSurName\">Tetzlaff<\/span>\u00a0<span id=\"cb1bf924-0401-4ecc-a494-1ef49e8e1a23\" class=\"RefGivenName\">J<\/span><\/span>,\u00a0<span id=\"ea4fb034-15da-4ea7-a228-1f375a3ec9b9\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"ef974fd8-3511-4dda-91ef-b3037f982c67\" class=\"RefArticleTitle\">The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions:\u00a0<span id=\"1da0c125-4b22-49c4-949c-5db620c989f0\" class=\"changeCase sty cts-2\">E<\/span>xplanation and elaboration<\/span>.\u00a0<span id=\"74514824-79d7-469c-8277-7bdf407610d3\" class=\"RefJournalTitle\"><em id=\"502c6d32-5f6e-47af-b810-5aae327673c5\">BMJ<\/em><\/span>.\u00a0<span id=\"53375797-2366-429b-8afe-92fcc6547fd3\" class=\"RefYear\">2009<\/span>;<span id=\"1ac731e8-c60f-4175-968b-0fad697a994c\" class=\"RefVolume\">339<\/span>:<span id=\"9d76faf9-9548-4bd4-9c18-88c7020a1d9f\" class=\"RefELocation\">b2700<\/span>.\u00a0<span class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"213c7683-e7e4-4719-81c9-2b50420850c6\" class=\"RefDOI\">10.1136\/bmj.b2700<\/span>.<\/p>\r\n<p id=\"R15\" class=\"jrnlRefText\"><span id=\"f65b395f-e2f7-4a96-921b-8ab6d3aafe28\" class=\"RefSlNo\">15.<\/span>\u00a0<span id=\"071030d9-279f-4216-9209-5799520604e9\" class=\"RefAuthor\"><span id=\"5bced862-a974-4b1e-81df-f1cd6a3c43ec\" class=\"RefSurName\">Dutta<\/span>\u00a0<span id=\"a2c3dfdb-eb8d-4d73-bee1-e5f2c750a598\" class=\"RefGivenName\">D<\/span><\/span>,\u00a0<span id=\"87b57f41-4886-4676-bf36-ec776e241643\" class=\"RefAuthor\"><span id=\"2cfca443-d2a9-4df1-8991-ab66110f6a23\" class=\"RefSurName\">Agarwal<\/span>\u00a0<span id=\"f96ad3e8-9fbb-4b85-a785-ff834f226c3b\" class=\"RefGivenName\">A<\/span><\/span>,\u00a0<span id=\"deb52e4c-1f5a-457b-9b25-59190debb817\" class=\"RefAuthor\"><span id=\"bf2f3bd0-26e5-4837-97cb-074283f22097\" class=\"RefSurName\">Maisnam<\/span>\u00a0<span id=\"69e2996c-8817-4c03-afc5-d7d7ddca67cf\" class=\"RefGivenName\">I<\/span><\/span>,\u00a0<span id=\"73127054-8ffc-4dc6-a03f-41bd63fc5554\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"6bcde0e3-785f-4fc8-bec3-959ef2fedbbc\" class=\"RefArticleTitle\">Efficacy and safety of the novel dipeptidyl peptidase-4 inhibitor gemigliptin in the management of type 2 diabetes: A meta-analysis<\/span>.\u00a0<span id=\"83213a63-b913-490d-a9b7-df8e6222a2b3\" class=\"RefJournalTitle\"><em id=\"74754f34-d7f0-4c40-8aa5-0a0c7b368212\">Endocrinol Metab<\/em><\/span>.\u00a0<span id=\"726bf545-5a90-41f7-ab39-ffc57471f1bb\" class=\"RefYear\">2021<\/span>;<span id=\"025f8d14-bf1c-4472-a11e-ff7ec1e85a98\" class=\"RefVolume\">36<\/span>:<span id=\"8ba33dcf-81be-4f37-a46f-0b30e57a4faa\" class=\"RefFPage\">374<\/span>\u2013<span id=\"e84c28f8-28bf-41b8-b899-ca506955a4b3\" class=\"RefLPage\">87<\/span>.\u00a0<span id=\"15df890b-4030-48fc-bb3b-1983822b6e97\" class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"c83fa333-2cb3-4694-9e61-e366bdce9745\" class=\"RefDOI\">10.3803\/EnM.2020.818<\/span>.<\/p>\r\n<p id=\"R16\" class=\"jrnlRefText\"><span id=\"e320224c-359d-443e-ac7f-12a3dbadd6c3\" class=\"RefSlNo\">16.<\/span>\u00a0<span id=\"f95f62de-4f5f-4d78-aba2-c6c99e7a7d1b\" class=\"RefAuthor\"><span id=\"839c1d5b-32ca-4c4c-8796-d39eaa5415bf\" class=\"RefSurName\">Dutta<\/span>\u00a0<span id=\"0ded29be-ae30-4286-8515-14bf7b4d0a5a\" class=\"RefGivenName\">D<\/span><\/span>,\u00a0<span id=\"dffd638f-b6c4-47a7-81d0-66f0f82229f2\" class=\"RefAuthor\"><span id=\"fa85eb29-816e-45da-b53d-b01db74818dd\" class=\"RefSurName\">Bhattacharya<\/span>\u00a0<span id=\"aa6bc50a-ffbd-495a-bb19-641de2b6d9f6\" class=\"RefGivenName\">S<\/span><\/span>,\u00a0<span id=\"4ee9689e-0313-4453-80d1-39dfb35360f3\" class=\"RefAuthor\"><span id=\"1fedba46-f240-422d-be69-e89aeb60b30a\" class=\"RefSurName\">Surana<\/span>\u00a0<span id=\"eed6238f-cce0-4cbf-b323-7b899e5edb49\" class=\"RefGivenName\">V<\/span><\/span>,\u00a0<span id=\"490fc81a-452e-49dc-a8da-b252fa293fd9\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"88c6aa07-c0da-4e5a-9a77-651721fa571c\" class=\"RefArticleTitle\">Efficacy and safety of saroglitazar in managing hypertriglyceridemia in type-2 diabetes: A meta-analysis<\/span>.\u00a0<span id=\"c11b5c3f-385f-4827-931e-29be91a29a32\" class=\"RefJournalTitle\"><em id=\"1d0281e1-c49f-428a-90f6-f10f0ee4a206\">Diabetes Metab Syndr<\/em><\/span>.\u00a0<span id=\"2f6b3c1e-3108-492f-8ecc-d0814e66b3f9\" class=\"RefYear\">2020<\/span>;<span id=\"8338a364-a4f8-4a20-97f0-6dbc50204bfb\" class=\"RefVolume\">14<\/span>:<span id=\"3bbf95b9-cb2f-4a6b-a4d8-d93b44bfca19\" class=\"RefFPage\">1759<\/span>\u2013<span id=\"2f72cf46-3ada-4d42-962e-52a0dcc23d56\" class=\"RefLPage\">68<\/span>.\u00a0<span id=\"50333004-5739-4701-b727-634b9c76f0cc\" class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"d4f49d77-a7bb-45fb-aa1d-c2f283d36526\" class=\"RefDOI\">10.1016\/j.dsx.2020.08.039<\/span>.<\/p>\r\n<p id=\"R17\" class=\"jrnlRefText\"><span class=\"RefSlNo\">17.<\/span>\u00a0<span id=\"612335cb-cba1-45f5-b069-ea035a6d5117\" class=\"RefAuthor\"><span id=\"0750806e-352f-4010-a9d6-16ea8c63e833\" class=\"RefSurName\">Guyatt<\/span>\u00a0<span id=\"bd0957aa-df2b-48c8-ba08-4098ba9e179e\" class=\"RefGivenName\">GH<\/span><\/span>,\u00a0<span id=\"d76bed29-21b4-4221-984c-5bd894f18f32\" class=\"RefAuthor\"><span id=\"918fa988-aacd-4a6d-9346-3c672083fde7\" class=\"RefSurName\">Oxman<\/span>\u00a0<span id=\"25d7ad58-b137-44e5-acff-dbb8e74f43ed\" class=\"RefGivenName\">AD<\/span><\/span>,\u00a0<span id=\"50fa94ce-f3f4-461e-9d8e-8591fc5fd997\" class=\"RefAuthor\"><span id=\"bd2e67fb-3715-445f-83d4-b06b5cd7eea0\" class=\"RefSurName\">Vist<\/span>\u00a0<span id=\"5daec934-0438-4e45-990e-43135bb8bf22\" class=\"RefGivenName\">GE<\/span><\/span>,\u00a0<span id=\"ed240a91-17e0-4f60-ad25-1265b9a823a1\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"a9aca5dc-a66e-4367-b62c-189a10671790\" class=\"RefArticleTitle\">GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. <\/span><span id=\"3e933030-f8ff-47eb-a4d0-0c5ebbb179ef\" class=\"RefJournalTitle\"><em id=\"53ec4695-0b38-4c4f-afd6-584ae775b69e\">BMJ. <\/em><\/span><span id=\"dc77f9ea-9c0e-487a-b21c-8e9e12387804\" class=\"RefYear\">2008<\/span>;<span id=\"e837ebfa-28ef-4fc8-b877-377e1d509ff3\" class=\"RefVolume\">336<\/span>:<span id=\"fdc97a29-c1df-49d8-b177-7de814eff06d\" class=\"RefFPage\">924<\/span>\u2013<span id=\"ffd1fc34-c41a-4c93-97a5-db6ed7ab8159\" class=\"RefLPage\">6. <\/span><span class=\"RefComments\">DOI<\/span>: 1<span id=\"3f9cc3d7-8d4a-4cb0-acf0-91d0c9bd47b5\" class=\"RefDOI\">0.1136\/bmj.39489.470347.AD<\/span>.<\/p>\r\n<p id=\"R18\" class=\"jrnlRefText\"><span class=\"RefSlNo\">18.<\/span>\u00a0<span id=\"51b83d65-a596-4938-885e-68601a7a068b\" class=\"RefAuthor\"><span id=\"be0926fa-b6d6-483d-8520-72b69ba99e2f\" class=\"RefSurName\">Song<\/span>\u00a0<span id=\"14daeadd-e282-4183-8ab7-4f1d766a63fc\" class=\"RefGivenName\">F<\/span><\/span>,\u00a0<span id=\"17f228b3-9e9e-4d7f-bd87-70b89cd59385\" class=\"RefAuthor\"><span id=\"5da7ab80-b345-49ed-916d-838f88cbd7db\" class=\"RefSurName\">Eastwood<\/span>\u00a0<span id=\"3d2d2377-962f-4757-aadd-f8594ab033ac\" class=\"RefGivenName\">AJ<\/span><\/span>,\u00a0<span id=\"9bc47a3b-cbee-4c24-a59d-17e0107d1e70\" class=\"RefAuthor\"><span id=\"9fead28b-68c5-4c5f-b3b6-ccbf8f4853bb\" class=\"RefSurName\">Gilbody<\/span>\u00a0<span id=\"19083f83-d873-4ad1-952c-bbd069a4724c\" class=\"RefGivenName\">S<\/span><\/span>,\u00a0<span id=\"6c8e75f7-0b95-4015-9ce8-f553d4524e05\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"7de110dd-e50c-4880-b58d-12c95db3f8f4\" class=\"RefArticleTitle\">Publication and related biases<\/span>.\u00a0<span id=\"a2650306-f578-4b36-b45a-905a6c7dba0b\" class=\"RefJournalTitle\"><em id=\"b660f2c2-3665-4d00-93ec-902e08488eb9\">Health Technol Assess<\/em><\/span>.\u00a0<span id=\"9afe41dc-ceac-404b-84e0-8075c83d2e0f\" class=\"RefYear\">2000<\/span>;<span id=\"2b182279-5314-4d08-be8f-c65f356113f1\" class=\"RefVolume\">4<\/span>:<span id=\"8bcbe344-83ef-4faf-afb5-25152c41a7f8\" class=\"RefFPage\">1<\/span>\u2013<span id=\"9ec5a52c-3d8f-41c6-9b3a-95ada2b7957e\" class=\"RefLPage\">115<\/span>.\u00a0<span class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"88e77d56-eabe-4cd7-ba3e-674d103e4c61\" class=\"RefDOI\">10.3310\/hta4100<\/span>.<\/p>\r\n<p id=\"R19\" class=\"jrnlRefText\"><span class=\"RefSlNo\">19.<\/span>\u00a0<span id=\"c593a5e3-f34d-46d9-b1c0-3c27f04b40b6\" class=\"RefAuthor\"><span id=\"dc6c9bb7-1142-4346-8d13-75cf874585b1\" class=\"RefSurName\">Benedikt<\/span>\u00a0<span id=\"bdc20824-3cfd-40b6-8982-d1658959fb19\" class=\"RefGivenName\">M<\/span><\/span>,\u00a0<span id=\"de1588a1-40fc-4ce6-af09-8ef00ec35c3c\" class=\"RefAuthor\"><span id=\"849ebec0-7d29-43ca-adf9-ff70415abe16\" class=\"RefSurName\">Mangge<\/span>\u00a0<span id=\"4722f751-db5b-4f78-80d2-52d7c4ee154e\" class=\"RefGivenName\">H<\/span><\/span>,\u00a0<span id=\"ba2130b3-a68f-42f8-a1c6-7bef0a6740c3\" class=\"RefAuthor\"><span id=\"6f774dde-fe14-4c18-8292-780bf0e40bda\" class=\"RefSurName\">Aziz<\/span>\u00a0<span id=\"05c0ede7-dc7e-4ca3-ba89-2b540bdd43df\" class=\"RefGivenName\">F<\/span><\/span>,\u00a0<span id=\"ec64b49e-763a-40d9-84eb-23504ee3aec5\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"ddc295d7-f43a-477f-b0c7-0e854d4eab84\" class=\"RefArticleTitle\">Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute\u00a0<span id=\"d7ec905c-ee86-4524-afa7-241f2e226a59\" class=\"forceJustify\"><\/span>myocardial infarction \u2013 A post-hoc analysis of the EMMY trial<\/span>.\u00a0<span id=\"87619220-ac56-4566-a41e-f06c2331b899\" class=\"RefJournalTitle\"><em id=\"b74906bf-a95a-4a63-82af-2520693d2c3b\">Cardiovasc Diabetol<\/em><\/span>.\u00a0<span id=\"d0994685-3f2c-4dee-bce9-de40faa5483f\" class=\"RefYear\">2023<\/span>;<span id=\"937892ab-45be-42f5-9fd4-f92b3b41744e\" class=\"RefVolume\">22<\/span>:<span id=\"33cb28a6-f636-4fbc-8c58-cb66ef33b43c\" class=\"RefELocation\">166<\/span>.\u00a0<span class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"6d7eb4d8-f309-402c-9f92-4afd922ba605\" class=\"RefDOI\">10.1186\/s12933-023-01904-6<\/span>.<\/p>\r\n<p id=\"R20\" class=\"jrnlRefText\"><span class=\"RefSlNo\">20.<\/span>\u00a0<span id=\"ea4ca589-b068-4807-b305-1f2ccb3d5b35\" class=\"RefAuthor\"><span id=\"b6f60552-e38a-4c23-9a65-595d12a14e58\" class=\"RefSurName\">Sourij<\/span>\u00a0<span id=\"484fa960-2699-4962-bf4b-a23df2a9eb96\" class=\"RefGivenName\">C<\/span><\/span>,\u00a0<span id=\"470dbfb1-4a7a-4572-a02f-edad196b2741\" class=\"RefAuthor\"><span id=\"b70b7b1f-dce5-4754-bd55-47197cac81a5\" class=\"RefSurName\">Aziz<\/span>\u00a0<span id=\"308c68f5-74d4-4f6e-9546-2113edccf34b\" class=\"RefGivenName\">F<\/span><\/span>,\u00a0<span id=\"ff2e004b-9a85-41b5-8eed-fbc7347614a6\" class=\"RefAuthor\"><span id=\"00ed6fed-a41b-4807-a4f1-76f54a24ffab\" class=\"RefSurName\">Tripolt<\/span>\u00a0<span id=\"4162fd99-8672-4de7-ba4d-715688c80c2c\" class=\"RefGivenName\">NJ<\/span><\/span>,\u00a0<span id=\"665ceac9-792f-4307-a19d-78879c6689ca\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"5e6a6af7-dfe4-4f11-8fea-ef907665021b\" class=\"RefArticleTitle\">Effects of empagliflozin in women and men with acute myocardial infarction:\u00a0<span id=\"ee949044-1548-4564-854a-aeb99c8f0b59\" class=\"changeCase sty cts-2\">A<\/span>n analysis from the EMMY trial<\/span>.\u00a0<span id=\"67d23140-4672-4b19-ad56-cca0aa3d86f3\" class=\"RefJournalTitle\"><em id=\"d8fe4a87-eb6d-4aa9-bbf5-e9765d5e5b98\">Hellenic J Cardiol<\/em><\/span>.\u00a0<span id=\"93991194-9e93-4c00-baee-dcbd608e089f\" class=\"RefYear\">2024<\/span>;<span id=\"7848c31a-c46a-47bd-a083-a78f535072f0\" class=\"RefVolume\">75<\/span>:<span id=\"1d33872c-7130-401b-a5b9-65f785256ef2\" class=\"RefFPage\">3<\/span>\u2013<span id=\"71248cf3-10dd-48a0-b8c4-42aa1313785e\" class=\"RefLPage\">8<\/span>.\u00a0<span class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"88e9a38c-3980-4e7d-a03b-1391603d9d5b\" class=\"RefDOI\">10.1016\/j.hjc.2023.05.007<\/span>.<\/p>\r\n<p id=\"R21\" class=\"jrnlRefText\"><span id=\"7709247b-5c1e-4c09-87c8-fb7b9078e850\" class=\"RefSlNo\">21.<\/span>\u00a0<span id=\"5ccd7f57-23e1-45ca-b76f-1d8f5adc75fe\" class=\"RefAuthor\"><span id=\"012d64cf-cb23-475c-bbd8-569c4c25ce8c\" class=\"RefSurName\">Mozawa<\/span>\u00a0<span id=\"f6fc778a-495a-4912-a801-893e079f8e0d\" class=\"RefGivenName\">K<\/span><\/span>,\u00a0<span id=\"269ea52f-334a-4f68-8d55-9944b17818b3\" class=\"RefAuthor\"><span id=\"f4bb9d23-bea2-4964-80b4-bd88e868a2a8\" class=\"RefSurName\">Kubota<\/span>\u00a0<span id=\"26e8b20a-5572-4ff6-90f8-8ec2052bda53\" class=\"RefGivenName\">Y<\/span><\/span>,\u00a0<span id=\"e0a36dd8-7020-4da8-b0c3-92b316135ca6\" class=\"RefAuthor\"><span id=\"6a93dd46-bc14-4737-832d-f003390c13c8\" class=\"RefSurName\">Hoshika<\/span>\u00a0<span id=\"9d69ae59-44cd-47b6-8f0e-5d0586159918\" class=\"RefGivenName\">Y<\/span><\/span>,\u00a0<span id=\"8e7df44d-a243-4e7d-918f-aa3f7e01eedf\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"32eaccbf-b1f2-430f-8c60-90731331f774\" class=\"RefArticleTitle\">Empagliflozin confers reno-protection in acute myocardial infarction and type 2 diabetes mellitus<\/span>.\u00a0<span id=\"93625593-e51d-40fe-96cd-b25cd949c73b\" class=\"RefJournalTitle\"><em id=\"3ff97252-253b-4b2f-87b1-456221769a94\">ESC Heart Fail<\/em><\/span>.\u00a0<span id=\"f8e56d2c-4507-4b6e-b3a0-ee7da8af716c\" class=\"RefYear\">2021<\/span>;<span id=\"1b310c9b-df26-4a91-9cd4-1d34cf692dcb\" class=\"RefVolume\">8<\/span>:<span id=\"afb8d892-7b57-4ccd-aa86-c2dd70c9b799\" class=\"RefFPage\">4161<\/span>\u2013<span id=\"f170dad1-971a-4d11-b5f7-c00a602e61fd\" class=\"RefLPage\">73<\/span>.\u00a0<span id=\"13b0ed86-6139-4102-99cf-1a8c1a42ff93\" class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"f03a5d56-46ca-4c0a-86f9-db705fdad5d8\" class=\"RefDOI\">10.1002\/ehf2.13509<\/span>.<\/p>\r\n<p id=\"R22\" class=\"jrnlRefText\"><span class=\"RefSlNo\">22.<\/span>\u00a0<span id=\"6f38c461-e535-488d-8fc4-fbc0bb958300\" class=\"RefAuthor\"><span id=\"db7860fd-7cc4-4f6c-b9e5-e8e4723f59bc\" class=\"RefSurName\">Hoshika<\/span>\u00a0<span id=\"6e18d3ff-8dd9-4784-bfd3-e79e5915d3e0\" class=\"RefGivenName\">Y<\/span><\/span>,\u00a0<span id=\"4968efe5-3a67-42de-a3b1-3d3c59a0f8ce\" class=\"RefAuthor\"><span id=\"fb27ab5c-c2a4-4acb-94b4-3eb3ea67c9b0\" class=\"RefSurName\">Kubota<\/span>\u00a0<span id=\"446dce2c-2f26-4747-803d-c1cb29f3df03\" class=\"RefGivenName\">Y<\/span><\/span>,\u00a0<span id=\"a7dbd36b-47d0-4156-b53f-2494933a714e\" class=\"RefAuthor\"><span id=\"e0999629-6946-44a2-9a59-0f1e016c3f95\" class=\"RefSurName\">Mozawa<\/span>\u00a0<span id=\"46613a45-1302-4dc2-83f9-083503112eb6\" class=\"RefGivenName\">K<\/span><\/span>,\u00a0<span id=\"3b5c1e0a-0fcb-4898-b9d5-4494a1784864\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"acbe3751-d0d6-4972-96e1-0fc80ac072a1\" class=\"RefArticleTitle\">Effect of empagliflozin versus placebo on body fluid balance in patients with acute myocardial infarction and type 2 diabetes mellitus:\u00a0<span id=\"b6d7865f-a528-4e59-80f5-b166ff5dc443\" class=\"changeCase sty cts-2\">S<\/span>ubgroup analysis of the EMBODY trial<\/span>.\u00a0<span id=\"9b10b333-9a96-4fbb-bf24-b5ab0ab89d2d\" class=\"RefJournalTitle\"><em id=\"3d8c8dd8-28da-45f5-8b1c-730c7ed718ba\">J Card Fail<\/em><\/span>.\u00a0<span id=\"01cc00d5-0942-4549-b634-b8ba4e385a03\" class=\"RefYear\">2022<\/span>;<span id=\"dfa5ed51-f420-4cbf-b19b-08f6fe046827\" class=\"RefVolume\">28<\/span>:<span id=\"bbb995af-657b-46ef-9232-a258a7f2b8ae\" class=\"RefFPage\">56<\/span>\u2013<span id=\"8ce13be3-7efd-4622-a0c6-877f2594a0ac\" class=\"RefLPage\">64<\/span>.\u00a0<span class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"4b6aa7a7-ea45-4688-8ceb-ad1f7ded28ab\" class=\"RefDOI\">10.1016\/j.cardfail.2021.07.022<\/span>.<\/p>\r\n<p id=\"R23\" class=\"jrnlRefText\"><span id=\"a0f4f180-eb25-442a-b1bb-13f0e39797f8\" class=\"RefSlNo\">23.<\/span>\u00a0<span id=\"52608300-0d06-4b00-b721-351c7addc494\" class=\"RefAuthor\"><span id=\"c25d8e51-2a5a-4cb3-9c46-9a9ff6b4656c\" class=\"RefSurName\">Adel<\/span>\u00a0<span id=\"66771f55-862b-4521-b6b5-b3adfb65f187\" class=\"RefGivenName\">SMH<\/span><\/span>,\u00a0<span id=\"5fd3fc2a-d659-4ee8-a237-e7b96a4b320b\" class=\"RefAuthor\"><span id=\"767bd5fa-159f-4fcd-89db-458126bf1043\" class=\"RefSurName\">Jorfi<\/span>\u00a0<span id=\"6b1c7e8c-31c7-4c8e-bcbc-746d2ebf60b0\" class=\"RefGivenName\">F<\/span><\/span>,\u00a0<span id=\"cb55260f-b3ce-4fdc-8c96-8c49a6692c11\" class=\"RefAuthor\"><span id=\"d70549ee-f100-4591-9a36-276f98de8111\" class=\"RefSurName\">Mombeini<\/span>\u00a0<span id=\"738c25e6-7d3b-4638-a489-ce4919fc0880\" class=\"RefGivenName\">H<\/span><\/span>,\u00a0<span id=\"54add10c-d10d-4ee0-bedd-0a7efe05ac77\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"c9dc3541-7049-4774-987c-538aaa9fdb94\" class=\"RefArticleTitle\">Effect of a low dose of empagliflozin on short-term outcomes in type 2 diabetics with acute coronary syndrome after percutaneous coronary intervention<\/span>.\u00a0<span id=\"88a07902-3473-4d18-bd8a-2e0d50c63426\" class=\"RefJournalTitle\"><em id=\"cfb729a3-9070-4cf4-bb2f-30ea4bf059ae\">Saudi Med J<\/em><\/span>.\u00a0<span id=\"d9ff0846-a1ef-43da-8138-5377c1018246\" class=\"RefYear\">2022<\/span>;<span id=\"4e8348b2-082e-4b2b-8dab-d47059fae8f9\" class=\"RefVolume\">43<\/span>:<span id=\"0fff3290-9749-4d61-a5f2-ac09b6865dcd\" class=\"RefFPage\">458<\/span>\u2013<span id=\"10afeff3-b807-4129-b361-41539deddf11\" class=\"RefLPage\">64<\/span>.\u00a0<span id=\"26bb1353-6676-4442-914c-501ea4ca67cc\" class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"977124ff-27b8-4a92-8c63-800b9cdee7f4\" class=\"RefDOI\">10.15537\/smj.2022.43.5.20220018<\/span>.<\/p>\r\n<p id=\"R24\" class=\"jrnlRefText\"><span class=\"RefSlNo\">24.<\/span>\u00a0<span id=\"479639ed-b6fd-463a-8e51-075f5c241b68\" class=\"RefAuthor\"><span id=\"9844f350-8f0a-4c0d-900e-b1add9c895cb\" class=\"RefSurName\">Fortin<\/span>\u00a0<span id=\"d5ba5004-4f71-4683-a712-3439e4a9d487\" class=\"RefGivenName\">E<\/span><\/span>,\u00a0<span id=\"15cd29b2-7b0a-47d9-8017-909c6f356fb4\" class=\"RefAuthor\"><span id=\"cc79d188-e631-422b-89bc-3ec8e1b9a070\" class=\"RefSurName\">Lundin<\/span>\u00a0<span id=\"9f07f446-cc54-422a-8782-b3021c824676\" class=\"RefGivenName\">M<\/span><\/span>,\u00a0<span id=\"33af17b4-3b77-4a18-aaea-2a87ceae3a42\" class=\"RefAuthor\"><span id=\"3d8cf8a0-b8c7-4bde-9117-63aba3332cdc\" class=\"RefSurName\">Mellbin<\/span>\u00a0<span id=\"3236ef6a-b3c1-4515-a1b2-eb47bb4d67d2\" class=\"RefGivenName\">L<\/span><\/span>,\u00a0<span id=\"38741eb5-667d-4db9-87b8-b00cd8110841\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"73a86c61-b5f0-4ded-a1e1-1a7b489086e3\" class=\"RefArticleTitle\">Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia: Experiences from the randomized, controlled SOCOGAMI trial<\/span>.\u00a0<span id=\"ac77203b-da89-4c7a-a74e-5abd13f3bd42\" class=\"RefJournalTitle\"><em id=\"a3a0e081-8d50-4343-948e-3aed89a28856\">Cardiovasc Diabetol<\/em><\/span>. 2<span id=\"32237cf7-a9a1-44ef-a569-8749bd2dec63\" class=\"RefYear\">023<\/span>;<span id=\"ab2ee2e0-82fe-430b-87b8-05eadef46c81\" class=\"RefVolume\">22<\/span>:<span id=\"0a6d5d81-6ad9-45b7-a09e-b555e39910c4\" class=\"RefELocation\">208. <\/span><span class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"8b5f41ed-bfca-4950-844b-33eca3854cac\" class=\"RefDOI\">10.1186\/s12933-023-01950-0<\/span>.<\/p>\r\n<p id=\"R25\" class=\"jrnlRefText\"><span id=\"f559a5ca-c74c-498b-af10-d589b30da1be\" class=\"RefSlNo\">25.<\/span>\u00a0<span id=\"7ac48db6-2fd8-4528-9aeb-e5285666d17b\" class=\"RefAuthor\"><span id=\"97d96d8e-5137-496c-8ec2-ff79ef1e02fe\" class=\"RefSurName\">Lundin<\/span>\u00a0<span id=\"1da7d991-3dd0-4987-b365-5a836c3a0147\" class=\"RefGivenName\">M<\/span><\/span>,\u00a0<span id=\"2da46d73-9018-4134-8367-cad6ed95590c\" class=\"RefAuthor\"><span id=\"9d685352-6271-4003-9155-e6397109f3df\" class=\"RefSurName\">Ferrannini<\/span>\u00a0<span id=\"61225096-98c6-4e61-b1bf-59cde84922dc\" class=\"RefGivenName\">G<\/span><\/span>,\u00a0<span id=\"56430fad-3a0c-4394-9f10-16b2a62b031f\" class=\"RefAuthor\"><span id=\"59760f97-b9f4-4249-8585-a46f7fc8fcc3\" class=\"RefSurName\">Mellbin<\/span>\u00a0<span id=\"6d73a6f1-2e67-4fb6-ace7-06af36f92a65\" class=\"RefGivenName\">L<\/span><\/span>,\u00a0<span id=\"933df257-0296-4dfd-9935-2d15108bb865\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"971b2d0b-17ed-4f16-b0d9-2430ff4a7ba6\" class=\"RefArticleTitle\">SOdium-glucose CO-transporter inhibition in patients with newly detected glucose abnormalities and a recent myocardial infarction (SOCOGAMI)<\/span>.\u00a0<span id=\"83b6de3f-5fb0-496b-b74f-e78ead31a05f\" class=\"RefJournalTitle\"><em id=\"d2991ad6-3446-473b-9611-49ef460ff58e\">Diabetes Res Clin Pract<\/em><\/span>.\u00a0<span id=\"dd0ce180-e46a-4e39-80d6-a8bd76f598be\" class=\"RefYear\">2022<\/span>;<span id=\"06947798-f7c9-4d26-b511-abb0342f092e\" class=\"RefVolume\">193<\/span>:<span id=\"f676f9c0-485a-4ce1-bfe2-b9d8dd1aabf4\" class=\"RefFPage\">110141<\/span>.\u00a0<span id=\"bb48669b-da05-4007-b675-b4b8fa20c100\" class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"e43f7bf9-c269-4f1d-8469-52267da9fee5\" class=\"RefDOI\">10.1016\/j.diabres.2022.110141<\/span>.<\/p>\r\n<p id=\"R26\" class=\"jrnlRefText\"><span class=\"RefSlNo\">26.<\/span>\u00a0<span id=\"9e334d2d-2f0e-46cb-ba60-50e1593d2ad5\" class=\"RefAuthor\"><span id=\"17198e39-74bd-4dd1-84c4-88b6e3f9d89a\" class=\"RefSurName\">Khiali<\/span>\u00a0<span id=\"78cbe876-8824-44ef-b0a6-97fe0d26961e\" class=\"RefGivenName\">S<\/span><\/span>,\u00a0<span id=\"7f8be641-642c-434e-a992-f4f18231a915\" class=\"RefAuthor\"><span id=\"25fc984b-6ec0-405f-b692-d1f50da87f03\" class=\"RefSurName\">Taban-Sadeghi<\/span>\u00a0<span id=\"e585452b-606d-429b-8a6c-f8ce2988b1c4\" class=\"RefGivenName\">M<\/span><\/span>,\u00a0<span id=\"4273fdd0-38d8-4458-a71e-c529952f5fd3\" class=\"RefAuthor\"><span id=\"88eceaef-6b36-47d0-bd19-72317ab42fdb\" class=\"RefSurName\">Sarbakhsh<\/span>\u00a0<span id=\"7a79bfdf-ac16-4da2-9fe1-694d6f307d78\" class=\"RefGivenName\">P<\/span><\/span>,\u00a0<span id=\"29b51b94-2335-4f01-a27e-3915c2d65662\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"e5801327-5d87-4e1b-9fec-ff65086ffa60\" class=\"RefArticleTitle\">Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction:\u00a0<span id=\"c8a06fe5-3c3f-4467-ac7c-fb704cb3d2c1\" class=\"changeCase sty cts-2\">A<\/span>\u00a0randomized, double-blinded, three-arm parallel-group, controlled trial<\/span>.\u00a0<span id=\"d2fb5d09-ba55-42aa-94a9-32b82a7dc39d\" class=\"RefJournalTitle\"><em id=\"c4a34504-719e-475d-aa94-75d9a8b65988\">Eur J Clin Pharmacol<\/em><\/span>.\u00a0<span id=\"585fd79d-ec48-4614-92db-6a36699506b3\" class=\"RefYear\">2024<\/span>;<span id=\"78f77f3a-1e95-457b-b740-7f8626fc231c\" class=\"RefVolume\">80<\/span>:<span id=\"0e8d239b-ca70-4f85-a22f-1983d73c51a7\" class=\"RefFPage\">93<\/span>\u2013<span id=\"3c090cdc-9be6-49d5-98df-8c9ccb48cdd0\" class=\"RefLPage\">104<\/span>.\u00a0<span class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"cccd9199-d2ea-49d8-9496-0a7189fd7fc6\" class=\"RefDOI\">10.1007\/s00228-023-03582-5<\/span>.<\/p>\r\n<p id=\"R27\" class=\"jrnlRefText\"><span class=\"RefSlNo\">27.<\/span>\u00a0<span id=\"3dad8e8d-dd1d-440c-b034-158afb1d3a41\" class=\"RefAuthor\"><span id=\"bc5a8b77-b99e-44f3-8ae8-c5105d17e51a\" class=\"RefSurName\">Karetnikova<\/span>\u00a0<span id=\"8178cee1-fbcb-433c-86dc-5a0b8f8a1b90\" class=\"RefGivenName\">VN<\/span><\/span>,\u00a0<span id=\"a20c3899-b948-485b-918d-f5eba6fc46bf\" class=\"RefAuthor\"><span id=\"19a8c665-fb09-401a-984c-8355bee83d05\" class=\"RefSurName\">Kchorlampenko<\/span>\u00a0<span id=\"14ca6de3-d5b7-441c-950e-bed4ea38828b\" class=\"RefGivenName\">AA<\/span><\/span>,\u00a0<span id=\"ee2783b0-57c6-4818-a080-26a0a9d9eb66\" class=\"RefAuthor\"><span id=\"bb113dfd-4709-4a7d-af24-56ad7a1b1e10\" class=\"RefSurName\">Kochergina<\/span>\u00a0<span id=\"dcfae853-fb18-462e-b441-3a003197ae17\" class=\"RefGivenName\">AM<\/span><\/span>,\u00a0<span id=\"136acce1-b634-4e8f-be1f-0d842bc07324\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"0db7f03d-781a-4797-a1bf-667c9977737b\" class=\"RefArticleTitle\">Cardiometabolic effects of empagliflozin in patients undergoing elective percutaneous coronary intervention for type 2 diabetes mellitus<\/span>.\u00a0<span id=\"9a47f7bf-5163-47a3-90d2-3c886f0f0330\" class=\"RefJournalTitle\"><em id=\"b6133bbb-8665-4a97-bb22-d62d0c9a0fa4\">Kardiologiia<\/em><\/span>.\u00a0<span id=\"3f4668f0-6dfe-46a2-8b40-3984b17cf5a7\" class=\"RefYear\">2022<\/span>;<span id=\"e8bf24b7-c164-46e4-8ebb-175f2ca18ebb\" class=\"RefVolume\">62<\/span>:<span id=\"f95c3c0a-54c7-40b7-a410-ae706c0fec9d\" class=\"RefFPage\">64<\/span>\u2013<span id=\"c953f85a-5370-40aa-b30f-5606b22c2e0b\" class=\"RefLPage\">72<\/span>.\u00a0<span class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"0f66983a-820d-49e3-9d0c-bdee48466bb7\" class=\"RefDOI\">10.18087\/cardio.2022.12.n1838<\/span>.<\/p>\r\n<p id=\"R28\" class=\"jrnlRefText\"><span id=\"26ea5c38-7ab9-46b9-9e9a-8362c1d8dedb\" class=\"RefSlNo\">28.<\/span>\u00a0<span id=\"3711dfe0-be39-466f-9397-2ae440bcf554\" class=\"RefAuthor\"><span id=\"961927b9-e242-440c-8011-b9c9a55db6d2\" class=\"RefSurName\">Zinman<\/span>\u00a0<span id=\"ef7bbec2-28ad-472e-903c-cb887d581750\" class=\"RefGivenName\">B<\/span><\/span>,\u00a0<span id=\"e694f12e-b090-4bdc-9353-3802a5b63282\" class=\"RefAuthor\"><span id=\"bd80abb1-fbe8-406c-b21e-0819b329cc76\" class=\"RefSurName\">Wanner<\/span>\u00a0<span id=\"f6020bac-5870-44c9-b8e5-89b5ee4d50c3\" class=\"RefGivenName\">C<\/span><\/span>,\u00a0<span id=\"6c145bfc-52a4-4df0-87a2-a08aec3340d1\" class=\"RefAuthor\"><span id=\"91bdf29e-cf30-479d-921a-8e7f2fc22fb1\" class=\"RefSurName\">Lachin<\/span>\u00a0<span id=\"4c5ced19-e507-42ea-b51d-8aaa58bdf055\" class=\"RefGivenName\">JM<\/span><\/span>,\u00a0<span id=\"7d593797-0731-4ade-8d06-07738557464d\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"67ccf2ec-dcd2-4bed-b681-90d79cd533bc\" class=\"RefArticleTitle\">Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes<\/span>.\u00a0<span id=\"84c5a4d9-ff7a-4bab-b099-f52d40b1a127\" class=\"RefJournalTitle\"><em id=\"034d5cb0-8c5e-4e9d-810f-e2aaa52f79b8\">N Engl J Med<\/em><\/span>.\u00a0<span id=\"92533d43-3d61-4ae7-945b-97e0c8af7e56\" class=\"RefYear\">2015<\/span>;<span id=\"5ef9870e-9563-4808-8002-a978e07a28ab\" class=\"RefVolume\">373<\/span>:<span id=\"9ed621ac-c79d-4458-972a-c58a4d69ad32\" class=\"RefFPage\">2117<\/span>\u2013<span id=\"ba38f571-1ca5-4232-8f6a-16583addf11a\" class=\"RefLPage\">28. <\/span><span id=\"b3bd59fb-6153-49de-86ac-14e0ae2a597c\" class=\"RefComments\">DOI: 1<\/span><span id=\"659d5aa5-6bea-4716-b425-b69900ee0df3\" class=\"RefDOI\">0.1056\/NEJMoa1504720<\/span>.<\/p>\r\n<p id=\"R29\" class=\"jrnlRefText\"><span id=\"0eda504b-fa3a-43ca-a1bf-68061e5371fd\" class=\"RefSlNo\">29.<\/span>\u00a0<span id=\"5470d9ea-7056-4348-a71c-2135f8679ffb\" class=\"RefAuthor\"><span id=\"8d66e1c8-e4ac-4a32-ad02-0a5a3d3ea3f9\" class=\"RefSurName\">Neal<\/span>\u00a0<span id=\"d0a36488-9ee1-482a-a480-2c50b8f66ca4\" class=\"RefGivenName\">B<\/span><\/span>,\u00a0<span id=\"758da684-05ff-4a70-a966-090d7f7f28ca\" class=\"RefAuthor\"><span id=\"c4a81d4d-1636-4e01-baae-52d2a41788e8\" class=\"RefSurName\">Perkovic<\/span>\u00a0<span id=\"3e78bc90-9247-4237-8a5b-7e5d94d6eb67\" class=\"RefGivenName\">V<\/span><\/span>,\u00a0<span id=\"7e59f4e5-414e-4172-91ee-14122468fd28\" class=\"RefAuthor\"><span id=\"36707e49-0224-4e82-affd-1cca37c3693d\" class=\"RefSurName\">Mahaffey<\/span>\u00a0<span id=\"8d9deb41-88bc-4457-b423-e3275b12c305\" class=\"RefGivenName\">KW<\/span><\/span>,\u00a0<span id=\"89875fe8-dd70-4629-a260-1a99cb7dd6b7\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"569a802c-2afd-47c8-83a0-5f32e4164886\" class=\"RefArticleTitle\">Canagliflozin and cardiovascular and renal events in type 2 diabetes<\/span>.\u00a0<span id=\"599cd300-1abe-4f80-84f9-4ac349a708c2\" class=\"RefJournalTitle\"><em id=\"ef77c262-9848-4ab4-90be-00b526b235cf\">N Engl J Med<\/em><\/span>.\u00a0<span id=\"43938036-85d8-4204-90ed-313ba1ce7214\" class=\"RefYear\">2017<\/span>;<span id=\"6105f73e-1f22-43c1-9e18-d3e3095d161e\" class=\"RefVolume\">377<\/span>:<span id=\"bac2ebc6-9c19-4992-877f-9a1b1454a707\" class=\"RefFPage\">644<\/span>\u2013<span id=\"1e4bfb51-e96c-4286-accf-2505079f4510\" class=\"RefLPage\">57<\/span>.\u00a0<span id=\"1cc83b92-e4c1-4644-8ac6-b0e7a641483f\" class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"330676d1-61b3-44ba-b0f0-9f37e483d058\" class=\"RefDOI\">10.1056\/NEJMoa1611925<\/span>.<\/p>\r\n<p id=\"R30\" class=\"jrnlRefText\"><span id=\"11806144-b9a7-41cf-8bd1-3057dd9b6d05\" class=\"RefSlNo\">30.<\/span>\u00a0<span id=\"3ed994d3-6752-49b2-8bdd-47288ddce842\" class=\"RefAuthor\"><span id=\"c41bf659-83f4-442d-919a-1a677da5565c\" class=\"RefSurName\">Wiviott<\/span>\u00a0<span id=\"86f81caf-6786-4f1e-aba2-df0ca65ee0e0\" class=\"RefGivenName\">SD<\/span><\/span>,\u00a0<span id=\"9cca7074-414a-46fc-858d-509afcafc509\" class=\"RefAuthor\"><span id=\"cf93c443-efe8-478e-928d-a3e1da42a912\" class=\"RefSurName\">Raz<\/span>\u00a0<span id=\"dc4250aa-74f9-4a12-987f-c630e183791a\" class=\"RefGivenName\">I<\/span><\/span>,\u00a0<span id=\"d3ad4274-739d-4f74-8852-82b1b2c72f69\" class=\"RefAuthor\"><span id=\"3a2b6819-872e-478f-9bbc-8f28c47a8985\" class=\"RefSurName\">Bonaca<\/span>\u00a0<span id=\"a4d38deb-ca56-4bef-980c-053012f5510e\" class=\"RefGivenName\">MP<\/span><\/span>,\u00a0<span id=\"e72b2e80-599d-4700-8d39-1c889e61fd19\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"fbd83dda-b990-4b81-b935-daaf4d0a8550\" class=\"RefArticleTitle\">Dapagliflozin and cardiovascular outcomes in type 2 diabetes<\/span>.\u00a0<span id=\"18dd8d5f-2afb-4bd1-91d1-3a46e69c73cf\" class=\"RefJournalTitle\"><em id=\"9562a9b2-c850-4fe1-b9f3-e6be8152a32b\">N Engl J Med<\/em><\/span>.\u00a0<span id=\"6c92010f-4237-4cfd-8325-9fb69c686b92\" class=\"RefYear\">2019<\/span>;<span id=\"3e976ce2-ab17-4388-9578-79bd0f3ec0b7\" class=\"RefVolume\">380<\/span>:<span id=\"cfe8f315-2db7-4c2b-b910-c35a55677251\" class=\"RefFPage\">347<\/span>\u2013<span id=\"bf158ac5-dfca-4293-ab2e-acba4962b2fc\" class=\"RefLPage\">57. <\/span><span id=\"57a92a34-b298-4665-9391-4f1a56cbffd4\" class=\"RefComments\">DOI<\/span>: 1<span id=\"81c2c65b-c40f-4a95-b9fc-57dffced78e7\" class=\"RefDOI\">0.1056\/NEJMoa1812389<\/span>.<\/p>\r\n<p id=\"R31\" class=\"jrnlRefText\"><span id=\"8fa7fda1-6045-46d2-82c8-9d2e007f2546\" class=\"RefSlNo\">31.<\/span>\u00a0<span id=\"cd7e7030-9227-4521-bbb7-bcc2e90c491b\" class=\"RefAuthor\"><span id=\"8f4e718b-0a8c-432f-bdd9-e2d01eb290a0\" class=\"RefSurName\">Cannon<\/span>\u00a0<span id=\"cfdae810-2a2c-4a44-b21d-58dc3e897d11\" class=\"RefGivenName\">CP<\/span><\/span>,\u00a0<span id=\"df541425-d99b-4906-a12f-05e603bd7304\" class=\"RefAuthor\"><span id=\"808b42af-8bd9-4e31-928f-2ed93eb717c6\" class=\"RefSurName\">Pratley<\/span>\u00a0<span id=\"5b146e78-4dd8-4cb8-9a42-4ba883f9081f\" class=\"RefGivenName\">R<\/span><\/span>,\u00a0<span id=\"51f2484b-a3c6-4431-8743-c3fe87f6a3c7\" class=\"RefAuthor\"><span id=\"0dcd961f-54bc-4ff2-8544-f7b5a070b99b\" class=\"RefSurName\">Dagogo-Jack<\/span>\u00a0<span id=\"0d530153-f3bd-4db5-85cb-6672566f930e\" class=\"RefGivenName\">S<\/span><\/span>,\u00a0<span id=\"3c71db1e-79b0-48fe-9bb5-bc09e8703c10\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"b637bf58-4fbb-4f1b-b014-08fc2df20e75\" class=\"RefArticleTitle\">Cardiovascular outcomes with ertugliflozin in type 2 diabetes<\/span>.\u00a0<span id=\"ce66db79-02fb-45cf-ba28-4a4237fc921f\" class=\"RefJournalTitle\"><em id=\"95594555-bd08-414c-a05a-4abe751e8adf\">N Engl J Med<\/em><\/span>.\u00a0<span id=\"0c04e980-032a-43bb-b8a9-ae346f077f6d\" class=\"RefYear\">2020<\/span>;<span id=\"891ab39e-4e6d-403a-8228-f0bc01af0042\" class=\"RefVolume\">383<\/span>:<span id=\"4dba04f1-6bd1-4771-9f7d-e50c15eee8d3\" class=\"RefFPage\">1425<\/span>\u2013<span id=\"babb3172-00bb-4853-8ac7-781ffab604dc\" class=\"RefLPage\">35<\/span>.\u00a0<span id=\"ec04715c-4369-449c-ad35-acf419176a0f\" class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"179fa52d-8a8a-4178-a378-fc02ddaa823b\" class=\"RefDOI\">10.1056\/NEJMoa2004967<\/span>.<\/p>\r\n<p id=\"R32\" class=\"jrnlRefText\"><span id=\"5343c549-d571-4452-a763-6a409e2d5c14\" class=\"RefSlNo\">32.<\/span>\u00a0<span id=\"762944d2-779d-4dcc-a5b6-3f4ec4678a84\" class=\"RefAuthor\"><span id=\"9d6ca0fe-0783-407c-a36c-9493114c04c4\" class=\"RefSurName\">Bhatt<\/span>\u00a0<span id=\"3fe7a47a-1d78-4b84-a83b-741e850b1115\" class=\"RefGivenName\">DL<\/span><\/span>,\u00a0<span id=\"b9bc1711-0ac4-4fca-8fa9-7853d8be92a0\" class=\"RefAuthor\"><span id=\"d35d6ea1-0fbb-40d6-b237-2fcdb8f627da\" class=\"RefSurName\">Szarek<\/span>\u00a0<span id=\"8792b49f-34ab-442f-b938-2fe978ea2e96\" class=\"RefGivenName\">M<\/span><\/span>,\u00a0<span id=\"b53d62ac-8cdc-4811-91fb-213b09c0f35a\" class=\"RefAuthor\"><span id=\"101c8fee-f460-45f4-a114-11aa9b6eace7\" class=\"RefSurName\">Pitt<\/span>\u00a0<span id=\"bd8d8437-8922-4be4-b14f-f050007fbc7c\" class=\"RefGivenName\">B<\/span><\/span>,\u00a0<span id=\"4ac1cad8-a91b-4a34-ab5b-d70dfec20f79\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"6fbda78c-1b2d-4926-a812-48e5e227bed2\" class=\"RefArticleTitle\">Sotagliflozin in patients with diabetes and chronic kidney disease<\/span>.\u00a0<span id=\"0e780b7c-07ff-49fb-a7cd-8ab7d70f02d1\" class=\"RefJournalTitle\"><em id=\"7230340c-e7f2-4e7b-b008-590b9c5fd1c8\">N Engl J Med<\/em><\/span>.\u00a0<span id=\"65f2224f-0fa6-463b-991d-69715fac06ee\" class=\"RefYear\">2021<\/span>;<span id=\"d1b44f96-fdce-4bdc-a4d0-d929829e90b0\" class=\"RefVolume\">384<\/span>:<span id=\"eabe6c31-0ac4-4bdf-8d5d-90c36ce0217b\" class=\"RefFPage\">129<\/span>\u2013<span id=\"8342a617-eb87-409b-87cd-f869836bc22c\" class=\"RefLPage\">39. <\/span><span id=\"6ce61549-d87a-4a21-8714-52a9d4697219\" class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"fef8dab7-4036-4952-854f-bc59d03897a5\" class=\"RefDOI\">10.1056\/NEJMoa2030186<\/span>.<\/p>\r\n<p id=\"R33\" class=\"jrnlRefText\"><span class=\"RefSlNo\">33.<\/span>\u00a0<span id=\"d97a209f-239b-44fc-a175-4637b1c46c71\" class=\"RefAuthor\"><span id=\"37df61a9-8c91-40b2-b549-fc2ea13e5a96\" class=\"RefSurName\">Mukhopadhyay<\/span>\u00a0<span id=\"79b1ebfb-23c3-4437-b0db-cd1f9c014449\" class=\"RefGivenName\">P<\/span><\/span>,\u00a0<span id=\"d04fb8c0-752c-40ed-bd7b-acf8dfd1b442\" class=\"RefAuthor\"><span id=\"1c76beef-a734-4353-a6a9-e7747f11e002\" class=\"RefSurName\">Sanyal<\/span>\u00a0<span id=\"5e189f13-6a0f-4dcb-8664-f4eae17ebd16\" class=\"RefGivenName\">D<\/span><\/span>,\u00a0<span id=\"0d2f2e1a-b528-475b-819e-cf09b3900fff\" class=\"RefAuthor\"><span id=\"29c969c8-f350-4e1f-b181-097839d91f6a\" class=\"RefSurName\">Chatterjee<\/span>\u00a0<span id=\"50887d48-94ca-4d1d-a33f-8b2f587be17c\" class=\"RefGivenName\">P<\/span><\/span>,\u00a0<span id=\"f330d4b4-b4bc-44c9-a2f8-6d4a11d595c9\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"f4974043-a337-4d7d-ba0d-e07c38082f7d\" class=\"RefArticleTitle\">Different sodium-glucose cotransporter-2 inhibitors:\u00a0<span id=\"4216cec5-364e-4d19-ae80-ca095bf1c2e2\" class=\"changeCase sty cts-2\">C<\/span>an they prevent death?<\/span>\u00a0<span id=\"b6b5fdd9-af9a-480d-aa2c-e06d6a645e0e\" class=\"RefJournalTitle\"><em id=\"2fa0a4a5-c760-4c9b-a763-4aee6e6841f8\">Endocr Pract<\/em><\/span>.\u00a0<span id=\"4f6378fb-e587-4655-b3c9-5598cbd85f47\" class=\"RefYear\">2022<\/span>;<span id=\"116969a0-447e-44fd-a703-2cd67fd258fc\" class=\"RefVolume\">28<\/span>:<span id=\"0676a859-3bb3-47c9-b45d-d3424f0df1ee\" class=\"RefFPage\">795<\/span>\u2013<span id=\"1c29dd59-989e-4cb8-8e0f-6fbad66ef597\" class=\"RefLPage\">801<\/span>.\u00a0<span class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"4c54ea32-b06f-4f20-83a8-da24ef5111aa\" class=\"RefDOI\">10.1016\/j.eprac.2022.05.005<\/span>.<\/p>\r\n<p id=\"R34\" class=\"jrnlRefText\"><span id=\"5cd3ab01-d7d9-4645-847b-6c9bf2517044\" class=\"RefSlNo\">34.<\/span>\u00a0<span id=\"9818e0a9-5980-4a86-baf5-185e64fc2a55\" class=\"RefAuthor\"><span id=\"23a1de89-5654-48af-9530-8a7b059c8f6b\" class=\"RefSurName\">Karakasis<\/span>\u00a0<span id=\"8440863f-481c-4395-8578-7a5c211a504b\" class=\"RefGivenName\">P<\/span><\/span>,\u00a0<span id=\"547726b5-0b4b-42ae-be0d-851ed5164cbb\" class=\"RefAuthor\"><span id=\"97ea2422-03af-4744-be4a-35e126bf2ac5\" class=\"RefSurName\">Fragakis<\/span>\u00a0<span id=\"929008dd-65df-4a1b-9c1a-a84a42b6f9bb\" class=\"RefGivenName\">N<\/span><\/span>,\u00a0<span id=\"81c59098-db4f-434a-b638-87c3e897096b\" class=\"RefAuthor\"><span id=\"acb16b42-bc9c-4cd5-9a55-0d19ec9f2b4d\" class=\"RefSurName\">Kouskouras<\/span>\u00a0<span id=\"d867af03-8f0f-456b-976a-70c2a5cb69f8\" class=\"RefGivenName\">K<\/span><\/span>,\u00a0<span id=\"71f2ca8f-31bc-4c18-9307-552f1905624a\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"8a58d035-0fe4-439a-ac70-4219d718310f\" class=\"RefArticleTitle\">Sodium-glucose cotransporter-2 inhibitors in patients with acute coronary syndrome: A modern cinderella?<\/span>\u00a0<span id=\"800ceb24-f376-4b7f-b353-eb839884afcc\" class=\"RefJournalTitle\"><em id=\"378b28ef-9070-4b3d-a936-00fc67770d35\">Clin Ther<\/em><\/span>.\u00a0<span id=\"085a2f83-33ce-4a3f-85dd-0116220b7958\" class=\"RefYear\">2024<\/span>;<span id=\"445fb415-640d-4e71-a80c-c720a9a5c80c\" class=\"RefVolume\">46<\/span>:<span id=\"c4eb13b3-4e21-4e08-9b18-9bd25b832160\" class=\"RefFPage\">841<\/span>\u2013<span id=\"c7fd0d7f-4aac-4089-b308-af80a926ba23\" class=\"RefLPage\">50<\/span>.\u00a0<span id=\"876011e6-58ca-40d6-821c-88288c94931a\" class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"dbf27f9a-41bc-4338-9b82-32cf3a1a8ee4\" class=\"RefDOI\">10.1016\/j.clinthera.2024.06.010<\/span>.<\/p>\r\n<p id=\"R35\" class=\"jrnlRefText\"><span class=\"RefSlNo\">35.<\/span>\u00a0<span id=\"cc28724e-a3aa-4b1d-9452-7c5909d36618\" class=\"RefAuthor\"><span id=\"5891e6c5-d0ce-4661-ab3d-4afca8b780f3\" class=\"RefSurName\">Mukhopadhyay<\/span>\u00a0<span id=\"2e26be1e-f5d9-46bb-adc6-91fdcf7c21e4\" class=\"RefGivenName\">P<\/span><\/span>,\u00a0<span id=\"230cc112-56fc-4c52-b718-ef62b1bd9002\" class=\"RefAuthor\"><span id=\"74e89309-5085-4891-83d6-0cbfcc63a207\" class=\"RefSurName\">Sanyal<\/span>\u00a0<span id=\"32236baf-4ac6-48c6-91e0-6d40aabf0875\" class=\"RefGivenName\">D<\/span><\/span>,\u00a0<span id=\"705bd584-998b-4fd8-8632-a2d1b7f06de6\" class=\"RefAuthor\"><span id=\"46f9abe7-cd6f-4e00-a4c4-aaf666296ade\" class=\"RefSurName\">Chatterjee<\/span>\u00a0<span id=\"a72ed2a9-fdb8-4604-9d31-214c5f9ddb22\" class=\"RefGivenName\">P<\/span><\/span>,\u00a0<span id=\"f6142a47-ebaa-467b-ba2c-c09c53791bda\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"ab3e11d8-88bf-4da9-844e-85dfaa53bcc2\" class=\"RefArticleTitle\">SGLT2 inhibitors:\u00a0<span id=\"a05c72e8-3473-417a-8d93-2b688dd083ac\" class=\"changeCase sty cts-2\">E<\/span>ffect on myocardial infarction and stroke in type 2 diabetes<\/span>.\u00a0<span id=\"a10b6bf3-19bd-4787-ad1d-43aab609d1d7\" class=\"RefJournalTitle\"><em id=\"dd871a55-7011-43b1-938b-085579426fbb\">J Clin Endocrinol Metab<\/em><\/span>.\u00a0<span id=\"24dd1ffd-0814-4de0-bd64-49858569217a\" class=\"RefYear\">2023<\/span>;<span id=\"3db2dc49-0e89-4ae8-83a4-987f1c86dc82\" class=\"RefVolume\">108<\/span>:<span id=\"4dfa3dab-3d04-4b85-99cb-113bf690cb72\" class=\"RefFPage\">2134<\/span>\u2013<span id=\"1f9f2e5e-77b2-4107-a3ee-2d737fecb64e\" class=\"RefLPage\">40<\/span>.\u00a0<span class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"eec27931-ada5-4aef-bd1d-af19e5ac13a1\" class=\"RefDOI\">10.1210\/clinem\/dgad113<\/span>.<\/p>\r\n<p id=\"R36\" class=\"jrnlRefText\"><span id=\"45061478-0b5c-4b76-9ac5-a0dcbaae9b9b\" class=\"RefSlNo\">36.<\/span>\u00a0<span id=\"48b69e83-3447-4590-962e-ea75b993ae21\" class=\"RefAuthor\"><span id=\"0ef64612-3893-4fe2-af2b-761069cd91fd\" class=\"RefSurName\">Rouleau<\/span>\u00a0<span id=\"4e8d4b31-32f2-4c4c-bbf7-d652f094526c\" class=\"RefGivenName\">J<\/span><\/span>.\u00a0<span id=\"ff9c4803-ce96-4f26-8c55-292a90b8104e\" class=\"RefArticleTitle\">Decreasing the risk of heart failure in a changing post-myocardial infarction environment<\/span>.\u00a0<span id=\"31eb97fe-0f02-4b05-8686-d736d2061c8a\" class=\"RefJournalTitle\"><em id=\"7c591827-dcae-46c8-b4df-1cfef4d6a4b5\">N Engl J Med<\/em><\/span>.\u00a0<span id=\"6b1a9e17-2e3a-4311-a49a-f90a0d1fa3c1\" class=\"RefYear\">2024<\/span>;<span id=\"68302a3e-beb9-4091-aff9-70d0585dc51c\" class=\"RefVolume\">390<\/span>:<span id=\"1752a7f0-dca5-4990-9875-271d35221c46\" class=\"RefFPage\">1524<\/span>\u2013<span id=\"69830ac0-8d1b-43bc-88f5-7ee63657bac6\" class=\"RefLPage\">6. <\/span><span id=\"ac2ce4f8-5e49-4ae6-9e55-965cc7a790b2\" class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"da96d812-bd05-44b1-bf22-2c217c05880e\" class=\"RefDOI\">10.1056\/NEJMe2402719<\/span>.<\/p>\r\n<p id=\"R37\" class=\"jrnlRefText\"><span id=\"9872a0a2-9cc5-4c79-bff8-7e8245c40b67\" class=\"RefSlNo\">37.<\/span>\u00a0<span id=\"3e0859f5-4bac-4169-990d-63839a30616f\" class=\"RefAuthor\"><span id=\"4e61839c-b6b7-40a4-b74b-48412e6424aa\" class=\"RefSurName\">Karakasis<\/span>\u00a0<span id=\"4750faa8-39e6-43c9-b9a5-2ddad2798783\" class=\"RefGivenName\">P<\/span><\/span>,\u00a0<span id=\"fb42c31f-a432-4d08-b393-a857d23fe586\" class=\"RefAuthor\"><span id=\"1579aaa0-7735-4b25-9e4b-47b0ede77efc\" class=\"RefSurName\">Patoulias<\/span>\u00a0<span id=\"e76afdde-b4b4-4a14-9f1e-1eafa4004529\" class=\"RefGivenName\">D<\/span><\/span>,\u00a0<span id=\"97738e39-ff4a-4218-8b4b-f81fdf9251c5\" class=\"RefAuthor\"><span id=\"6b7ab3bd-a901-46a2-9746-2885511ae570\" class=\"RefSurName\">Kassimis<\/span>\u00a0<span id=\"83292291-4e5d-4eee-ad4f-83bc73572fd8\" class=\"RefGivenName\">G<\/span><\/span>,\u00a0<span id=\"5f5d6aa3-c79a-4566-a116-0d2d797384a6\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"1e0bedba-0cac-41c3-951d-bf6973677d7b\" class=\"RefArticleTitle\">Therapeutic potential of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists for patients with acute coronary syndrome: A review of clinical evidence<\/span>.\u00a0<span id=\"548abece-98d5-473c-bd91-799bceb9abb9\" class=\"RefJournalTitle\"><em id=\"95ce7da4-fa3b-43d9-8cfa-5e9cb461fcc5\">Curr Pharm Des<\/em><\/span>.\u00a0<span id=\"ffedb20e-861b-487a-9f39-fdbea505b58e\" class=\"RefYear\">2024<\/span>;<span id=\"d56570c1-896f-4593-a541-5751d7400121\" class=\"RefVolume\">30<\/span>:<span id=\"2babea1a-4ace-4327-acf9-7106b6addfb8\" class=\"RefFPage\">2109<\/span>\u2013<span id=\"2032cc93-7d80-46f9-b4fb-cf6322b44f3d\" class=\"RefLPage\">19. <\/span><span id=\"80cca76f-4755-45a1-aee4-37203a8e42a7\" class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"bea83e37-940c-4e14-ac7d-c114187290fe\" class=\"RefDOI\">10.2174\/0113816128304097240529053538<\/span>.<\/p>\r\n<p id=\"R38\" class=\"jrnlRefText\"><span class=\"RefSlNo\">38.<\/span>\u00a0<span id=\"44ff3e18-7cd3-4ae5-a269-db6c00fd7a15\" class=\"RefAuthor\"><span id=\"047bebbb-355f-4c47-ba88-4e0676b4725b\" class=\"RefSurName\">Huang<\/span>\u00a0<span id=\"ca8ca6d0-271b-4a0e-8a5c-100e4c7b7340\" class=\"RefGivenName\">M<\/span><\/span>,\u00a0<span id=\"46771e34-cc09-4a70-a090-99ddc4c210e5\" class=\"RefAuthor\"><span id=\"dc90a2b4-0b73-4677-bfe8-d18979ab213e\" class=\"RefSurName\">Wei<\/span>\u00a0<span id=\"99fbc103-3e37-4e35-b0c6-63d9e08569a5\" class=\"RefGivenName\">R<\/span><\/span>,\u00a0<span id=\"fef583d7-5852-449a-a6b2-08cfd6e582e6\" class=\"RefAuthor\"><span id=\"3d9f0569-c740-4a68-8a06-99f31241e60a\" class=\"RefSurName\">Wang<\/span>\u00a0<span id=\"3ff61378-e446-4cbc-8569-bc721ac9acad\" class=\"RefGivenName\">Y<\/span><\/span>,\u00a0<span id=\"8fd9341f-db6e-4ad4-8368-5d7f1dc939a4\" class=\"RefEtal\">et al<\/span>.\u00a0<span id=\"ea19779a-bbd5-460f-bbd3-672dd7c387dd\" class=\"RefArticleTitle\">Protective effect of glucagon-like peptide-1 agents on reperfusion injury for acute myocardial infarction:\u00a0<span id=\"4a96dedb-4054-4f53-b68f-23189f318088\" class=\"changeCase sty cts-2\">A<\/span>\u00a0meta-analysis of randomized controlled trials<\/span>.\u00a0<span id=\"8e2edde9-d60b-4c45-a11f-fadd97f24cf7\" class=\"RefJournalTitle\"><em id=\"3bf9c48f-0259-4c21-8922-8f6756097871\">Ann Med<\/em><\/span>.\u00a0<span id=\"78f8e46e-d206-4916-9571-9bba50c7e4b3\" class=\"RefYear\">2017<\/span>;<span id=\"bbb9b253-f5f7-441e-93d9-aeb23f6b22bf\" class=\"RefVolume\">49<\/span>:<span id=\"7b4f2ac3-fde8-440d-b167-8feb2657fc9a\" class=\"RefFPage\">552<\/span>\u2013<span id=\"df6afd03-655c-4b4d-a6d3-6eafb0a0f20e\" class=\"RefLPage\">61<\/span>.\u00a0<span class=\"RefComments\">DOI<\/span>:\u00a0<span id=\"3c439171-c9d5-4b88-bd15-aa55cf319447\" class=\"RefDOI\">10.1080\/07853890.2017.1306653<\/span>.<\/p>","wpcf-article_received_date":"20240909","wpcf-article_accepted_date":"20241214","wpcf-article_published_online":"20250209","wpcf-podcast":"","wpcf-ogg":"","wpcf-article_end_page":"","wpcf-article_start_page":"","wpcf-acknowledgements":"","wpcf-errata_pdf":"","wpcf-article_flipper_image":"","wpcf-corrected_online":null,"wpcf-supplementary_information":"https:\/\/touchendocrinology.com\/wp-content\/uploads\/sites\/5\/2025\/02\/Supplementary-Materials.pdf","wpcf-article_highlight_pdf":"","data_availability":"<div class=\"\">\r\n<div id=\"78f3001f-184a-4ae6-8c88-6d22d064c725\" class=\"jrnlFN\">\r\n<div class=\"jrnlFNText\">\r\n<p id=\"aabc065b-950d-497e-b923-c148251e14b3\" class=\"jrnlFNPara\">The datasets generated during and\/or analysed during the current study are available from the corresponding author on reasonable request.<\/p>\r\n\r\n<\/div>\r\n<\/div>\r\n<\/div>","digital_features":""},"_links":{"self":[{"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/posts\/104762"}],"collection":[{"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/users\/100365"}],"replies":[{"embeddable":true,"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/comments?post=104762"}],"version-history":[{"count":17,"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/posts\/104762\/revisions"}],"predecessor-version":[{"id":104902,"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/posts\/104762\/revisions\/104902"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/media\/104812"}],"wp:attachment":[{"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/media?parent=104762"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/categories?post=104762"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/tags?post=104762"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}